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gEnErAl inTrODucTiOn
α-Particles can be used to deliver a highly efficacious targeted therapy of (metastasized) 
cancer with an α-emitting radionuclide stably labelled to a cancer-specific targeting li-
gand. Such ligands like somatostatin-derived peptides have a proven track record of stable 
labelling with γ-ray and β-particle emitting radionuclides for diagnostic and therapeutic 
applications in patients with neuroendocrine tumours (NETs), respectively. Stabilized 
somatostatin-based peptides with radiometal-bifunctional chelators form ideal experimen-
tal model systems to test aspects of radiochemistry, in vitro cell irradiation and in vivo 
therapy using α-emitter labelled peptides.
nEurOEnDOcrinE TumOurs AnD sOmATOsTATin 
AnAlOguEs
The neuroendocrine system produces hormones e.g. somatostatin and dopamine, which are 
released in the bloodstream to regulate body functions. Tumour cells originating from this 
system often (over)express somatostatin receptors to which the peptide somatostatin can 
bind with high, i.e. nanomolar, affinity. Native somatostatin consists in two forms, one con-
taining 14 amino acids (somatostatin-14) and the other 28 amino acids (somatostatin-28). 
Both target somatostatin receptors (SSTRs) through specific receptor-mediated processes 
[1]. Five subtypes of SSTRs are known; SSTR1, SSTR2, SSTR3, SSTR4 and SSTR5 [2]. 
Upon binding to the receptor, receptor agonistic somatostatin analogues inhibit the secre-
tion of a wide range of hormones from the neuroendocrine system [3, 4]. Somatostatin can 
also inhibit proliferation of tumour cells that overexpress SSTRs, including various NETs. 
Several studies have been performed to evaluate the inhibition of NET growth by native 
somatostatin, but unfortunately the results obtained were not promising [5–7]. One of the 
reasons was believed to be the poor biological stability of native somatostatin after release 
into the bloodstream, due to rapid enzymatic degradation (within 2–3 minutes) [8, 9]. 
Therefore, stabilized somatostatin analogues, such as octreotide, have been developed with 
shortened peptide length and the introduction of D-amino acids. Radiolabelled somatostatin 
analogues have become very attractive for visualization of NETs. 123I-Tyr3-octreotide was 
the first radioactive somatostatin analog developed for in vivo imaging [10–12]. Tumour 
lesions could be visualized with this radioactive somatostatin analog, however, the radio-
labelled analog was not stable due to dehalogenation of 123I-Tyr3 causing undesired uptake 
in thyroid and gastro-intestinal tract. Therefore, alternative methods have been explored to 
increase the stability of radioactive somatostatin analogues.
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chElATOrs AnD chOicE Of rADiOnucliDEs
Chelators can bind metals through ionic interaction and are attractive for labelling of radio-
metals. Somatostatin analogues can be radiolabelled with clinically attractive radiometals 
via bifunctional chelators, such as DTPA (diethylenetriaminepentaacetic acid), DOTA 
(1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid), CHX-A’’DTPA ([(R)-2-Amino-
3-(p-isothiocyanatophenyl)propyl]-trans-(S,S)-cyclohexane-1,2-diamine-pentaacetic acid) 
and NOTA (1,4,7-triazacyclononane-N,N’,N’’-triacetic acid) [13], see Fig. 1. The choice 
of radionuclides depends on physical and biochemical characteristics and the effective half-
life. The physical characteristics include the physical half-life with an attractive half-life 
between 6h-7d [14], type of emission, energy of the radiation and decay chain. Biochemical 
characteristics include the pharmacokinetics within the patient, in vivo stability, efficacy 
and toxicity [13, 15, 16]. The effective half-life is considered to be the most important 
factor. The effective half-life is the net half-life derived from both the physical half-life 
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figure 1, Chelators used in targeted radionuclide therapy with radiometals, DOTA = 1,4,7,10-tetraazacy-
clododecane-1,4,7,10-tetraacetic acid, CHX-A’’DTPA=[(R)-2-Amino-3-(p-isothiocyanatophenyl)
propyl]-trans-(S,S)-cyclohexane-1,2-diamine-pentaacetic acid, DTPA= diethylenetriaminepentaacetic 
acid and NOTA = 1,4,7-triazacyclononane-N,N’,N’’-triacetic acid.
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and the biological half-life of the radionuclide within a patient’s body or organs [16]. Other 
important parameters related to the choice of radionuclide are availability, production and 
the chemical properties to bind to a biofunctional ligand [15, 16].
After successful modification and in vivo stabilization of somatostatin analogues, the con-
cept to use radiolabelled somatostatin analogues, e.g. DTPA-DPhe1octreotide, DOTA-Tyr3-
octreotide (DOTATOC) or DOTA-Tyr3-octreotate (DOTATATE) radiolabelled with 111In to 
visualize NETs in vivo, was born and introduced as peptide receptor scintigraphy (PRS). 
Since then, 111In-DTPA-DPhe1-octreotide (Octreoscan®) has been routinely applied in the 
clinical setting as a diagnostic tool in patients with NETs and their metastases with SSTR2 
expression, see Fig. 2. Nowadays 68Ga-DOTATATE is considered to be a better diagnostic 
radiolabelled peptide than Octreoscan®, since the consensus is that 68Ga-DOTATATE offers 
diagnostic images with greater sensitivity and specificity [17, 18], although evidence in 
large multi-centre trials is missing.
figure 2, SPECT imaging in a patient after injection with 111In-DTPA-DPhe1-octreotide (Octreoscan®). 
Dark spots indicate accumulation of radioactivity.
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pEpTiDE rEcEpTOr scinTigrAphy AnD pEpTiDE 
rEcEpTOr rADiOnucliDE ThErApy (prrT)
PRS applies radiolabelled peptides to visualize and localize tumour lesions with Positron 
Emission Tomography (PET) or Single Photon Emission Computed Tomography (SPECT) 
techniques. Besides visualization and localization in combination with Computed Tomo-
graphy (CT), PET and SPECT imaging can provide information on tumour staging. Based 
on the characteristics of the radionuclide, PET or SPECT can be applied.
radionuclides for imaging
SPECT cameras can measure γ-rays emitted by radionuclides. A collimator is placed in front 
of the scintillation crystal and only γ-rays traversing through the holes of the collimator can 
reach the scintillation crystal. Collimators are generally made of tungsten or lead. Several 
collimators are available: low-, medium- or high-energy and high-resolution, all-purpose 
and high-sensitivity, each with a specific thickness, hole shape, hole diameter and septal 
thickness. The resolution obtained depends on the size of the holes in the collimator used. 
Through several reconstruction algorithms, a three-dimensional image can be obtained via a 
series of two-dimensional projections images obtained from SPECT. Most commonly used 
radionuclides for SPECT are 111In (half-life = 2.8 days) and 99mTc (T1/2 = 6.0 hours). Table 1 
lists other commonly used radionuclides for SPECT imaging. SPECT cameras for clinical 
applications mostly use parallel collimators and preclinical applications pinhole collimators. 
Pinhole collimators allow high magnification to achieve submillimeter resolution [19].
The concept of PET is similar to that of SPECT, but one of the major differences being that 
for PET β+ (positron)-emitting radionuclides are applied. Commonly applied radionuclides 
are 18F (half-life = 109.8 min), 68Ga (half-life = 67.7 min), and 11C (half-life = 20.3 min). 
Table 1, Physical characteristics of commonly applied radionuclides for SPECT
radionuclide half-life Decay mode (%) Enp (keV) Eγ (keV) Abundance (%) production
123i 13.3 h ε (100 %) Auger L (3.2)
Auger K (22.7)
CE-K (127.2)
159.0
529.0
83.3
1.4
Cyclotron
111in 2.8 d ε (100 %) Auger L (2.3)
Auger K (19.3)
CE-K (144.6)
CE-K (218.6)
171.3
245.4
90.7
94.1
Cyclotron
99mTc 6.0 h β- (0.004)
IT (99.9963)
Auger L (2.2)
CE-K (1.6)
140.5 89.1 99Mo/99mTc 
Generator 
d=days, h=hours, ε=electron capture, IT=internal transmission, Enp = energy of neutron converses to 
proton, Eγ= γ energy
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These radionuclides can be covalently bound or linked via a bifunctional chelator to a 
pharmaceutical. β+-Emitters emit positrons, which collide with electrons and undergo anni-
hilation. After annihilation, two γ-rays with energies of 511 keV will be emitted in opposite 
directions. PET camera detectors can detect both annihilation photons without a collimator 
and after mathematical processing and reconstruction, PET images can be generated. Due 
to the physical properties of the PET camera, PET can offer higher sensitivity and higher 
spatial resolution images than SPECT. Table 2 lists some commonly used radionuclides for 
PET imaging.
radionuclides for therapy
PRRT uses the same targeting concept as PRS. Through a receptor-mediated process, the 
radiolabelled peptide can bind to receptors on tumour cells; this way radioactivity and 
consequently radiation exposure can be delivered to the cells. β--Emitters like 177Lu and 
90Y are the most commonly used radionuclides for PRRT. These radionuclides are suitable 
candidates for therapy in large solid tumours rather than in small clusters of tumour and 
small metastases, due to their relative large penetration depth in tissue: 1–12 mm [20]. 
Radiation exposure by β--particles can eradicate tumour cells.
Development of next generation somatostatin analogues
In nuclear medicine, PRRT has been applied in patients with NETs since more than 25 
years, mostly with 177Lu-DOTA-Tyr3-octreotate (DOTATATE) or 90Y-DOTA-Tyr3-octreotide 
(DOTATOC), both radiolabelled somatostatin analogs, see Fig. 3.
In most studies, applied in > 10.000 patients with NET, good clinical outcome with low 
toxicity and an improvement in quality of life was found in patients treated with PRRT [21, 
22]. In a phase 3 study, 177Lu-DOTATATE resulted in markedly longer progression-free 
survival in patients with well-differentiated, metastatic midgut NET. A progression-free 
Table 2, Physical characteristics of commonly applied radionuclides for PET
radionuclide half-life Decay mode (%) Eβ+ (keV) Abundance (%) production
11C 20.4 m β+ 385.6 99.8 Cyclotron
13N 10.0 m β+ 491.8 99.8 Cyclotron
15O 2.0 m β+ 735.3 99.9 Cyclotron
18F 109.8 m β+ 249.8 96.7 Cyclotron
64Cu 12.7 h ε (61.5 %)
β+ (17.6 %)
β- (38.5 %)
278.2 17.4 Reactor or Cyclotron
68Ga 67.7 m ε (10 %)
β+ (90 %)
836.0 88.9 68Ge/68Ga Generator
m=minutes, h=hours, ε=electron capture, Eβ
+= mean β+ energy
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survival of 20 months was found compared to that in patients treated with high dose oc-
treotide, with no evidence of renal toxicity during this time-frame [23]. However, complete 
remission of the disease, once metastasized, is still rare. Therefore continuation of the 
research aiming at safe and more powerful treatment for NET patients is still ongoing.
Linear Energy Transfer and relative biological effect
A promising approach radionuclide therapy is the use of exposure to particle radiation with 
high Linear Energy Transfer (LET), because of its high cytotoxic capabilities [24–26]. LET 
refers to the number of ionizations per unit of path length and is often expressed as keV/
μm. Particles with a LET > 100 keV/μm are classified as high LET [27]. Absorbed dose and 
the induced biological effects are dependent on the LET-nature of the radiation, see Fig. 4.
figure 3, Chemical sequences of DOTATOC and DOTATATE, red circles indicating the chemical dif-
ference between DOTATOC and DOTATATE.
figure 4, Principle of dose related effects of low and high LET, adapted from Strauma et al. [28]. LET= 
Linear energy transfer.
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Dosimetry is an important tool to judge the probability of tumour reduction against the 
probability of normal organ toxicity after targeted radionuclide therapy. The MIRD 
formalism is a well-established method for calculating absorbed doses in normal organs 
and tumours for low-LET β- and γ-emitters. The absorbed dose is the average absorbed 
energy in the target volume (normal organ or tumour) from radiation emitted from a source 
volume. α-Particles with their short path length and high LET might not be well represented 
by the average energy absorption assumption. A single α-particle track can lead to cell 
death when traversing the cell nucleus and its DNA, while the average absorbed dose to 
the cell is low. Single cell dosimetry should therefore be based on the micro-dosimetric ap-
proach (microdosimetry), taking into account the stochastic variation of energy deposition 
and probability of cell nucleus hits. Multi-cellular dosimetry can be based on the average 
absorbed energy macrodosimetry model with source and target equivalent, assuming that 
crossfire doses from source to other target volumes are limited and healthy tissue surround-
ing the target will not be affected. This approach is used to calculate the absorbed dose 
for β- and γ-emitters, stochastic variation of energy deposition cause by short path length, 
inhomogeous distribution and small size of target volume are neglected [29, 30]. The 
calculated absorbed dose can also be used to determine the relative biological effect (RBE).
The relative biological effectiveness of radiation indicates the ratio of macroscopic ab-
sorbed doses for a certain type of ionizing radiation compared to a reference type of radia-
tion, usually X-rays, both causing the same biological effect endpoint. Typical RBE-values 
of α-particles range from 3–7 in comparison to irradiation with photons or electrons at the 
same endpoint [30]. According to the International Commission on Radiological Protection 
(ICRP Publication 92), the current weighting factor is set to be 20 for α-particles and 1 for 
β-emitters, for late stochastic effects (cancer induction). The weighting factor is used to 
estimate the effective absorbed dose (in Sv, Sievert), which is related to the stochastic effect 
endpoint caused by different types of radiation [30, 31].
TArgETED AlphA ThErApy (TAT)
α-Particle emitting radionuclides (α-emitters) emit high energy α-particles (positively dou-
ble-charged helium nuclei) that have a higher LET compared to β-particles and γ-radiation. 
Typically energies of the α-particles emitted are in the range of 5–8 MeV. Due to these 
physical properties, α-particles show more potent cytotoxic effects than β-particles; 
α-particles cause more irreparable DNA clusters and double-strand breaks in cells than low 
LET radiation types [32]. The penetration depth in tissue of an α-particle is relatively short 
(50–100 µm). Therefore, α-particles are thought to be most suitable for treatment of small 
clusters of tumours and/or metastases. Inhomogeneous uptake of α-emitter labelled radio-
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pharmaceuticals in larger tumours may seriously jeopardize the therapeutic advantages. 
Table 3 shows typical physical characteristics of α-emitters versus β--emitters.
By linking α-emitters through covalent binding or through a bifunctional chelator to bio-
logically functionally molecules with a selectively binding ligand, α-emitters can reach 
their target; this process is defined as targeted alpha therapy (TAT). High LET α-particles 
might lead to severe damage of the DNA of tumour cells, leading to cell death.
The first introduction of α-emitters as candidates for clinical application as brachytherapy 
[33] or external therapy [34] dates back to the early 1900 [35]. The first phase I clinical 
study in patients with leukemia treated with 213Bi-HuM195mA as TAT dates back to 1997, 
patients treated with 213Bi-HuM195mA showed remarkable results [36], since then vari-
ous (pre)clinical studies have been performed on the use of α-emitters, but also potential 
limitations for clinical application, including toxicity, have been investigated. 213Bismuth 
(213Bi, half-life 46 min) has been applied in several (pre)clinical studies on TAT. 213Bi is a 
decay product of 225Actinium (225Ac), with a T1/2 of 45.6 min, emitting α-particles of 8.4 
MeV and γ-rays of 440 keV. Figure 5 demonstrates the decay scheme of 225Ac to 209Bi, 213Bi 
decays via 213Polonium (213Po) or 209Thallium (209Tl) to stable 209Bi. 213Po emits α-particles 
with 8.38 MeV energy and by its short half-life of 3.7 μs 213Po decays in equilibrium with 
the parent 213Bi.
213Bi-DOTATOC showed dose-related anti-tumour efficacies in rats, without acute or chronic 
hematological toxicity and tolerated nephrotoxicity [37]. Kratochwil et al. published the 
first clinical study with 213Bi-DOTATOC [38]. After treatment using 213Bi-DOTATOC in 
7 patients with progressive advanced neuroendocrine liver metastases, refractory to treat-
ment with 90Y/177Lu-DOTATOC, tumour response was observed. An overview of clinical 
applications with 213Bi conjugated ligands is shown in Table 4. Recently, 225Ac was ap-
plied; 225Ac-PMSA inhibitor demonstrated to be effective in treatment of two patients with 
metastatic castration-resistant prostate cancer (mCRPC) in a pilot study without relevant 
hematological toxicity [39]. In a study that followed, 11 patients were treated with 225Ac-
PSMA-617. Xerostomia was found to be the dose-limiting factor in this study. Overall, a 
Table 3, Overview of the radioactivity characteristics of α versus β--radiation
properties α β-
particle mass in (u) 4.00 5.49x10–4
penetration depth in tissues 50-100 μm 1–12 mm
LET (keV/μm) 60-230 0.1–1.0
ion pair/µm 2000-7000 5-20
DnA hits cell kill 1-4 > 1000
Example 213Bi, 225Ac 177Lu, 90Y
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treatment of 100 kBq/kg with a re-treatment interval of 8 weeks was found to be promising 
for anti-tumour effect with tolerable side-effects [40].
Only a limited number of α-emitting radionuclides is suitable for TAT and has been investi-
gated in humans or animal models. In this next paragraph we will discuss the potential, the 
availability and the feasibility of some of these radionuclides.
225Ac
221Fr
217At
213Bi 213Po
209Tl 209Bi
α: 5.8 MeV
9.920 days
α: 6.4 MeV
4.806 min
α: 7.1 MeV
32.8 ms
α: 5.87 MeV
45.62 min
1.94%
β−: 434 keV
45.62 min
97.91%
β−: 655 keV
2.2 min
β−: 197 keV
3.232 h
α:8.38 MeV
3.708 µs
209Pb
figure 5, Decay scheme of 225Ac to 209Bi, including half-lifes of the daughters and energy of particles 
emitted by the daughters.
Table 4, Overview clinical applications of 213Bi
213Bi conjugate cancer Type phase reference 
hum195mAb Leukemia Phase I/II [36, 41]
9.2.27mAb Melanoma Phase I [42–44]
substance-p Glioma Pilot Phase I [45]
DOTATOc NETs Pilot [38]
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225Actinium (225Ac)
225Ac (half-life, 10.0 days) decays via a cascade of six daughters to 209Bi. 225Ac emits a netto 
of 4 α-emitting particles with a cumulative energy of 28 MeV and two β-disintegrations 
with a maximum energy of 1.6 and 0.6 MeV, see Fig. 5. 225Ac is produced via radiochemical 
extraction from a decay product of 229Th (T1/2 = 7340 y), 229Th being a natural decay product 
of 233U. Another route to produce 225Ac is by irradiation of 226Ra through accelerator-based 
methods using the 226Ra (p,n) reaction [46, 47]. 225Ac has been used to construct 213Bi produc-
ing generators. Molecules labelled or drug carriers encaptured with 225Ac are very attractive 
for application in theranostic radiopharmaceuticals [48, 49]. γ-Ray detection of 225Ac is also 
possible, due to γ-emissions of decay daughters 221Fr (218 keV, abundance 11.6 %) and 213Bi 
(440 keV, abundance 26.1 %). Conjugated 225Ac can act as an atomic nanogenerator due to 
the cascade of emitted α-particles, making 225Ac even much more potent than its daughter 
213Bi. Despite and due to the fact that 225Ac seems to be more cytotoxic than other α-emitters, 
concerns were raised about potential toxicity caused by free daughters, released into the 
circulation, by recoil effects during the decay of 225Ac [50]. Therefore, the search for the ideal 
“carrier/chelator” for 225Ac is still ongoing. Although DOTA is not the ideal chelator for 225Ac, 
due to the recoil effect, it is as yet the most often used chelator for 225Ac.
213Bismuth (213Bi)
213Bi is obtained from the decay of 225Ac. 213Bi can be eluted from a generator with 225Ac 
entrapped on a cation-exchange resin column [51]. With its relative short half-life (46 min), 
213Bi has been a commonly used α-emitter for TAT. 213Bi decays to 209Bi by emitting one 
α-particle per desintegration. A γ-photon of 440 keV enables visualization/calculation of 
biodistribution, pharmacokinetics studies and dosimetry calculations for preclinical ap-
plications. After eluting 213Bi from the generator, 213Bi can be labelled by conjugation to a 
peptide [37, 52], nanobody, liposome or antibody [53] through bifunctional chelators e.g. 
DOTA, or CHX-A’’DTPA [54].
212Bismuth (212Bi)
212Bi with a half-life of 60.6 min can be eluted from a generator containing 224Ra as par-
ent radionuclide. 212Bi emits an α-particle with a mean energy of 7.8 MeV per decay and 
finally decays to stable 208Pb. Emission of a γ of 2.6 MeV along with other medium to high 
γ-radiation by the daughter 208Tl, requires heavy shielding for radiation exposure, limiting 
the use of 212Bi in clinical as well as in preclinical settings. Chelators suitable for 213Bi 
labelling can be used for the labelling of 212Bi as well, since the chemical properties of these 
radionuclides are equal.
1General introduction | 19
211Astatine (211At)
211At (half-life 7.3 hr) is produced in a cyclotron. The reaction occurs by bombardment of 
209Bi with α-particles, via an (α, 2n) reaction. 211At has more a halogenic character than 
metallic, therefore the labelling methods of 211At are different from α-emitting radiometals. 
211At is often covalently linked to the target biomolecule through labelling methods with 
e.g. electrophilic demetallation with stannyl or silyl precursors [55, 56]. 211At-labelled ra-
diopharmaceuticals have been applied in several preclinical studies for treatment of ovarian 
cancer, glioma, leukemia, lymphoma and prostate cancer. Clinical trials have been performed 
in patients with primary brain tumour and ovarian carcinoma using 211At-antibodies [57–59].
223radium (223ra)
223Ra in the form of 223RaCl2 is the first FDA approved α-emitting radiopharmaceutical 
for clinical use in patients with castration-resistant prostate cancer and symptomatic bone 
metastases. 223Ra has a half-life of 11.4 d. 223Ra is actually a byproduct produced during 
neutron irradiation of 226Ra to produce 227Ac, which decays to 223Ra through 227Th. 223Ra acts 
like a calcium mimetic and targets the bone area undergoing changes induced by tumour 
lesions. 223Ra emits four α-emitting particles per desintergration and is considered to be 
potent for therapeutic applications in tumours. However, there are currently no chelators 
which can form stable complex with 223Ra, it can therefore not be conjugated to tumour 
targeting molecules for TAT [57].
227Thorium (227Th)
227Th (half-life = 18.7 d) is one of the decay daughters from natural 235U. 227Th can also 
be obtained from decay of 227Ac, as indicated above. 227Th decays to 223Ra by emission of 
an α-particle with an average energy of 5.9 MeV. In the 1990s, 227Th was mainly used as 
a generator for 223Ra. 227Th binds stably to DOTA-derivative chelators and can therefore 
conjugated to e.g. antibodies. Conjugated 227Th-antibodies have been used in several pre-
clinical studies to evaluate their therapeutic potential in TAT [60–63].
chAllEngEs AnD limiTATiOns Of TAT wiTh 213Bi in (prE)
clinicAl ApplicATiOns
177Lu-DOTATATE has been applied in our department for decades in patients with NETs, 
complete cure in patients with metastasized NETs is however rarely achieved. 213Bi might 
improve PRRT by eradicating small metastases, which have escaped from e.g. 177Lu therapy.
This thesis focuses on 213Bi-labelled DOTATATE application in preclinical models of 
NETs. In general, to deliver an absorbed dose to the tumour through receptor-mediated 
uptake that is therapeutically efficacious in vivo can be challenging. Several factors can 
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influence the delivered absorbed dose e.g. the limited number of available binding sites, 
distribution patterns, tumour perfusion and elimination from the tumour. Apart from these 
in vivo challenges, the chemical and physical properties of 213Bi can also provide hurdles. 
In the following paragraphs, several of these limitations will be discussed.
chemical and physical challenges
In general for PRRT and especially in small animals, a labelled peptide with a relatively 
high molar activity (MA, expressed as MBq/nmol peptide) with high in vivo stability is 
required to deliver sufficient dose to the tumour. MA is expressed as the maximum amount 
of radioactivity per nmol of peptide [64–66]. For the labelling of 213Bi, the MA is dependent 
on the interaction between chelator and 213Bi, whereas the electric charge, stereometric 
hindrance, thermodynamic stability and kinetic stability play a major role in the chemical 
stability of the labelled peptide as described below. The most commonly used chelator for 
213Bi is DOTA, with a thermodynamic stability constant of Log K 30.3. DOTA conjugated 
ligands demonstrate high in vitro and in vivo stability with 213Bi3+. Impurities in the labelling 
process may however often lead to a lower MA obtained. These impurities can be formed 
during from the production of the 225Ac, decay products of 213Bi, derived from the solvent 
used for elution, or buffers and quenchers used for the labelling reaction. In general, these 
impurities have no influence on the labelling when they have no affinity for the chelator. 
However, when these impurities do show affinity for the chelator, the MA might decrease, 
the effect being dependent on the stability of this complex. During labelling of 213Bi the 
resulting radiopeptide can be damaged by radicals (·OH) or directly by high LET α-particle 
tracks in the labelling reaction mixture, potentially resulting in decrease of chemical purity 
and (partial) loss of affinity to the target. The extent of radical formation in the labelling 
is dependent on the type of radionuclide, the duration of exposure and also on the energy 
release by the radionuclide. Addition of quenchers or scavengers during radiolabelling will 
limit the damage to the peptide due to radicals, thus maintaining the stability of the radio-
peptide when the damage is mainly indirect due to radicals. De Blois et al. demonstrated the 
importance of quenchers e.g. addition of ascorbic acid, gentisic acid, ethanol, to minimize 
the damaging effects of radicals to the radio-peptide with 177Lu and 111In [67].
The most commonly applied methods used to determine the quality and stability of ra-
dioligands in the field of nuclear medicine are by instant thin layer chromatography or 
high performance liquid chromatography (HPLC). HPLC can also be used to determine the 
radiochemical purity (RCP) of the labelled compounds.
(pre)clinical challenges of prrT and TAT
For receptor-mediated processes the most challenging aspect is to deliver a therapeutic 
dose to the tumour with acceptable toxicity, so the ideal radiolabelled peptide combines 
low a-specific binding to normal tissues with high specific binding to tumour lesions. Since 
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the numbers of receptors available for binding of radiopeptides are limited and the injected 
amount of peptide can therefore influence tumour uptake, administration of a radioligand 
with high MA is highly recommended, to avoid saturation of the receptors. (Partial) satura-
tion of the receptors by unlabelled peptide will result in lower uptake of the radiolabelled 
peptide in the tumour cells, potentially leading to insufficient absorbed dose delivered to 
the tumour cells in the case of e.g. β-emitters. As mentioned before, α-emitters are more 
cytotoxic than β-emitters. Only 1–4 hits are required for cell death, provided the high LET 
α-particles traverse the nucleus of the tumour cell, causing irrepairable complex DNA dam-
age, leading to cell death.
Off-targeting or binding to healthy organs is a major issue in receptor-mediated processes, 
either by the labelled peptide itself, by its metabolites or de-chelated radionuclide. Espe-
cially α-emitters have a high risk to cause undesirable radiation damage to healthy organs 
and tissues when used for therapeutic applications. This effect could be minimized several 
ways; most often modification of the radio-peptide is applied, by e.g. selecting the most 
suitable chelator or changing the peptide sequence of the radiopeptide. Other options 
to improve in vivo stability are to reduce the enzymatic degradation by co-injection of 
peptidase inhibitors [68] or by saturating the receptors on healthy organs and tissue by 
unlabelled peptides to decrease uptake [69]. The latter can have a negative influence on 
the tumour uptake, since tumour uptake for somatostatine analogues is dependent on the 
peptide amount injected [70].
PRRT with the β--particle emitter 177Lu coupled to DOTATATE is generally well tolerated 
by patients with NETs, if necessary precautions are taken, e.g. co-administration of amino 
acids, without severe side effect. Kidneys and bone marrow are critical organs, although 
kidney it is not dose-limiting with 177Lu in contrast to 90Y-labelled peptides [71–73]. The 
most common subacute side effect of bone marrow irradiation is haematological toxicity, 
which occurs 4–6 weeks after PRRT. This toxicity is often mild and reverses within weeks 
after treatment cessation [74]. Renal retention of radiopeptides remains a problem in PRRT, 
in particularly for TAT [75]. The partial retention of the radioactivity in the kidneys is 
mainly caused by tubular reabsorption caused by the interaction between the radiopeptide 
with the receptor complex of megalin/or cubulin [76]. Megalin and cubulin work in close 
interaction with each other and are situated in the proximal tubules in the renal cortex and 
their function is to reabsorb glomerular filtered substances through mediated endocytosis.
Beside megalin and cubilin, 213Bi-conjugated complexes can also have strong interaction 
with a metallothionein in the kidney [77], which might result in a higher absorbed dose and 
leading to loss of renal function and nephrotoxicity. Retention of radio-peptides in kidneys 
can be reduced by co-administration of kidney protectants like lysine/arginine during PRRT 
[78]. The technique to use lysine/arginine to compete with the ligand binding site cluster of 
megalin and cubilin is routinely applied during PRRT application with 177Lu-DOTATATE 
and 90Y-DOTATOC.
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Renal function during and after PRRT can be monitored using renal biomarkers e.g. creati-
nine clearance/EGFR and biomarkers like 99mTc-dimercaptosuccinic acid (99mTc-DMSA) or 
99mTc-mercaptoacetyltriglycine (99mTc-MAG3) [79]. 99mTc-DMSA is used as renal cortical 
imaging agent [80] and 99mTc-MAG3 is typically used to determine renal tubular func-
tion. 99mTc-MAG3 however, has shown to have limited value for the prediction of late 
radiation induced nephropathy by 177Lu-DOTATATE or 177Lu-DOTATOC [81]. Permanent 
renal toxicity normally appears 6–12 months after PRRT [72, 74]. The threshold dose for 
late-stage kidney radiation damage was set to be 23 Gy, this was according to the dose 
obtained from external beam radiation therapy [82]. Bergsma et al. found that a threshold 
dose for kidney of 28 Gy was more a conservative value for therapy with 177Lu-DOTATATE 
[73]. To investigate long-term nephrotoxicity after PRRT, classical approach is often used; 
creatinine clearance [83]. Creatinine is filtered through the glomeruli. However, the level of 
serum creatinine is generally not sufficiently accurate for analytical measurement. Due to 
several factors such as age, diet, and muscle mass can influence creatinine levels in serum 
[84]. Nowadays, novel renal markers e.g. Neutrophil Gelatinase-Associated Lipocalin 
(NGAL) [85, 86] can be used to evaluate renal dysfunction at early events. This biomarker 
has shown to be sensitive and specific as renal marker for acute kidney injury [86].
One of the most challenging issues regarding application of conjugated 213Bi for TAT is the rela-
tively short half-life. For clinical purposes, generators with 225Ac activity of 4 GBq and more are 
produced. However, for preclinical applications, typical generators are produced containing less 
than 222 MBq, due to the limited availability of 225Ac; studies with these low activity generators 
are even more challenging. Apart from using the low activity generator, 213Bi has to be eluted from 
the generator in an acidic environment containing 0.1 M/0.1M HCl/NaI in a relative large volume 
(> 600 µL). 213Bi conjugates are labelled generally at pH 3.5 or higher, and highly concentrated 
buffers are to be used to adjust the pH of the labelling. Addition of quenchers or scavengers to 
protect the labelled peptide from radicals during labelling, increases the osmolarity (Osmol/L) of 
the labelling reaction even further than 0.3 Osmol/L. Direct administration of the 213Bi-labelled 
conjugated is impossible in small animals such as mice, since the maximum volume for intravenous 
injection in mice is 200 µL, at pH 7.4 with a osmolarity close to 0.3 Osmol/L, to avoid e.g. loss of 
venous endothelial cells and inflammatory cell infiltration, and to maintain homeostasis [87]. The 
requirements for (pre)clinical applications with PRRT or TAT are again summarized below.
The following requirements are typically required for PRRT or TAT in (pre)clinical ap-
plications:
• High molar activity radioligand with high tumour affinity and fast clearance from 
kidney and circulation
• Stable radioligand in vitro and in vivo
• Small injected volume (~200 µL) for small animals
• Physiological conditions of the drug (~pH 7.4, 0.3 Osmol/L)
• Renal protection
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OuTlinE Of This ThEsis
In this thesis we describe research on applications, limitations, and problems regarding 
213Bi for TAT in preclinical studies. DOTATATE was used as a model peptide, being a 
peptide analogue widely applied in NET patients. The objectives of this thesis were:
1. Optimizing 213Bi DOTA-peptide labelling for applications in mice
2. Determine the maximum tolerated dose and reduce nephrotoxicity using the kidney 
protectant L-lysine in mice
3. Pharmacokinetic and pharmacodynamics studies of 213Bi-DOTATATE in different NET 
models in mice
4. Comparison of the therapeutic effects of the α-emitter 213Bi, the β-emitter 177Lu and 
external beam radiation in in vitro studies
5. 213Bi-SPECT imaging in vivo in mice.
In our research we focused on 213Bi for PRRT/TAT in SSTR-expressing NET mouse models. 
In this first chapter the concept of PRS and PRRT and advantages of the use of α-emitters 
for TAT are explained. Moreover, the requirements for the labelling procedure and preclini-
cal applications of TAT are presented in Chapter 1.
Chapter 2 describes the optimized labelling procedure required for preclinical applications. 
The labelling conditions were adapted to meet the requirements for preclinical studies and 
to preserve the stability of 213Bi-DOTATATE.
In Chapter 3, peptide amount-dependent uptake in tumour tissue is described. L-Lysine, 
an amino acid to inhibit renal uptake, was applied during TAT with 213Bi-DOTATATE to 
decrease renal radioactivity and prolong survival. Furthermore, the maximum tolerated 
dose was estimated for renal tissue with and without renal protection. Acute kidney injury 
after TAT with 213Bi-DOTATATE was investigated to determine its dose-dependency by 
using NGAL, as renal marker of acute nephrotoxicity.
Chapter 4 describes the therapeutic efficacy of 213Bi-DOTATATE in different somatostatin 
receptor positive tumour models: CA20948 (rat pancreatic tumour) and H69 (human small 
lung carcinoma). Besides different tumour models, investigation of different tumour sizes 
was performed in tumours with sizes of 50 mm3–200 mm3, this to answer the question 
whether TAT with 213Bi-DOTATATE is suitable for therapy of larger tumours as well. Renal 
function was monitored by SPECT/CT after administration of 99mTc-DMSA.
In Chapter 5, a comparison of cytotoxic effects induced by213Bi-conjugates, 177Lu-conju-
gates and external radiation was performed in CA20948 and BON (human carcinoid) cell 
lines. In addition, the absorbed dose was calculated using a small-scale dosimetry model to 
compare the relative biological effects of these radiation types.
Chapter 6 describes the feasibility of imaging 213Bi with a dedicated small animal SPECT 
imaging device. Settings were tested related to the energy windows and image reconstruc-
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tion methods for 440 keV γ-rays and the lower energy X-rays. SPECT imaging of tumour 
uptake and physiological distribution was investigated. Ultimately dynamics scan was 
performed and the absorbed dose to the kidneys was calculated based on dynamic imaging 
data obtained with this SPECT system.
Chapter 7 provides the summary and concluding remarks.
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ABsTrAcT
Background:
213Bismuth (213Bi, T1/2 = 45.6 min) is one of the most frequently used α-emitters in cancer 
research. High specific activity radioligands are required for peptide receptor radionuclide 
therapy. The use of generators containing less than 222 MBq 225Ac (actinium), due to 
limited availability and the high cost to produce large-scale 225Ac/213Bi generators, might 
complicate in vitro and in vivo applications though.
Here we present optimized labelling conditions of a DOTA-peptide with an 225Ac/213Bi gen-
erator (< 222 MBq) for preclinical applications using DOTA-Tyr3-octreotate (DOTATATE), 
a somatostatin analogue. The following labelling conditions of DOTATATE with 213Bi were 
investigated; peptide mass was varied from 1.7–7.0 nmol, concentration of TRIS buffer 
from 0.15 mol.L-1 to 0.34 mol.L-1, and ascorbic acid from 0 to 71 mmol.L-1 in 800 µL. All 
reactions were performed at 95°C for 5 min. After incubation, DTPA (50 nmol) was added 
to stop the labelling reaction. Besides optimizing the labelling conditions, incorporation 
yield was determined by ITLC-SG and radiochemical purity (RCP) was monitored by RP-
HPLC up to 120 min after labelling. Dosimetry studies in the reaction vial were performed 
using Monte Carlo and in vitro clonogenic assay was performed with a rat pancreatic 
tumour cell line, CA20948.
results:
At least 3.5 nmol DOTATATE was required to obtain incorporation ≥ 99 % with 100 MBq 
213Bi (at optimized pH conditions, pH 8.3 with 0.15 mol.L-1 TRIS) in a reaction volume 
of 800 µL. The cumulative absorbed dose in the reaction vial was 230 Gy/100 MBq in 30 
min. A minimal final concentration of 0.9 mmol.L-1 ascorbic acid was required for ~100 
MBq (t = 0) to minimize radiation damage of DOTATATE. The osmolarity was decreased 
to 0.45 Osmol/L.
Under optimized labelling conditions, 213Bi-DOTATATE remained stable up to 2 h after 
labelling, RCP was ≥ 85 %. In vitro showed a negative correlation between ascorbic acid 
concentration and cell survival.
conclusion:
213Bismuth-DOTA-peptide labelling conditions including peptide amount, quencher and pH 
were optimized to meet the requirements needed for preclinical applications in peptide 
receptor radionuclide therapy.
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BAckgrOunD
Peptide receptor radionuclide therapy (PRRT) is an effective treatment for metastatic and 
inoperable neuroendocrine tumours [1–3]. The most common radionuclides used for PRRT 
include 177Lu (β--emitter, T1/2 = 6.71 days, 149 and 497 keV) and 90Y (β--emitter, T1/2 = 64.1 
h, 935 and 2284 keV).
α-Emitters have been demonstrated to offer an additional treatment option for patients 
refractory to standard PRRT with β--emitters or chemotherapy [4–6]. Moreover, α-particles 
have short path length in tissue (~80 μm), sparing non-target tissues from radiation. 213Bi 
(T1/2 = 45.6 min) is an α-emitter and has been applied in several (pre)clinical research stud-
ies of targeted alpha therapy (TAT) [4, 5, 7–9].
PRRT is based on receptor-mediated processes. In order to achieve treatment success, 
a sufficient cytotoxic dose of radio-peptide must be delivered to the targeted cells [10]. 
Moreover, the number of receptors available on the cell membrane is limited, so high specific 
activity (SA, expressed in MBq per nmol of peptide) of labelled peptides is advantageous 
for administration in small animals e.g. mice (~25 g) [11–13]. Besides high SA, other 
requirements for preclinical applications include high stability of the radio-peptide at 
physiological conditions in vitro (~0.3 Osmol.L-1, pH ~7.4) and in vivo. In additional, a 
high osmolarity of the drug-containing solution is inconsistent with maintenance of physio-
logical conditions for in vitro and in vivo applications.
Due to the limited availability and the high cost to produce large-scale 225Ac/213Bi genera-
tors, preclinical studies with 213Bi are often being performed using relatively low activity 
generators (e.g. 222 MBq 225Ac). Under these conditions, the standard clinical labelling 
procedure for 213Bi, which was designed for high activity generators (up to 4 GBq) with a 
reaction volume of 2 mL at > 0.7 Osmol.L-1 [14], probably needs to be adjusted. Therefore, 
the labelling conditions for preclinical applications required modifications.
In this study, we systematically studied the consequences using the somatostatin analogue 
[DOTA0, Tyr3]-octreotate (DOTATATE) as a model for optimizing labelling conditions of 
213Bi for preclinical applications, starting from the standard labelling protocol.
Herein we varied the labelling conditions such as peptide amount, quenchers and pH. The 
stability of the labelled peptide and the radiochemical purity (RCP) was monitored up to 2 h 
after labelling. The absorbed dose rates of 213Bi, 213Po, 209Tl and 209Pb (mGy.s-1) as function 
of reaction volume were calculated. The use of the absorbed dose rate is investigated as 
a possible surrogate indicator for the ionization probability and consequential radiolysis 
to the peptide in the reaction vial. And lastly, in vitro clonogenic assay was performed to 
investigate the influence caused by labelling conditions used.
The objective of this study was to establish a practical, ready to use, and reproducible 
labelling procedure of 213Bi-DOTATATE to meet the constraint for the use of peptide as 
radiopharmaceutical for preclinical applications.
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mEThODs
213Bi-elution
The 225Ac/213Bi generator (222 MBq) was supplied by the Institute for Transuranium Elements 
(ITU), Germany. Prior to elution, the column was rinsed with diluted HCl (0.01 mol.L-1). 213Bi 
was eluted from the 225Ac/213Bi generator by NaI/HCl (0.1 mol.L-1/0.1 mol.L-1) in a volume of 
600 µL. After elution the column was rinsed and stored with diluted HCl (0.01 mol.L-1) [15].
standard protocol radiolabelling of 213Bi-DOTATATE
DOTATATE (DOTA-DPhe-Cys-Tyr-DTrp-Lys-Thr-Cys-Thr, Mw 1436 g/mol) was pur-
chased from BioSynthema (St. Louis, MO, USA). All chemicals were purchased from 
Sigma-Aldrich (Zwijndrecht, the Netherlands).
The following standard labelling protocol was applied: 213Bi (600 µL) was added to DOTA-
TATE (7.0 nmol), TRIS buffer (0.34 mol.L-1), ascorbic acid (71 mmol.L-1) and MilliQ water 
in a final volume 800 µL at pH 8.7. The reaction was incubated for 5 min at 95°C. The 
radionuclide incorporation reaction was halted by cooling the mixture for 2 min in ice and 
through the addition of 50 nmol diethylenetriaminepentaacetic acid (DTPA, Erasmus MC 
Pharmacy) to chelate any unbound or “free” 213Bi.
labelling optimization for preclinical studies
Standard labelling protocol was used as described above, while varying the following condi-
tions:
1. Peptide mass; labelling was performed with 1.7, 3.5 and 7.0 nmol DOTATATE.
2. pH dependence study; 7.0 nmol DOTATATE was labelled in a reaction containing 71 
mmol.L-1 ascorbic acid and 0.15 mol.L-1 and 0.34 mol.L-1 TRIS buffer.
3. Quencher dependence study; in absence of ascorbic acid and 0.1, 0.3, 0.9, 2.6, 7.9, 24 
and 71 mmol.L-1 ascorbic acid.
Quality control of radiolabelled peptide
The quality control of labelled peptides was determined by ITLC-SG (instant thin layer 
chromatography silica gel, Varian) and HPLC (high performance liquid chromatography).
Incorporation yield (expressed as mean ± SD) was determined by ITLC using sodium 
citrate (0.1 mol.L-1, pH 5) as mobile phase. The 213Bi activity was determined by HPGe 
detector with a pulse height multichannel analysis (MetorX, Goedereede, The Netherlands 
and Software Genie 2000 Canberra) at fixed geometry, all measurements were performed 
for the 440 keV γ-emission by 213Bi with a yield of 0.261 per decay. The counting efficiency 
of the HPGe detector at 440 keV γ-emission was determined using a known amount of 
225Ac activity provided and calibrated by ITU, Germany [15–17].
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The RCP (expressed as percentage ± SD intact radio-peptide of interest, compared to other 
detectable radioactive compounds in the same analysis) and stability of the labelled peptide 
as function of time were determined by HPLC. HPLC-grade methanol and trifluoracetic 
acid (TFA) were purchased from Mallinckrodt Baker (Deventer, the Netherlands). The 
HPLC system (Waters 2695 separation module, Alliance, Waters, Etten-Leur, The Nether-
lands) consisted of a quaternary pump and an autosampler, Waters 2996 photodiode array 
detector (Waters, Etten-Leur, The Netherlands), radiometric sodium iodide detector (Can-
berra, Canberra, Genie 2000) and symmetry C18 5µm column, 4.6 mm×250 mm (Waters, 
Etten-Leur, The Netherlands). The mobile phase consisted of buffer A (0.1 % TFA in water) 
and buffer B (Methanol). The gradient used for the analysis was as described earlier [18]. 
The retention times of the unlabelled DOTATATE and 213Bi-DOTATATE were 12.0 ± 0.3 
min and 13.0 ± 0.3 min, respectively.
Dosimetry model of 213Bi exposure in reaction vials
The degradation of radiopharmaceuticals by radiolysis is dependent on the amount of energy 
absorbed within the ligand. Most of the α-particle energy emitted by 213Bi and its daughter 
213Po will be absorbed within the reaction vial with the 213Bi-labelled compound, as their 
particle ranges in water are smaller than the vial dimensions. The energy emitted by the α- and 
β--particles from 213Bi itself and its daughters 209Tl and 209Pb, however, will not be completely 
absorbed within the small vials. The activity as a function of time for 213Bi, 213Po, 209 Tl and 
209Pb was calculated by the Bateman equations, see Equation 1. The β--emission spectra are 
summarized in Table 1 together with their ranges in water, from the NIST Star database 
(http://www.nist.gov/pml/data/star/; assessed 27–11-‘15). The α-particle energies from 213Bi 
and 213Po are also indicated with their projected ranges as calculated with the Stopping and 
Range of Ions in Matter (SRIM version 2013.00 software; www.SRIM.org). The recoil ener-
gies from the α-particle emissions are 112 keV (213Bi) and 160 keV (213Po) [19].
Table 1, α- and β-particle emissions by 213Bi and its daughters, emission abundances per decay of 213Bi 
or daughter nuclide and energies are from the MIRD Radionuclide data and decay schemes book (Eck-
erman, 2008). Particle ranges (mm) in water were determined from the NIST Star database (electrons) 
and with the SRIM code (α-particles). Abundance (Ab.) is expressed in % decay and energy (E) in MeV
α-particles Ab. (%/decay) E (meV) range (µm)
213Bi 1.94 5.87 46.47
213po 100 8.38 81.75
β-particles Ab. (%/decay) Emean (meV) range (mm) Emax (meV) range (mm)
213Bi 97.91 0.434 1.45 1.422 6.65
209Tl 100 0.655 2.55 1.944 9.48
209pb 100 0.197 0.44 0.644 2.49
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Radiation transport was calculated for 213Bi containing liquid inside reaction vials to determine the 
absorbed energy and absorbed dose to the hot liquid. The Monte Carlo codes MCNP5 [20] and MCNPX 
[21] were used for the calculations. Calculations for the α-particles from 213Bi and 213Po were performed 
with MCNPX using the α-particle energies listed in Table 1. The β--spectra and low-energy internal 
conversion and Auger electron spectra for 213Bi, 209Tl and 209Pb from MIRD Radionuclide data and decay 
schemes book [19] were used in MCNP5. Particulate radiation emissions with the given energy spectra 
were simulated so as to be uniformly distributed within a conical reaction vial with isotropic direction 
emission. All physics processes were taken into account by choosing either the α (MODE A) or the 
photon–electron mode (MODE P E) and the default PHYS cards with the default cut-off energy at 1 keV 
for electrons and photons and 4 MeV for α-particles. The *F8 tally determined energy absorption within 
the hot reaction fluid. Sufficient particle histories (NPS) were used to reduce the variation in the data to be 
less than 5% for most cases; NPS was set to 1 × 107 particles. A conically shaped 1 mL reaction vial was 
modelled with various volumes of radioactive fluid inside the vial. The MCNP-model geometry for a vial 
containing 0.8 mL liquid is shown in Fig. 1. The labelling volumes were modelled: 10, 50, 100, 200, 400 
and 800 µL by adjusting the reaction fluid level accordingly. Average dose rates were determined in the 
vial volume. 
  
Radiation transport was calculated for 213Bi containing liquid inside reaction vials to 
determine the absorbed energy and absorbed dose to the hot liquid. The Monte Carlo 
codes MCNP5 [20] and MCNPX [21] were used for the calculations. Calculations for the 
α-particles from 213Bi and 213Po were performed with MCNPX using the α-particle energies 
listed in Table 1. The β--spectra and low-energy internal conversion and Auger electron 
spectra for 213Bi, 209Tl and 209Pb from MIRD Radionuclide data and decay schemes book 
[19] were used in MCNP5. Particulate radiation emissions with the given energy spectra 
were simulated so as to be uniformly distributed within a conical reaction vial with isotropic 
direction emission. All physics processes were taken into account by choosing either the 
α (MODE A) or the photon–electron mode (MODE P E) and the default PHYS cards with 
the default cut-off energy at 1 keV for electrons and photons and 4 MeV for α-particles. 
The *F8 tally determined energy absorption within the hot reaction fluid. Sufficient particle 
histories (NPS) were used to reduce the variation in the data to be less than 5 % for most 
cases; NPS was set to 1 × 107 particles. A conically shaped 1 mL reaction vial was modelled 
with various volumes of radioactive fluid inside the vial. The MCNP-model geometry for 
a vial containing 0.8 mL liquid is shown in Fig. 1. The labelling volumes were modelled: 
10, 50, 100, 200, 400 and 800 µL by adjusting the reaction fluid level accordingly. Average 
dose rates were determined in the vial volume.
In vitro clonogenic assay
For in vitro clonogenic assays the CA20948 cell line (derived from a rat pancreas tumour 
at our institute Erasmus MC) was used. CA20948 is a rat pancreatic tumour cell line 
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with relative high expression of somatostatin receptor type 2 (SSTR2), and was cultured 
in DMEM supplemented with 10 % fetal calf serum (FBS, Gibco, Life technologies). 
Cells (500 cells/well) were seeded in 6-wellplates pre-coated with poly-l-lysine 24 h 
before exposure to the compounds used for labelling, except for peptide and 213Bi. For 
clonogenic assay, 400 µL of standard labelling procedure was used, and diluted in 8 mL 
incubation medium containing 30 mmol.L-1 HEPES and 0.25 % BSA. The concentra-
tion of TRIS, ascorbic acid, NaI, HCl and DTPA corresponded to 16, 3.4, 3.6, 3.6, and 
6.1×10–3 mmol.L-1, respectively. Cells were incubated with compounds for 1 h at 37°C in 
a humidified atmosphere of 5 % CO2 and 95 % air. Untreated CA20948 cells were used as 
control. After 1 h, incubation medium containing labelling compounds was removed from 
cells, cells were washed twice with PBS and incubated with culture medium containing 
10 % FBS for 12 days. Every 2 or 3 days, culture medium was replaced by fresh me-
dium. At day 12, colonies were fixed with 100 % ethanol and stained with hematoxyline. 
Survival colonies were counted and the survival CA20948 was determined. Clonogenic 
assay with CA20948 as function of ascorbic acid was also performed with the method 
described above.
rEsulTs
labelling
The standard labelling protocol 213Bi-DOTATATE resulted in an incorporation > 99 % and a 
RCP > 85 % at pH 8.7 for up to 2 h after labelling. The calculated osmolarity of the labelling 
using the standard procedure was 0.7 Osmol.L-1.
figure 1, MCNP geometry input for 1 mL reaction vial with 0.8 mL radioactive fluid (in blue), water 
with density 1 g/mL. The vial wall (in grey) had a thickness of 0.65 mm and was polyethylene with 
density 0.9 g/mL.
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Labelling with 1.7 nmol DOTATATE in 800 µL resulted in low incorporation of 6 ± 4 % and 
poor RCP of 5 ± 5 % (median: 6.9 % (range: 0 – 8.6 %)), see Fig. 2. A high incorporation and 
high RCP were found when labelled with 3.5 nmol (incorporation was 99 ± 1 %, RCP was 
89 ± 4 %) and 7.0 nmol peptide (incorporation was 99 ± 1 %, RCP was 88 ± 6 %).
Reducing the amount of TRIS buff er in the labelling did not show an eff ect on the incorporation 
of the labelled compound, incorporation of > 99 % and a RCP of > 85 % were found for labelling 
with 0.15 mol.L-1 and 0.34 mol.L-1 TRIS, corresponding to pH 8.3 and 8.7, respectively.
After labelling in the presence of ascorbic acid under the standard procedure, an incorpora-
tion of > 99 % and a RCP of > 85 % were found, Fig. 3A. Labelling in absence of ascorbic acid 
however showed a high incorporation of 99 ± 1 % but at poor RCP, < 5 % 213Bi-DOTATATE 
remained intact after labelling, as shown in the HPLC chromatogram, Fig. 3B.
To decrease the osmolarity 213Bi-DOTATATE labelling, labelling as function of ascorbic 
acid was performed, it showed that at least 0.9 mmol.L-1 ascorbic acid was required 
to maintain high incorporation and high RCP (> 85 %). The labelled peptide showed a 
RCP > 85 % up to 2 h after labelling. A RCP of 75 ± 8 %, 83 ± 1 %, 87 ± 1 %, 86 ± 1 %, 
86 ± 1 %, 87 ± 1 %, 88 ± 0.4 % were found by addition of 0.1 mmol.L-1, 0.3 mmol.L-1, 
0.9 mmol.L-1, 2.6 mmol.L-1, 7.9 mmol.L-1, 24 mmol.L-1 and 79 mmol.L-1 ascorbic acid, 
respectively. Addition of less than 0.9 mmol.L-1 ascorbic acid resulted in high incorporation 
directly after radiolabeling, however the RCP decreased over time, see Fig. 4.
The adjusted labelling conditions in our experiment were 3.5–7.0 nmol peptide, in 0.15 
mol.L-1 TRIS buff er containing 2.6 mmol.L-1 ascorbic acid in a reaction volume of 800 µL 
with 71 ± 28 MBq 213Bi, with a calculated osmolarity of 0.45 Osmol.L-1.
figure 2, The incorporation (%) of 213Bi-DOTATATE 71 ± 28 MBq determined by ITLC analysis as 
function of peptide amount in a reaction volume of 800 µL. An S-shaped cureve has been fi tted through 
the data with an incorporation of 50 % at 2.4 ± 0.09 nmol and a slope of 0.25 ± 0.03 nmol peptide, n≥ 3.
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figure 3, HPLC chromatogram of 213Bi-DOTATATE in presence (A) and absence (B) of ascorbic acid 
during labelling (n≥ 3). Peak A; RT = 13.0 min and peak B; RT = 16.3 min. The y-axis represents the 
detected radioactive signals (mV) and x-axis represents the RT in minutes.
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figure 4, Stability as function of time of 213Bi-DOTATATE with different concentration ascorbic acid 
added during labelling, y-axis is RCP expressed in mean percentage ± SD and x-axis time in minutes 
after labelling (n≥ 3).
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Dosimetry
The absorbed fraction of energy from the α-particles from 213Bi was almost complete within 
the reaction fluids, 98.9 % for the 10 µL reaction volume and further rose to 99.7 % for 800 
µL. The higher energy α-particles from 213Po showed a little more energy transfer to the vial 
wall; 97.2 % was absorbed in 10 µL and 99.2 % in 800 µL. The absorbed dose rate caused 
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figure 5, Time-integrated activity of 213Bi, 213Po, 209Tl and 209Pb determined by Bateman equations (A) 
and the resultant total absorbed dose rate (B) as a function of time, see Table 2. The majority of the ab-
sorbed dose rate (96 % at 60 min) is caused by the α-particles from 213Bi and 213Po.
Table 2, Absorbed dose rates per unit activity (S-values, in mGy/MBq.s) in the reaction fluid for dif-
ferent volumes of 213Bi, 213Po, 209Tl and 209Pb. The different contributes to the S-value (α, β, low energy 
electrons and γ-rays) are indicated separately
213Bi 10 µl 50 µl 100 µl 200 µl 400 µl 800 µl
 5.97MeV α 1.94 0.39 0.19 0.097 0.049 0.024
β-particles 2.98 0.80 0.44 0.24 0.13 0.066
Auger + ic e- 0.20 0.048 0.026 0.013 0.0067 0.0034
γ-rays 0.0054 0.0019 0.0012 0.0007 0.0005 0.0003
Total 5.12 1.24 0.67 0.35 0.18 0.094
213po
8.38MeV α 130 26.4 13.3 6.6 3.3 1.7
209Tl
β-particles 3.17 0.94 0.55 0.30 0.17 0.08
Auger + ic e- 0.36 0.08 0.04 0.02 0.01 0.01
γ-rays 0.04 0.02 0.01 0.01 0.00 0.00
Total 3.57 1.03 0.60 0.33 0.18 0.09
209pb
β-particles 2.33 0.53 0.28 0.14 0.07 0.04
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by 213Bi, 213Po, 209 Tl and 209Pb were predominantly contributed by the α-particles from 
213Bi and 213Po, see Fig. 5A. The β--particles and low energy electrons were less absorbed 
within the reaction fluid, e.g. the absorbed fraction of energy by β--particles from 213Bi 
ranges from 44 % (10 µL) to 77 % (800 µL). The relative contribution of the β--particles 
to the total 213Bi S-value thus raised from 58 % to 70 %. The absorbed dose rate caused by 
α-particles (initially 165 mGy.s-1) continued to be high compared to the absorbed dose rate 
of β--particles (initially 7 mGy.s-1), see Fig. 5B.
Based on the absorbed dose rate, see Table 2, the estimated absorbed dose for 100 MBq was 
> 230 Gy at 30 min in a reaction vial containing 800 µL hot reaction fluid. The absorbed 
dose was predominantly caused by the decay of α-particles, see Fig. 5B.
clonogenic assay
In all cells treated in present of ascorbic acid (corresponding to 3.4 mmol.L-1 in incubation 
medium), a significant decrease of survival was found compared to control cells, P < 0.05, see 
Fig. 6. Control cell survival was 100 % with a standard deviation of 12 %. The mean cell survival 
± SD of CA20948 after exposure to ascorbic acid or in combination with TRIS, NaI, HCl and 
DTPA was listed in Table 3. The concentration of TRIS, NaI, HCl, and DTPA in incubation 
medium was 16 mmol.L-1, 3.6 mmol.L-1, 3.6 mmol.L-1 and 6.1×10–3 mmol.L-1, respectively.
Reducing the concentration of ascorbic acid during the labelling, resulted in an increase of 
cell survival, see Fig. 7.
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figure 6, Survival (%) ± SD of CA20948 after exposing to the compounds used in standard labelling 
procedure, n = 3. Concentration in incubation medium was; [TRIS] = 16 mmol.L-1, [AA]=ascorbic acid, 
3.4 mmol.L-1, [NaI] = 3.6 mmol.L-1, [HCl] = 3.6 mmol.L-1 and [DTPA] = 6.1×10–3 mmol.L-1.
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DiscussiOn
A cytotoxic dose within the tumour cells is required to cause a therapeutic effect of TAT, 
when using a receptor-mediated process as dose delivery method. In the clinical situation 
using β--emitters, this cytotoxic dose is in the order of 200 Gy for neuroendocrine tumours 
[22, 23] and in the preclinical situation this dose is in the order of 70 Gy for cure of 
CA20948 (rat pancreatic) tumour [24]. The limited number of receptors available on the 
cell membrane and relative short half-life of 213Bi however, require radioligands with high 
SA to obtain a curative tumour dose. The optimal characteristics of radioligands for TAT 
applications in a preclinical setting include a low injection volume, physiologic osmolarity, 
high SA, and suitable stability. Labelling with a radionuclide generator yielding relatively 
low radioactivity is a barrier for high SA radiolabelling.
The most commonly techniques used to increase the SA are purification of the elution by 
ion-exchange chromatography or by radiolabelling using fractionated elution to reduce the 
Table 3, CA20948 clonogenic survival in mean percentage ± SD after exposing to ascorbic acid or 
in combination with TRIS, NaI, HCl and DTPA, n = 3. Concentration in incubation medium was; 
[TRIS] = 16 mmol.L-1, [AA] = ascorbic acid, 3.4 mmol.L-1, [NaI] = 3.6 mmol.L-1, [HCl] = 3.6 mmol.L-1 
and [DTPA] = 6.1×10–3 mmol.L-1
compounds survival %
AA 11 ± 1
Tris+AA 1 ± 1
nai+hcl+AA 27 ± 5
Tris+nai+hcl+AA+DTpA 1 ± 1
AA+nai 11 ± 4
AA+hcl 12 ± 7
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figure 7, Survival (%) ± SD of CA20948 as function of concentration of ascorbic acid in DMEM incu-
bation medium containing 30 mM HEPES and 0.25 % BSA (total volume was 8.4 mL), n = 3.
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reaction volume which may improve the reaction kinetics. This may allow high incorpora-
tion yield with lower peptide amounts and thus increase the SA of the radio-peptide. To 
mimic this concept, 213Bi-DOTATATE labelling was performed with half of the elution 
volume to a reach lower reaction volume (total 400 μL), high incorporation yield was 
achieved even at reduced amount of peptide, e.g. 1.7 nmol (data not shown).
The most practical method to achieve high SA radiolabelling for preclinical applications is 
the use of a higher activity 225Ac/213Bi generator to accomplish the requirements needed for 
preclinical applications. Purification, e.g. by HPLC or solid phase extraction, might increase 
the SA. However, introduction of an extra purification step also increases the time interval 
prior to injection and thus reduces the 213Bi radioactivity. Moreover, HPLC purification 
often introduces organic compounds e.g. methanol or acetonitrile into the radiolabelling, 
which might be harmful to animals and limit further translation to clinical studies.
We found a correlation of ascorbic acid on cell survival; at high concentration of ascorbic 
acid used for labelling (71 mmol.L-1, corresponding to 3.4 mmol.L-1 in incubation medium), 
a significant reduction of cell survival was observed. A lower reduction of cell survival was 
found with only or in combination with NaI, HCl, TRIS and DTPA compared to control 
cells, probably caused by the high osmolarity of NaI, HCl, TRIS or Zn-depletion to cells 
by DTPA [25], however this reduction was not significant. Ascorbic acid, functioning as 
pro-oxidant, is known to be selectively toxic, especially in vitro to certain type of tumour 
cells at high concentration [26]. C18 solid phase extraction can be an option to prevent this 
by removing ascorbic acid from the labelling reaction. However, radiolysis continues to 
occur after labelling, and removing ascorbic acid might increase peptide damage caused 
by radiolysis. After optimizing the labelling conditions, the concentration of ascorbic acid 
used for labelling (2.6 mmol.L-1, corresponding to 0.13 mmol.L-1 in incubation medium) 
did not interfere with the outcomes of in vitro studies, therefore direct application can be 
performed and no purifications steps were required for further in vitro and in vivo preclini-
cal applications.
In theory, one DOTA-peptide molecule can incorporate one atom 213Bi, thus at a molar ratio 
of 1 metal vs DOTA, under ideal condition the maximum theoretical SA will be 155 GBq 
213Bi /nmol DOTA-peptide. In a study investigating the highest achievable SA, 7.0 nmol 
DOTATATE was labelled with different mole ratios 209/213Bi using the standard labelling 
procedure. At mole ratio of 0.6 209/213Bi vs DOTATATE, the incorporation was ≥ 99 %. At 
mole ratio > 0.6, the incorporation started to decline, possibly caused by the presence of 
other cations (derived from decay product of 213Bi, quencher, buffer, elution solution) in the 
labelling reaction which interfered with the incorporation of 213Bi into DOTA-moiety [27, 
28]. In theory, a SA of 93 GBq/nmol DOTATATE (at mole ratio 213Bi 0.6) can be achieved 
under these labelling conditions.
Radiolabelling of 213Bi is less pH-dependent (in the range tested) as is the case of 111In 
and 177Lu with formation of insoluble 111InOCl or 177LuOCl [29]. Radiolabelling with 213Bi 
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can be performed at pH values ranging from 4.0 to 10 [7, 30, 31], due to the formation 
BiI4-/BiI52- after elution with 0.1 M/0.1 M HCl/NaI [15]. However, deprotonation of the 
carboxyl group of the DOTA appears faster at higher pH and resulting in more rapid 
radiolabelling kinetics [32, 33].
In this study, we highlighted that ITLC-SG alone as quality control is not sufficient, see 
labelling in absence and presence of ascorbic acid. HPLC provides beside the incorporation 
yield also information of peptide damage caused by α-track or radiolysis. The formation 
of free radicals is dependent on the type of radiation, the amount radioactivity present in 
the reaction mixture and on the duration of exposure, all of which have been shown to 
induce radiation damage of the peptide. Quenchers such as gentisic acid in combination 
with ascorbic acid and ethanol are often used to prevent radiolysis in radiolabelling with 
111In or 177Lu [34]. Radiolysis leads to damage of peptide and will decrease the RCP.
With α-radiation more water radicals, such as peroxide, will be formed besides the direct 
radiation damage from the high LET α-particle tracks [35]. Stanton et al. observed more 
biological efficacy on SV40 viral DNA in vitro caused by low LET compared to high LET 
and Sugo et al. demonstrated less degradation of TODGA, a tridentate complexing agent, 
after irradiation with helium ion beam than that by that of γ-ray irradiation [36, 37]. Since 
the activated radicals are formed along the α-particle tracks and therefore decreasing the 
probability for damage by both the direct and the radical induced effect in the reaction solu-
tion, thus a lower amount of quenchers is required to prevent radical damage to the peptide. 
In our case, ascorbic acid alone showed sufficient protection capacity to prevent damage to 
the peptide, so no other quenchers were introduced to the labelling, also to prevent further 
increase of the osmolarity. Higher osmolarity would require further diluting of the injection 
matrix for small-animals applications, leading to lower radioactivity injections for effective 
TAT in small animals.
Here we present detailed results obtained with MCNP calculations of the absorbed dose 
of 213Bi in the reaction vial. The calculated absorbed dose is an average absorbed dose 
estimated in a vial of 800 µL, mostly caused by α-particles, but also including doses from 
β--particles and γ-rays emitted by the decay daughters of 213Bi. As shown in Fig. 4, 0.9 
mmol.L-1 ascorbic acid was required to protect the peptide in a vial containing 71 ± 28 
MBq in 800 μL, with an absorbed dose of ~200 Gy. At higher radioactivities of 213Bi or 
smaller reaction volumes, more ascorbic acid was required to protect the peptide, since 
the absorbed dose in the reaction vial increased and formation of radicals also increased. 
These doses are much lower than the absorbed doses considered to cause radiation damage 
in DTPA and TODGA, which are in the order of 100 kGy [36, 37]. The main sensitive 
region for radiation damage will therefore be in the DOTATATE’s disulfide bond and its 
other ionized parts, as the DOTA cage may be considered not to be damaged at the “low” 
absorbed doses considered.
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The activation energy for the DOTA ring inversion process is in the order of 65 kJ/mol 
[38]. The initial dose rate by the α-radiation in the vial with 100 MBq 213Bi amounts 165 
mGy/s, which corresponds to an absorbed energy rate of 0.13 mJ/s in 800 μL with 7 nmol 
compound, or 19 kJ/mol.s. This indicative calculation shows that the momentary dose rate 
is on average not energetic enough to create configuration changes within the DOTA ring. 
The energy of 65 kJ/mol is reached within 3.5 s.
Stability, incorporation yield and SA of 213Bi-labelled peptides are influenced by the affin-
ity/stability of the metal-chelator complex, radiolysis or by the recoil effect both during 
and after labelling. High LET α-particles cause reactive hydrogen radicals in an aqueous 
environment [39]. These radicals damage the peptide, which can lead to losses of affinity 
of the peptide to its receptor. The relative high recoil energy of 213Po, 160 keV, is a critical 
challenge for the choice of chelator, since complexation of metal and chelator is dependent 
on the binding energy. This complex should remain stable until reaching the targeted 
receptor. DOTA (with a Log K of 30.3) is not considered to be the most suitable chelator 
for 213Bi, due to relative poor labelling kinetics compared to derivatives of DTPA, e.g. 
CHX-A-DTPA [40, 41]. Nevertheless, we demonstrated that 213Bi formed a highly stable 
complex with DOTA in a relative short radiolabelling time of 5 min. Furthermore, under 
optimized radiolabelling conditions, the labelling remained stable up to 2 h after labelling.
cOnclusiOn
The optimized 213Bi labelling conditions demonstrated to be suitable for labelling of 
DOTATATE and proofed ready-to-use for preclinical applications. The labelling procedure 
presented herein resulted in high incorporation yield, high RCP and high stability up to 2 h 
after labelling. The addition of quenchers such as ascorbic acid during labelling appeared 
essential for the protection of the peptide, since the absorbed dose rate within the reaction 
was high; > 165 mGy.s-1 with 100 MBq of 213Bi.
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ABsTrAcT
Background:
Targeted alpha therapy (TAT) offers advantages over current β-emitting conjugates for pep-
tide receptor radionuclide therapy (PRRT) of neuroendocrine tumours. PRRT with 177Lu-
DOTATATE or 90Y-DOTATOC has shown dose-limiting nephrotoxicity due to radiopeptide 
retention in the proximal tubules. Pharmacological protection can reduce renal uptake of 
radiopeptides, e.g. positively charged amino acids, to saturate in the proximal tubules, 
thereby enabling higher radioactivity to be safely administered. The aim of this preclinical 
study was to evaluate the therapeutic effect of 213Bi-DOTATATE with and without renal 
protection using L-lysine in mice. Tumour uptake and kinetics as a function of injected 
mass of peptide (range: 0.03–3 nmol) were investigated using 111In-DOTATATE. These re-
sults allowed estimation of the mean radiation absorbed tumour dose for 213Bi-DOTATATE. 
Pharmacokinetics and dosimetry of 213Bi-DOTATATE was determined in mice, in combina-
tion with renal protection. A dose escalation study with 213Bi-DOTATATE was performed 
to determine the maximum tolerated dose (MTD) with and without pre-administration of 
L-lysine as for renal protection. Neutrophil gelatinase-associated lipocalin (NGAL) served 
as renal biomarker to determine kidney injury.
results:
The maximum mean radiation absorbed tumour dose occurred at 0.03 nmol and the mini-
mum at 3 nmol. Similar mean radiation absorbed tumour doses were determined for 0.1 
nmol and 0.3 nmol with a mean radiation absorbed dose of approximately 0.5 Gy/MBq 
213Bi-DOTATATE. The optimal mass of injected peptide was found to be 0.3 nmol. Tumour 
uptake was similar for 111In-DOTATATE and 213Bi-DOTATATE at 0.3 nmol peptide. Lysine 
reduced the renal uptake of 213Bi-DOTATATE by 50 % with no effect on the tumour uptake. 
The MTD was < 13.0 ± 1.6 MBq in absence of L-lysine and 21.7 ± 1.9 MBq with L-lysine 
renal protection, both imparting an LD50 mean renal radiation absorbed dose of 20 Gy. A 
correlation was found between the amount of injected radioactivity and NGAL levels.
conclusion:
The therapeutic potential of 213Bi-DOTATATE was illustrated by significantly decreased 
tumour burden and improved overall survival. Renal protection with L-lysine immediately 
prior to TAT with 213Bi-DOTATATE prolonged survival providing substantial evidence for 
pharmacological nephron blockade to mitigate nephrotoxicity.
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BAckgrOunD
Targeted alpha therapy (TAT) has shown great promise in the treatment of both micro-
metastatic [1] and large solid tumours in preclinical and clinical studies [2, 3]. Alpha-
emitters emit high linear energy transfer (LET) α-particles, each causing dense ion pairs 
(2000–7000) within a relative short path length (50–100 µm) [3]. The radioactive decay of 
213bismuth (213Bi, T1/2 = 46 min) results in the emission of high-LET α-particles by 213Bi self 
and by its daughter 213Po around 100 keV/µm. Due to the relative short half-life of 213Bi, 
213Bi can deliver a high radiation dose rate to the target within a relatively short period of 
time. These physical characteristics make 213Bi, one of the most commonly used α-emitters 
for medical applications, with demonstrated promise as TAT in preclinical studies, in vivo 
imaging, and in clinical treatment of cancer patients [1, 4, 5].
Peptide receptor radionuclide therapy (PRRT) with radiolabelled somatostatin analogues 
is commonly employed in patients with inoperable neuroendocrine tumours (NETs) 
overexpressing somatostatin receptors subtype 2 (SSTR2). Current radiopeptides include; 
177Lu-[DOTA0,Tyr3]octreotate (177Lu-DOTATATE) and 90Y-[DOTA0,Tyr3]octreotide (90Y-
DOTATOC). Its efficacy depends on the radiation absorbed dose delivered to the tumour, 
which depends on SSTR2 targeting efficiency, clearance kinetics, perfusion, distribution, 
and tumour mass. High-specific activity radiopeptides are required to deliver adequate 
radiation absorbed dose to tumours, as the mass of injected peptide is limited by the high 
affinity but low capacity of SSTR2-expression systems. The mass of injected peptide influ-
ences the pharmacokinetics (PK) and absorbed doses in organs and tumours [6]. Therefore, 
the mass of injected peptide should be optimized to deliver efficacious tumour doses while 
avoiding toxic absorbed dose to organs, especially to the dose-limiting organs the kidneys 
and bone marrow [7, 8].
Radiolabelled somatostatin analogues are known to accumulate in the renal proximal 
tubules, due to their net charge, electrostatic forces, and charge distribution from metal-
chelation [9, 10]. This can result in a high absorbed dose and subsequent renal dysfunction. 
Co-infusion of L-lysine/L-arginine has been shown to reduce renal uptake in patients 
receiving 177Lu-DOTATATE or 177Lu-DOTATOC PRRT by 30–50 % [11].
Several preclinical studies showed that TAT with 213Bi resulted in high renal accumulation 
of radioactivity [12], causing nephrotoxicity and decreased survival without renal protec-
tion compared to animals receiving protection [13, 14]. Evidence of acute or chronic inter-
stitial nephritis was found in a previous dose escalation study in AR42J tumour-bearing rats 
using 213Bi-DOTATOC [2]. Nephrotoxicity was observed to be moderate in a clinical trial 
of 213Bi-DOTATOC, in combination with renal protection, in patients’ refractory to 177Lu-
DOTATATE or 90Y-DOTATOC PRRT [3]. Conventional approaches to determine kidney 
function use serum creatinine, or nuclear medicine imaging with 99mTc-MAG3 or 99mTc-
DSMA. However, these approaches are suboptimal to detect early-stage kidney disease. 
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Several renal biomarkers are commercially available to determine acute or chronic kidney 
injury [15]. However, those biomarkers have not yet been applied in PRRT for detection of 
nephrotoxicity. Neutrophil gelatinase-associated lipocalin (NGAL) is among the promis-
ing renal biomarkers for detection of acute or chronic kidney injury in humans with high 
specificity and sensitivity [16]. Therefore, NGAL is an interesting renal biomarker to study 
nephrotoxicity caused by TAT with 213Bi.
This study aimed to determine the suitability of 213Bi-DOTATATE for TAT. Administration 
of 213Bi-DOTATATE was optimized for in vivo applications in AR42J tumour-bearing mice. 
The rat AR42J tumour is known to express SSTR2 at high density; this model is commonly 
used for investigations using somatostatin analogues and PRRT. Additionally, investiga-
tions were performed on increasing 213Bi-DOTATATE’s efficacy by using L-lysine as a 
renal protectant, radiation dosimetry to determine the mean radiation absorbed dose to the 
tumour and kidney, the resultant dose-effect relation, and a pilot study to evaluate NGAL 
as a kidney injury biomarker.
mATEriAls AnD mEThODs
213Bi-DOTATATE labelling
213Bi was eluted from a 225Ac/213Bi generator (Oak Ridge National Laboratory) with 0.1 
M/0.1 M HCl/NaI. The resultant elution containing 213Bi (630–740 MBq) was used for 
labelling with 10 µg DOTATATE (BioSynthema) in a reaction vial including 0.15 M TRIS 
buffer and 2.6 mM ascorbic acid at pH 8.4. The reaction was incubated for 5 min at 95°C, 
cooled to ambient temperature for 2 min before adding 50 mM DTPA [17]. Instant Thin-
Layer Chromatography (ITLC-SG, Varian) was performed using 0.9 % NaCl as mobile 
phase to determine the radionuclide-peptide incorporation yield. High-Performance Liquid 
Chromatography (HPLC, Agilent) was performed to determine the radiochemical purity 
(RCP) of 213Bi-DOTATATE, being defined as percentage of intact radiopeptide of interest 
compared to other detectable radioactive compounds in the same HPLC analysis. HPLC 
was performed using a reverse phase C18 column (JT Baker, Bakerbond®, 4.6x250 mm) 
eluted with 0.1 % TFA and methanol [18].
111in-DOTATATE labelling
111InCl3 (GE Healthcare) was added to a vial containing 0.03, 0.1, 0.3, 1, or 3 nmol DOTA-
TATE. 115In(NO3)3 (0.01 g/L, ICP standard) was added to form a 1:1 M ratio reaction to 
peptide and NaOAc 4 M was used to adjust the pH to 4–5. The reaction was heated at 
80°C for 20 min and cooled to ambient temperature for 5 min before addition of DTPA (50 
mM) to incorporate potential free 111In3+. Incorporation yields of the labelled peptide were 
evaluated as described previously.
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Animal model
Athymic male nu/nu mice (Tachonic), 6–8 weeks old, were used in all studies. Tumour 
models were established by inoculating 5x106 rat pancreatic tumour AR42J cells (Ameri-
can Type Culture Collection) with high SSTR2 expression into the right hind flank of 
the animals. After 3 weeks, the tumour size reached approximately 200 mm3. All animal 
experiments were carried out following Institutional Animal Care and Use Committee-
approved protocol.
Comparison of biodistribution profiles of 111in-DOTATATE and 213Bi-
DOTATATE
AR42J tumour-bearing animals were used for the comparison of the uptake of 111In-
DOTATATE versus (vs.) 213Bi-DOTATATE in different organs and tumours. Biodistribution 
assays were performed with either 111In-DOTATATE or 213Bi-DOTATATE (0.3 nmol, n = 3/
cohort). Animals were euthanized 10 and 60 min post-injection (p.i.) by CO2 asphyxiation. 
Blood samples were collected and the following organs were harvested and counted in a 
γ-counter (Perkin Elmer): tumour, blood, heart, adrenals, kidneys, stomach without content, 
pancreas, liver, testicles, urinary bladder, femur, femur marrow, pituitary, and muscles. The 
uptake was expressed as percentage of injected activity per gram of tissue (%IA/g). The 
actual weight of all organs was used to calculate %IA/g.
Biodistribution 111in-DOTATATE
Xenograft AR42J nu/nu mice were used to determine PK as a function of injected mass 
of peptide (n = 4/cohort). Animals were injected intravenously (i.v) via the tail vein with 
0.03, 0.1, 0.3, 1, or 3 nmol (corresponding to 2x10–3, 7x10–3, 0.02, 0.07, and 0.22 mg/kg, 
respectively) of 111In-DOTATATE (range 0.6–2.9 MBq). Animals were euthanized by CO2 
asphyxiation at 3, 10, 30, and 60 min p.i. Blood samples, organs, and femur-containing 
femur marrow were harvested and counted as described previously. The uptake was ex-
pressed as percentage of injected activity per gram of tissue (%IA/g).
The effect of L-lysine on the biodistribution of 213Bi-DOTATATE in tumour 
and nontumour-bearing mice
Twenty AR42J tumour-bearing mice, 200 mm3 tumour volume, were injected intraperitone-
ally (i.p.) with or without (w/wo) 35 mg/200µL L-lysine (L-lysine monohydrochloride) 2–10 
min prior to 213Bi-DOTATATE administration i.v. (1–3 MBq/0.3 nmol). Mice were euthanized 
at 10 min and 60 min p.i. In a parallel study, 20 nontumour-bearing mice were injected i.p. 
w/wo L-lysine (35 mg/200µL) 2–10 min prior to 213Bi-DOTATATE (1–3 MBq/0.3 nmol) 
administration and were euthanized at 10 and 60 min p.i (n = 5/cohort). Blood, organs, and 
femur-containing femur marrow were collected and counted as described previously. The 
uptake was expressed as percentage of injected activity per gram of tissue (%IA/g).
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Toxicity and therapeutic efficacy of 213Bi-DOTATATE
Toxicity and therapeutic efficacy were investigated in 18 animals (n = 6/cohort): control, 
low-dose (cumulative 16.8 ± 1.3 MBq), and high-dose (cumulative 33.1 ± 3.7 MBq) cohorts. 
Treatment started 23 days after xenograft inoculation. Control mice received in total 4x0.3 
nmol DOTATATE on two consecutive days. Two injections of 0.3 nmol DOTATATE per 
day were given, with a time interval of at least 6 h. The low-dose cohort received two doses 
of 213Bi-DOTATATE on two consecutive days, one dose of 8.3 ± 1.0 MBq/0.3 nmol 213Bi-
DOTATATE each day. The high-dose cohort received four doses on two consecutive days, 
twice a day with a time interval of at least 6 h. Per dose, 213Bi-DOTATATE contained 8.3 ± 1.0 
MBq/0.3 nmol 213Bi-DOTATATE. Animals were monitored for 30 days starting on the day 
of treatment. Tumours were measured by caliper, and animals were weighed at least twice 
weekly. The endpoints chosen were weight loss > 15 % and tumour volume > 2000 mm3. At 
30 days post-treatment, blood samples were obtained for hematological analysis according to 
the standard operating procedures for clinical laboratory samples for creatinine, CBC, WBC, 
RBC, Hgb, Hct, MCV, MCHC, platelets, neutrophils, lymphocytes, monocytes, eosinophils, 
and basophils. Survival analysis was plotted according to the Kaplan-Meier fit model.
Tumour volume V(t) as a function of time was modeled according to the exponential growth 
function 
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maximum tolerated dose (mTD) of 213Bi-DOTATATE in nontumour-
bearing mice in combination of l-lysine
MTD was defined as the highest dose given to the animals allowing 100 % survival with no sig-
nificant weight loss > 15 % throughout the experiment. Nontumour-bearing mice were randomly 
divided into seven cohorts used to evaluate MTD; six treatments and one control (n = 8/cohort); 
see Table 1. Cohorts(+) received i.p. injections of L-lysine (35 mg/200µL) at 2–10 min prior to 
213Bi-DOTATATE administration via i.v. tail vein. Control mice received DOTATATE (4×0.3 
nmol) on four consecutive days. The animals were followed for 90 days. Serum was analyzed for 
the biomarker neutrophil gelatinase-associated lipocalin (NGAL) using ELISA (R&D Systems, 
450 nm). Survival analysis was plotted according to the Kaplan-Meier fit model.
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pharmacokinetics
Saturation of receptor-specific tumour uptake was investigated by determining the kinetics 
of the tumour uptake with increasing injected mass of peptide. The time-activity curves for 
the tumour and normal organs were fitted by single-exponential functions using Prism-5 
(GraphPad). Goodness of fit was analyzed with the Pearson correlation coefficient R2 > 0.8. 
Both F-test and the Aikake information criterion were used to decide on the complexity of 
the curves.
radiation Dosimetry
Cumulated radioactivity in the tumour and normal organs were estimated by integrating the 
time-activity curves fitted to the 111In-DOTATATE biodistribution data and folded with the 
decay curve of 213Bi and its daughters. Dosimetry was performed according to the MIRD 
schema by using the spherical nodes S-factors from the Olinda/EXM software [19]. S-
factors were interpolated from the actual weight of the organs and tissue. All organs and 
tissue were assumed to be spherical with a density of 1 kg/m3. Mean radiation absorbed 
doses were obtained as a function-injected mass of peptide, assuming a homogeneous dis-
tribution in the tumour and organs. The mean radiation absorbed dose obtained included the 
cumulative dose of α, β and γ from all daughters of 213Bi. Owing to the short path length of 
α-particles, only the self-dose within each organ was included. The threshold for lethality 
was determined with renal absorbed dose and injected activity as indicators. Logistic re-
gression analysis was used to determine the LD50 for presumed renal toxicity-related death.
statistics
Data analyses, graphs and calculations were performed in Prism-5. Mann-Whitney t-test 
was used to calculate the significance. The results of statistical tests were considered 
significant when P was < 0.05. Biodistribution data were expressed as mean ± standard 
Table 1, 213Bi-DOTATATE toxicity study in nontumour-bearing animals with or without pre-injection 
of L-lysine (35 mg), n = 8/cohort. Control animals received 4x0.3 nmol DOTATATE (n = 8). MTD= 
maximum tolerated dose
mTD study in nontumour-bearing animals in combination with l-lysine  
cohort 213Bi-DOTATATE (mBq) l-lysine Days of injection
low-dose(-) 13.0 ± 1.6 - 2
low-dose(+) 13.2 ± 0.9 + 2
medium-dose(-) 20.7 ± 0.8 - 3
medium-dose(+) 21.7 ± 1.9 + 3
high-dose(-) 28.7 ± 1.2 - 4
high-dose(+) 28.3 ± 0.8 + 4
control 0 4
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deviation (SD) and tumour volume data as mean ± standard error (SEM). Binary logistic 
analysis (forced entry method) was performed with SPSS software (IBM SPSS statistics, 
version 20).
rEsulTs
radiolabelling
The radiolabelling incorporation yield of 213Bi-DOTATATE was ≥ 95 % and RCP was 
≥ 85 %; the incorporation yield of 111In-DOTATATE was ≥ 95 %.
Biodistribution of 111in-DOTATATE as function of injected mass of peptide 
and time
In animals injected with < 0.3 nmol 111In-DOTATATE, higher tumour uptake was observed 
than in animals injected with > 0.3 nmol, Fig. 1A-1F. At lower injected mass of peptide 
(0.03, 0.1 and 0.3 nmol), tumour uptake increased as function of time. At > 0.3 nmol of 
injected peptide, the uptake of 111In-DOTATATE was more uniform and low compared 
to < 0.3 nmol of injected peptide, indicating the receptors on the tumours were partially 
saturated by the injected masses of unlabelled peptide. Renal uptake was higher compared 
to other organs for all injected mass of peptide at all time points, except for tumour. Organs 
uptake of 0.03–3 nmol mass of injected peptide are indicated in supplemental data, Table 
S1–5.
Decreased absorbed tumour doses from 213Bi-DOTATATE as a function of increased of 
injected mass of peptide was predicted based on the 111In-DOTATATE uptake data. The 
mean radiation absorbed tumour dose ranged between, 0.66 Gy/MBq 213Bi-DOTATATE at 
0.03 nmol peptide and 0.19 Gy/MBq 213Bi-DOTATATE at 3 nmol peptide; see Fig. 1F. A 
comparable mean radiation absorbed dose of 0.50 Gy/MBq was found for 0.1 and 0.3 nmol 
peptide.
Biodistribution of 111in-DOTATATE vs. 213Bi-DOTATATE
Tumour uptake of 213Bi-DOTATATE compared to 111In-DOTATATE was 5.3 ± 2.8 %IA/g vs. 
6.3 ± 1.3 %IA/g at 10 min p.i., respectively (P = 0.70). Similar results were observed at 60 
min p.i.: 6.5 ± 2.3 %IA/g vs. 6.0 ± 1.2 %IA/g, respectively (P = 1.0).
Renal activity at 60 min p.i. for 213Bi-DOTATATE was significantly higher than that of 
111In-DOTATATE: 17.4 ± 2.2 %IA/g and 10.9 ± 0.6 %IA/g, respectively (P = 0.0022). 111In-
DOTATATE was retained in the pancreas at 10 and 60 min p.i., whereas 213Bi-DOTATATE 
radioactivity in plasma was higher at 60 min p.i. and uptake in pituitary was higher at 10 
and 60 min p.i. All other organs showed similar uptakes for 111In-DOTATATE and 213Bi-
DOTATATE at 10 min and 60 min p.i, see Fig. 2.
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figure 1A-E, Tumour uptake of 111In-DOTATATE as function of time and injected mass of peptide 
(0.03–3 nmol, n = 4/cohort). The uptake was expressed as percentage of injected activity per gram of tis-
sue (%IA/g). 1F, Predicted absorbed tumour dose of 213Bi-DOTATATE was based on 111In-DOTATATE 
tumour biodistribution results.
58 | Chapter 3
Biodistribution of 213Bi-DOTATATE; influence of L-lysine
Figure 3 shows the uptake of 213Bi-DOTATATE with or without L-lysine pre-injection in 
different organs and tissues in tumour-bearing and nontumour-bearing animals. Lower 
renal uptake was observed in tumour-bearing mice receiving L-lysine prior to administra-
tion of 213Bi-DOTATATE versus mice without L-lysine (10 min p.i.; 21.3 ± 8.1 %IA/g vs. 
30.8 ± 5.8 %IA/g and 60 min p.i.; 5.7 ± 1.1 %IA/g vs. 18.4 ± 1.8 %IA/g (P < 0.0001)).
No differences in tumour uptake were found in animals w/wo L-lysine pretreatment. How-
ever, at 60 min p.i., a significant difference in stomach uptake was found in tumour-bearing 
animals with and without L-lysine; 0.9 ± 0.1 %IA/g versus 1.6 ± 0.5 %IA/g, P = 0.0079. 
Figure 3 shows the uptake of 213Bi-DOTATATE w/wo L-lysine pre-injection in different 
organs in tumour- and nontumour-bearing animals.
In tumour-bearing animals receiving L-lysine, the renal absorbed dose was 0.56 Gy/MBq 
vs. 1.1 Gy/MBq without L-lysine. In nontumour-bearing animals, the renal absorbed dose 
was 0.50 Gy/MBq with L-lysine versus 1.0 Gy/MBq without L-lysine, see estimated mean 
radiation absorbed dose in supplemental data Table S6.
pharmacodynamics of 213Bi-DOTATATE in Ar42J tumour-bearing animals
Tumour volumes significantly decreased in mice treated with low-dose (16.8 ± 1.3 MBq) 
and high-dose (33.1 ± 3.7 MBq) 213Bi-DOTATATE. Tumour regression was observed in both 
213Bi-DOTATATE cohorts. Tumour regrowth was delayed until 21 ± 9 days p.i. in animals 
treated with low-dose 213Bi-DOTATATE; see Fig. 4A. One animal in the low-dose showed 
a weight loss of > 15 % at day 27 post-treatment. Dramatic weight loss was observed in the 
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figure 2, Comparative biodistributions (%IA/g±SD) after i.v. administration of 213Bi-DOTATATE vs. 
111In-DOTATATE (0.3 nmol peptide, n = 3/cohort) at 10 min and 60 min p.i. in AR42J tumour-bearing 
mice. The uptake was expressed as percentage of injected activity per gram of tissue (%IA/g).
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figure 3, Biodistribution comparison of 213Bi-DOTATATE (0.3 nmol) with (w) or without (wo) L-lysine 
(35 mg) pre-injection. 3A) AR42J tumour-bearing animals 10 min p.i. 3B) AR42J tumour-bearing ani-
mals 60 min p.i. 3C) nontumour-bearing animals 10 min p.i. 3D) nontumour-bearing animals 60 min p.i., 
n = 5. The uptake was expressed as percentage of injected activity per gram of tissue (%IA/g).
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figure 4A, Tumour growth in mice before and after injection of DOTATATE in control animals (4×0.3 
nmol DOTATATE) and 213Bi-DOTATATE at different concentration, in low-dose cohort (16.8 ± 1.3 
MBq) and high-dose cohort (33.1 ± 3.7 MBq). Treatment started 23 days after inoculation of AR42J 
cells. The solid line indicates the extrapolated fit calculated for tumour growth, and dotted lines indicate 
the 95 % confidence interval for the fit. 4B, Survival of AR42J-bearing animals after 213Bi-DOTATATE 
therapy. Low-dose animals received 16.8 ± 1.3 MBq 213Bi-DOTATATE, high-dose 33.1 ± 3.7 MBq, and 
control 4×0.3 nmol DOTATATE on 2 consecutive days.
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high-dose cohort within 14 days post-treatment, necessitating euthanasia of 67 % of the ani-
mals; see Fig. 4B. Therefore, tumour regrowth doubling time in the high-dose cohort was 
not determined. The tumour doubling time in the control was 4.0 ± 0.2 days and both the 
initial growth and regrowth patterns in the therapy cohorts proceeded with similar doubling 
times. A median survival of 5 days was found in the control, > 30 days in the low-dose, 
and 13 days in the high-dose, see Fig. 4B. The tumour growth in one animal of the control 
cohort showed an unusual growth pattern; therefore the data of this animal was excluded 
from the calculation of the tumour doubling time and survival analysis.
Animals in the high-dose cohort showed significantly (P= < 0.05) elevated hemoglobin 
(Hgb) and hematocrit (Hct) values compared to the low-dose (Hgb (g/dL) 51 ± 7 vs. 39 ± 3; 
and Hct (%)16 ± 2 vs. 12 ± 1).
mTD in nontumour-bearing mice administration w/wo l-lysine
Renal protection using L-lysine prior to 213Bi-DOTATATE administration resulted in pro-
longed survival for both the medium-dose(+) (21.7 ± 1.9 MBq) and high-dose(+) cohorts 
(28.3 ± 0.8 MBq), Fig. 5. Medium- and high-dose cohorts without L-lysine showed reduced 
survival rates compared to medium- and high-dose cohorts pre-treated with L-lysine. No 
animals in high dose(-) cohort survived beyond 40 days following treatment. No significant 
difference in survival was observed following low-dose administration of 213Bi-DOTATATE 
with or without L-lysine (P = 0.32) or medium-dose with or without L-lysine (P = 0.06). 
Weight loss was observed in cohorts treated with medium-dose(-), high-dose(-) and high-
dose(+) cohorts.
At 90 days post-treatment, all control animals survived. A survival rate of 87.5 % was found 
in the low-dose(-) cohort, 62.5 % in the medium-dose(-) and 0 % in high-dose(-), Fig. 5A. 
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figure 5A-B, Survival percentage after 213Bi-DOTATATE therapy without (-) or with (+) L-lysine (35 
mg) pre-injection in nontumour-bearing mice; cohort low-dose(-) received cumulatively 13.0 ± 1.6 
MBq, low-dose(+) 13.2 ± 0.9 MBq, medium-dose(-) 20.7 ± 0.8 MBq, medium-dose(+) 21.7 ± 1.9 MBq, 
high-dose(-) 28.7 ± 1.2 MBq and high-dose(+) 28.3 ± 0.8 MBq (n = 8/cohort). Control animals received 
4×0.3 nmol DOTATATE (n = 8).
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Cohorts receiving L-lysine pre-treatment, Fig. 5B, a very high survival rate was observed: 
100 % in the low-dose(+) and 100 % in the medium-dose(+). In the high-dose(+) cohort, 
75 % of the animals survived. A median survival of > 90 days was found in control and all 
cohorts except the high-dose without L-lysine (median survival of 24 days, P = 0.0012).
By integrating the radioactivity over time in the kidney, data obtained from biodistribution 
study w/wo pre-treatment of L-lysine, a time-integrated activity coefficient (expressed as 
min/g tissue) of 6.0 ± 2.4 min/g in mice pre-treated with L-lysine and 12.0 ± 3.7 min/g in 
mice without pre-treatment of L-lysine was found. Based on logistic regression analysis, a 
LD50 of 20 ± 8 Gy was found; see Fig. 6. The number of mice that were euthanized within 
90 days was indicated as a function of renal absorbed dose obtained from both biodistribu-
tion studies w/wo L-lysine.
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figure 6, Dose-effect relation between mean renal radiation absorbed dose and the percentage of mice 
that died before the end of the experiment at 90 days. LD50 kidney dose was 20 ± 8 Gy, a threshold 
LD5 = 11 ± 4 Gy (P= < 0.001). All points represent at least three mice.
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figure 7, NGAL (ng/mL±SEM) level in control and 213Bi-DOTATATE-treated cohorts with (+) or 
without (-) pre-treatment of L-lysine (35 mg). Cohort low-dose(-) received cumulatively 13.0 ± 1.6 
MBq, low-dose(+) 13.2 ± 0.9 MBq, medium-dose(-) 20.7 ± 0.8 MBq, medium-dose(+) 21.7 ± 1.9 MBq, 
high-dose(-) 28.7 ± 1.2 MBq and high-dose(+) 28.3 ± 0.8 MBq. Control animals received 4×0.3 nmol 
DOTA TATE. ** P value < 0.01 and *** P value < 0.001 versus control values.
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The highest NGAL level was found in the high-dose(-) cohort, 15.8 ± 3.5 ng/mL. Whereas 
the NGAL level of control, low-dose cohort w/wo L-lysine was the lowest, 1.9 ± 0.9, 
1.9 ± 0.6 and 1.7 ± 0.7 ng/mL, respectively. A significant difference in NGAL level was 
found in medium-dose(-), high-dose(-), and high-dose(+) vs. control; see Fig. 7.
DiscussiOn
In this preclinical study, TAT with 213Bi-DOTATATE was systematically studied to un-
derstand the injected mass of peptide-dependent uptake, radioactivity-related toxicity, and 
reduction in tumour burden. 111In had already been used as a surrogate for 213Bi earlier 
in other preclinical studies [20, 21]. We demonstrated 111In is an appropriate surrogate 
radionuclide for in vivo preclinical studies of PK in tumours allowing the results obtained 
from 111In to be used for 213Bi-dosimetry calculation. Both 213Bi and 111In form highly stable 
complexes with DOTA-somatostatin analogues, including DOTATATE, and show similar 
affinities for SSTR2 in tumour.
For PRRT, it is essential to determine the optimal injected mass of radioligand by defining 
PK of radiopeptides in animal models, given that the injected mass of radioligand influ-
ences tumour uptake, the resultant radiation absorbed dose, and eventually the efficacy 
of the therapy. Moreover, increasing the injected mass of radioligand can diminish the 
pharmacological selectivity by binding to other SSTR-positive organs [22], which is not 
beneficial in the case of TAT and may cause off-target toxicities. The optimal injected mass 
of 111In-OctreoScan® to obtain the best signal to background ratio for tumour versus other 
organs was reported as 0.07 nmol in mice (3.5 pmol/g mice) [23]. De Jong et al. showed a 
“bell-shape” curve for dependent tumour uptake in AR42J tumour-bearing rats as a func-
tion of injected mass of peptide, where 0.4 nmol 111In-DOTATOC (1.8 pmol/g rat) gave the 
maximum tumour uptake [24].
In this study, the highest absorbed tumour dose (0.66 Gy/MBq) was found at injected mass 
of peptide of 0.03 nmol (1.07 pmol/g mice). However, lower and more practical specific 
activity (MBq/nmol) 213Bi-DOTATATE, 0.3 nmol (10.7 pmol/g mice) was chosen for the 
administration in this study allowing sufficient tumour uptake to realize therapeutic effects. 
A similar mean radiation absorbed dose of 213Bi-DOTATATE was determined for 0.1 and 
0.3 nmol injected mass of peptide, as the tumour uptakes as function of time of both 0.1 and 
0.3 nmol peptide were similar.
111In-DOTATATE is not an appropriate surrogate of 213Bi-DOTATATE to determine renal 
uptake as a significant difference was observed at 60 min p.i. between 111In-DOTATATE and 
213Bi-DOTATATE. With an absence of SSTR2 receptors in the kidney, the high renal uptake 
is not related to SSTR expression. The renal uptake of the labelled peptide is thought to 
be influenced by the difference in the electrostatic charge of DOTA-complex with 111In and 
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213Bi [9, 10, 25], leading to different interactions with megalin or cubilin [26]. Furthermore, 
213Bi3+ is known to bind strongly to metallothionein in the kidneys [27], which might lead 
to a high renal uptake. Apart from high renal uptake, a significantly higher uptake was 
also found in the pituitary and a higher radioactivity level in plasma. The pituitary gland 
is a very small organ. During organ harvesting, a systematic uncertainty is introduced by 
the chance to include surrounding tissue in the weight used for the uptake per gram cal-
culation, resulting to an under- or overestimation of pituitary uptake, which might explain 
our findings. The high renal uptake and slow clearance rate of 213Bi-DOTATATE indicates 
tubular reabsorption of 213Bi-DOTATATE; this might be the cause of higher radioactivity in 
plasma as well. 111In-DOTATATE showed a slightly significantly higher uptake than 213Bi-
DOTATATE in pancreas tissue, as yet we do not have an explanation for this difference.
In this study, we were not able to examine the differences in PKs of these radiopharmaceu-
ticals in pituitary, plasma and pancreas, due to the small number of animal per group and 
limited time points.
Despite the differences in PK profiles of 111In-DOTATATE and 213Bi-DOTATATE in some 
organs and tissues, 111In-DOTATATE still showed to be a proper substitute for tumour 
uptake, since the PK profile of the tumour uptake was similar to that of 213Bi-DOTATATE. 
However, the use of a surrogate radionuclide should to be carefully chosen, since each 
alternate radionuclide has limitations.
Weight loss in animals is often an indicator of toxicity, and the most radiosensitive or-
gans for PRRT are the bone marrow and kidney [8, 28, 29]. In this study, we observed 
severe weight loss in 67 % of animals exposed to high-dose 213Bi-DOTATATE (cumulative 
33.1 ± 3.7 MBq), within 2 weeks after treatment, indicating acute toxicity. This might be 
explained by the high renal uptake resulting in a high renal absorbed dose, which increased 
the risk of acute nephrotoxicity due to limited sublethal damage tissue repair. To investigate 
acute renal toxicity, a short-term toxicity study over 90 days was performed instead of a 
follow-up period over 6–12 months, which is commonly performed to investigate long-
term chronic nephrotoxicity. A significant reduction of renal activity (50 %) was found in 
animals pre-treated with L-lysine in this study. Our findings indicate that pre-treatment with 
L-lysine improved survival of animals receiving medium- and high-dose 213Bi-DOTATATE 
resulting from the reduction of renal activity. Song et al. showed in their study a threefold 
reduction in renal activity following lysine pre-treatment [13]. This result differs signifi-
cantly from our findings but might be attributed to their method of lysine application used 
during the therapy procedures, rather than immediately prior. Kobayashi et al. demonstrated 
that the kidney uptake was influenced by the timing of L-lysine administration [30], such 
that renal blocking by L-lysine was maximized when i.p. administration of L-lysine was 
given immediately before administration of the radiolabelled of anti-Tac murine MoAb 
fragment. In our study, we have chosen to start the therapy 2–10 min after i.p. administra-
tion of L-lysine to protect the kidneys, since DOTATATE is a relative small molecule and 
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rapidly cleared from the blood. Radioactivity in the blood or uptake of the bone marrow 
is generally used as an indicator for myelotoxicity. Pre-administration of L-lysine did not 
significantly affect the radioactivity measured in neither whole blood nor femur uptake 
in tumour-bearing mice. The mean radiation absorbed dose for whole blood and femur 
(see supplemental data) was 3.3 Gy and 1.3 Gy in mice with pre-treatment of L-lysine in 
the high-dose cohort, whereas without L-lysine, these values were 2.7 and 1.0 Gy. These 
absorbed doses were lower than the MTD of 25 MBq 213Bi-DOTA-AMBA in PC3-tumour 
bearing mice, corresponding to the MTD at a mean absorbed dose of 4 Gy in the blood [31]. 
Therefore, we concluded the bone marrow is not a limiting organ in our study.
The LD50 found for the renal absorbed dose was 20 Gy in this study. Acute renal toxicity at 
100–140 Gy was reported by Behr et al., after administration of 90Y-fab fragments, leading 
to death of all mice within 2–3 weeks [32]. This corresponds to our observation in cohorts 
after high-dose 213Bi-DOTATATE administration, with more than 90 % of the animals dead 
at radiation absorbed dose > 28 Gy. Hence, the relative biological effect (RBE) was 4–5 for 
acute renal toxicity, leading to death within 2–3 weeks, when comparing the absorbed doses 
in both studies. This estimate for the RBE for 213Bi-DOTATATE appears to be comparable 
to the RBE value of 4 used for delayed renal toxicity by Song et al. [13]. Specific uptake in 
functional units of the kidney might cause changes in radiation absorbed doses to radiation-
sensitive structures like the glomeruli that could result in less damage than predicted from 
whole-organ radiation dosimetry. Small-scale micro-dosimetry using the sub-organ model 
of Hobbs et al. [33] indicates a possible lowering of the absorbed dose to the glomeruli 
when 213Bi is taken up in the proximal tubules by 44 % in comparison to homogeneous 
uptake in the mouse cortex assuming equal kinetics. We found no indication for this sparing 
effect; otherwise, the RBE would be in the order of 6–8. A direct comparative study would 
be needed to determine both the RBE and the PK of 213Bi- and 90Y or 177Lu labelled peptides 
inside the kidneys and its functional units.
In this pilot study, NGAL was used as a biomarker to evaluate late-stage renal changes after 
therapy. NGAL is sensitive to acute kidney injury (AKI) for detection of renal functions 
in early nephrotoxicity state [16, 34]. No nephrotoxicity was found in the low-dose(-) and 
low-dose(+) cohorts, corresponding to another study done using similar injected mass of 
radioactivity (MBq) 213Bi-DOTATATE as TAT in nude mice in two different tumour models 
wherein nephrotoxicity was investigated by 99mTc-DMSA as a kidney marker [35]. Overall, 
NGAL levels were lower in mice pre-treated with L-lysine than mice without pre-treatment 
at similar dose of 213Bi-DOTATATE. However, no significant difference was found between 
those cohorts, which might be explained since NGAL was measured day 90 after TAT, 
whereby some repair and recovery of the kidney might already occur. Furthermore, the 
mean renal absorbed dose for the medium-dose(-) and the high-dose(+) cohorts was 23 Gy 
and 16 Gy, respectively. These absorbed doses were similar to the calculated renal LD50, 
at which 50 % of the treated animals would develop acute nephrotoxicity. The sigmoid 
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dose-effect curve for renal toxicity (Fig. 6) shows a steep slope, contributing to a great 
variation in NGAL values observed at absorbed doses just above and below the LD50 
value. In this study, NGAL proved to be a valuable tool to examine AKI for TAT using 
213Bi as radionuclide supporting its use in future investigations of nephrotoxicity caused 
by 213Bi. The use of NGAL as a biomarker of nephrotoxicity is feasible and cost effec-
tive compared to conventional approaches to determine renal functionality in preclinical 
studies. Creatinine, the most commonly used parameter to determine kidney injury, lacks 
the ability to evaluate kidney injury at early stages following PRRT. 99mTc-MAG3 and 
99mTc-DMSA for preclinical applications are invasive, by the use of high radioactivity for 
imaging, and require additional data extraction and analysis. In addition to NGAL, kidney 
injury molecule-1 (KIM-1) and cystatine-C are promising biomarkers for both acute and 
chronic kidney disease [15]. The ability to study early and late kidney injury is essential in 
TAT, using a combination of both conventional methods and these commercially available 
biomarkers could provide more information leading to more understanding of the underly-
ing mechanisms involved in kidney injury after TAT.
cOnclusiOn
213Bi-DOTATATE showed therapeutic effects to reduce tumour size and prolong survival. 
Potential nephrotoxicity caused by 213Bi-DOTATATE was overcome by pre-treatment with 
L-lysine. 213Bi-DOTATATE with L-lysine pre-treatment shows promise as TAT of SSTR2-
expressing tumours. The biomarker NGAL offers a new approach to study nephrotoxicity 
following TAT.
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supplEmEnTAl DATA
Table s1, Biodistribution data in AR42J tumour-bearing nude mice. Uptake at 3, 10, 30 and 60 min 
p.i. and expressed in percentage injected activity per gram tissue (%IA/g) after 111In-DOTATATE (0.03 
nmol, 1.07 pmol/g ) administration (n = 4/cohort)
111in-DOTATATE (0.03 nmol) uptake (%iA/g) in organs as function of time post injection
Organs 3 min 10 min 30 min 60 min
Tumour 6.9 ± 3.6 10.7 ± 2.5 15.1 ± 7.5 12.8 ± 6.7
muscles 1.2 ± 0.7 0.9 ± 0.3 0.3 ± 0.1 0.07 ± < 0.05
pancreas 6.0 ± 1.5 1.6 ± 1.4 4.7 ± 2.7 9.2 ± 1.9
stomach 5.6 ± 0.7 7.9 ± 2.2 8.1 ± 1.3 7.6 ± 1.1
kidney 19.2 ± 8.4 16.0 ± 4.1 14.0 ± 4.1 12.3 ± 3.7
pituitary 1.0 ± 1.7 0.2 ± 0.2 0.5 ± 0.8 < 0.05
red blood cell 3.5 ± 2.5 1.7 ± 0.5 0.6 ± 0.2 0.3 ± 0.08
plasma 13.3 ± 1.6 8.2 ± 1.6 3.2 ± 1.0 0.8 ± 0.1
Adrenals 2.7 ± 1.6 3.4 ± 2.3 4.7 ± 4.4 4.6 ± 5.6
Table s2, Biodistribution data in AR42J tumour-bearing nude mice. Uptake at 3, 10, 30 and 60 min p.i. 
and expressed in percentage injected activity per gram tissue (%IA/g) after 111In-DOTATATE (0.1 nmol, 
3.6 pmol/g mice) administration (n = 4/cohort)
111in-DOTATATE (0.1 nmol) uptake (%iA/g) in organs as function of time post injection
Organs 3 min 10 min 30 min 60 min
Tumour 2.8 ± 1.8 11.8 ± 3.6 10.9 ± 3.6 9.9 ± 2.6
muscles 1.5 ± 0.6 0.7 ± 0.2 0.4 ± 0.4 0.3 ± 0.4
pancreas 11.9 ± 4.0 9.9 ± 4.2 7.0 ± 1.4 4.7 ± 0.5
stomach 4.4 ± 1.1 5.2 ± 1.1 6.3 ± 2.0 6.0 ± 1.8
kidney 21.6 ± 3.9 15.6 ± 3.1 16.1 ± 5.5 16.7 ± 8.6
pituitary 0.3 ± 0.2 0.2 ± 0.09 0.1 ± 0.2 < 0.05
red blood cell 5.2 ± 0.7 1.7 ± 0.5 0.8 ± 0.4 0.2 ± 0.1
plasma 13.2 ± 1.7 8.6 ± 1.4 3.4 ± 1.7 1.0 ± 0.6
Adrenals 2.1 ± 0.6 1.9 ± 0.3 2.1 ± 0.7 1.3 ± 0.2
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Table s3, Biodistribution data in AR42J tumour-bearing nude mice. Uptake at 3, 10, 30 and 60 min p.i. 
and expressed in percentage injected activity per gram tissue (%IA/g) after 111In-DOTATATE (0.3 nmol, 
10.7 pmol/g mice) administration (n = 4/cohort)
111in-DOTATATE (0.3 nmol) uptake (%iA/g) in organs as function of time post injection
Organs 3 min 10 min 30 min 60 min
Tumour 4.9 ± 2.2 8.0 ± 1.2 9.9 ± 3.0 9.9 ± 0.7
muscles 1.1 ± 0.1 0.5 ± 0.1 0.3 ± 0.1 < 0.05
pancreas 4.9 ± 0.7 3.5 ± 0.3 3.2 ± 0.4 3.0 ± 1.0
stomach 4.5 ± 0.8 3.9 ± 0.4 3.5 ± 0.2 3.4 ± 0.8
kidney 17.2 ± 5.4 12.8 ± 2.2 16.9 ± 6.3 13.4 ± 2.8
pituitary 0.3 ±< 0.05 0.2 ± 0.05 0.1 ±< 0.05 < 0.05
red blood cell 2.6 ± 0.6 1.3 ± 0.4 0.6 ± 0.1 < 0.05
plasma 13.4 ± 1.4 7.2 ± 2.0 3.4 ± 0.5 0.7 ± 0.2
Adrenals 2.3 ± 0.6 1.2 ± 0.4 1.0 ± 0.1 0.8 ± 0.3
Table s4, Biodistribution data in AR42J tumour-bearing nude mice. Uptake at 3, 10, 30 and 60 min p.i. 
and expressed in percentage injected activity per gram tissue (%IA/g) after 111In-DOTATATE (1 nmol, 
35.7 pmol/g mice) administration (n = 4/cohort)
111in-DOTATATE (1 nmol) uptake (%iA/g) in organs as function of time post injection
Organs 3 min 10 min 30 min 60 min
Tumour 5.6 ± 2.0 6.7 ± 2.9 2.9 ± 0.6 7.0 ± 1.1
muscles 1.2 ± 0.4 1.0 ± 0.5 0.2 ± 0.09 < 0.05
pancreas 3.5 ± 2.4 1.9 ± 1.0 0.7 ± 0.2 1.5 ± 0.3
stomach 2.4 ± 1.1 1.7 ± 0.6 0.8 ± 0.2 1.8 ± 0.6
kidney 17.5 ± 9.7 14.2 ± 7.0 6.0 ± 1.8 14.1 ± 3.4
pituitary 0.1 ± 0.09 0.8 ± 1.4 < 0.05 < 0.05
red blood cell 2.3 ± 0.4 1.3 ± 0.5 0.3 ± 0.1 0.4 ± 0.1
plasma 11.3 ± 4.9 7.6 ± 3.1 1.4 ± 0.5 0.6 ± 0.2
Adrenals 1.4 ± 0.7 1.8 ± 1.1 0.5 ± 0.09 0.5 ± 0.05
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Table s5, Biodistribution data in AR42J tumour-bearing nude mice. Uptake at 3, 10, 30 and 60 min p.i. 
and expressed in %IA/g after 111In-DOTATATE (3 nmol, 107 pmol/g mice) administration (n = 4/cohort)
111in-DOTATATE (3 nmol) uptake (%iA/g) in organs as function of time post injection
Organs 3 min 10 min 30 min 60 min
Tumour 2.9 ± 1.1 3.8 ± 0.3 3.6 ± 0.2 3.3 ± 0.3
muscles 1.3 ± 0.3 0.8 ± 0.3 0.3 ± 0.1 < 0.05
pancreas 2.2 ± 0.4 1.6 ± 0.2 1.0 ± 0.2 0.8 ± 1.0
stomach 3.2 ± 0.5 2.3 ± 0.2 1.5 ± 0.6 1.6 ± 0.7
kidney 19.1 ± 3.1 14.6 ± 2.9 14.5 ± 1.1 14.7 ± 2.1
pituitary 0.2 ± 0.06 0.1 ± 0.06 0.08 ± 0.06 < 0.05
red blood cell 4.3 ± 1.9 2.4 ± 0.3 0.6 ± 0.2 < 0.05
plasma 13.8 ± 1.7 8.4 ± 0.9 2.8 ± 0.7 0.6 ± 0.2
Adrenals 1.9 ± 0.7 1.1 ± 0.7 0.6 ± 0.2 0.3 ± 0.06
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ABsTrAcT
Background:
Targeted alpha therapy has been postulated to have great potential for the treatment of small 
cluster of tumour cells as well as small metastases. 213Bismuth, an α-emitter with a half-life 
of 46 min, has shown to be effective in pre-clinical as well as in clinical applications. In this 
study we evaluated, whether 213Bi-[DOTA0, Tyr3]-octreotate (213Bi-DOTATATE), a 213Bi-labelled 
somatostatin analogue with high affinity for somatostatin receptor subtype 2 (SSTR2), is suitable 
for the treatment of larger neuroendocrine tumours overexpressing SSTR2 in comparison to its 
effectiveness for smaller tumours. We performed a preclinical targeted radionuclide therapy study 
with 213Bi-DOTATATE in animals bearing tumours of different size (50 and 200 mm3) using two 
tumour models: H69 (human small cell lung carcinoma) and CA20948 (rat pancreatic tumour).
methods:
Pharmacokinetics was determined for calculation of dosimetry in organs and tumours. 
H69- or CA20948- xenografted mice with tumour volumes of approximately 120 mm3 were 
euthanized at 10, 30, 60 and 120 min post injection of a single dose of 213Bi-DOTATATE 
(1.5–4.8 MBq). To investigate the therapeutic efficacy of 213Bi-DOTATATE, xenografted 
H69- and CA20948 tumour-bearing mice with tumour sizes of 50 or 200 mm3 were admin-
istered daily with a therapeutic dose of 213Bi-DOTATATE (0.3 nmol, 2–4 MBq) for three 
consecutive days. The animals were followed for 90 days after treatment. At day 90, mice 
were injected with 25 MBq 99mTc-DMSA and imaged by SPECT/CT to investigate possible 
renal dysfunction due to 213Bi-DOTATATE treatment.
results:
Higher tumour uptakes were found in CA20948 tumour-bearing animals compared to 
those in H69 tumour-bearing mice with the highest tumour uptake of 19.6 ± 6.6 %IA/g in 
CA20948 tumour-bearing animals, while for H69 tumour-bearing mice, the highest tumour 
uptake was found to be 9.8 ± 2.4 %IA/g. Nevertheless, as the anti-tumour effect was more 
pronounced in H69 tumour-bearing mice, the survival rate was higher. Furthermore, in the 
small tumour groups, no regrowth of tumour was found in two H69 tumour-bearing mice 
and in one of the CA20948 tumour-bearing mice. No renal dysfunction was observed in 
213Bi-DOTATATE-treated mice after the doses were applied.
conclusion:
213Bi-DOTATATE demonstrated a great therapeutic effect in both small and larger tumour 
lesions. Higher probability for stable disease was found in animals with small tumours. 
213Bi-DOTATATE was effective in different neuroendocrine (H69 and CA20948) tumour 
models with overexpression of SSTR2 in mice.
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BAckgrOunD
Peptide receptor radionuclide therapy (PRRT) is an effective treatment option for patients 
with an inoperable neuroendocrine tumour (NET) or with metastatic disease [1, 2]. Ap-
proximately 80 % of patients with NET show great anti-tumour response upon PRRT. The 
most commonly used radiolabelled peptides for treatment in NET are 177Lu-[DOTA0, Tyr3]-
octreotate (177Lu-DOTATATE) and 90Y-[DOTA0, Tyr3]-octreotide (90Y-DOTATOC). 90Y and 
177Lu are β-particles emitting radionuclides, with a maximum tissue penetration of 12 mm 
and 2 mm, respectively. For treatment of small tumour clusters and metastases, β-emitters 
may lack efficacy due to the relatively large tissue penetration and low linear energy trans-
fer (LET). Targeted alpha therapy (TAT) with α-emitters has been described to be more 
suitable for these purposes, since the path length in tissue of α-particles is relatively short 
(in tissue 50–100 µm) compared to that of β-particles. Moreover, α-particles have a much 
higher LET (~100 keV/μm) and are therefore more powerful than β-particles (0.2 keV/μm) 
for therapeutic applications [3]. Bismuth-213 (213Bi), an α-emitter with a T1/2 of 45.6 min, 
has already been proven to be effective in TAT [4–7]. Recently, a clinical trial showed a 
promising anti-tumour effect in patients with progressive advanced neuroendocrine liver 
metastasis refractory to 90Y-DOTATOC or 177Lu-DOTATOC treatment after treatment with 
213Bi-DOTATOC [8]. TAT with 213Bi-DOTATOC was able to overcome the resistance 
against β-radiation in patients with different neuroendocrine tumours, in metastasis and in 
primary tumours, resulting in a high number of long-lasting anti-tumour responses.
The objective of this study was to investigate the therapeutic efficacy of 213Bi-DOTATATE 
in tumours of different sizes in mice (small vs large). Two different tumour models with 
somatostatin receptor subtype 2 (SSTR2) expression were used: CA20948 (rat pancreatic 
tumour) and H69 (human small cell lung carcinoma). Both tumours have relatively high 
SSTR2 expression and both have often been applied as a model in preclinical studies of 
PRRT in NET [9–11]. The radiation sensitivity of CA20948 for low-LET radiation has 
been determined yielding α/β = 8.3 Gy [12]. The H69 cell line shows a higher radiation 
sensitivity α/β = 2.3 Gy [13]. Radiation damage by the high-LET α radiation from 213Bi is 
expected to follow a linear (-exponential) curve which was comparable for both cell lines.
For PRRT the dose-limiting organs are bone marrow and kidneys. 213Bi-DOTATATE shows 
accumulation in the kidneys, resulting in high radiation doses to the kidneys; in this study, 
we therefore determined the safe dose of radioactivity administered for TAT in this mouse 
model. Renal function was evaluated after TAT by SPECT/CT at different time points post 
treatment using 99mTc-DMSA (dimercaposuccinic acid), a renal marker for tubular damage.
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213Bi-eluate
A 213Bi/225Ac generator (222 MBq) was provided by the Institute for Transuranium Ele-
ments (Karlsruhe, Germany). Prior to elution, the generator was rinsed using 0.01 M HCl 
(3 mL) and eluted using 0.1 M/0.1 M HCl/NaI (0.6 mL). After elution, the generator was 
rinsed with 0.01 M HCl and stored in 0.01 M HCl [4].The activity of 213Bi was determined 
using a Germanium detector (MetorX, Genie 2000 software, Canberra) [14].
213Bi-DOTATATE labelling
Eluate containing 213Bi (0.1M/0.1M in HCl/NaI) was added to a solution containing 7.0 
nmol DOTATATE, 0.15 M TRIS buffer and 2.6 mM ascorbic acid in a total reaction volume 
of 800 µL. The reaction mixture was incubated for 5 min at 95°C followed by 5 min at room 
temperature. To chelate any unbound/free 213Bi, 50 nmol DTPA (Sigma Aldrich, Zwijn-
drecht, the Netherlands) was added (manuscript submitted). Analysis by instant thin-layer 
chromatography (ITLC, Varian) and reverse-phase high-performance liquid chromatogra-
phy (HPLC, 2695 separation module, Alliance, Waters, Etten-Leur, The Netherlands) of the 
labelled peptide was performed to determine the incorporation yield (%) and radiochemical 
purity (RCP) expressed as percentage of labelled peptide of interest compared to other 
detectable compounds [15]. The whole labelling procedure took on average 20 minutes to 
produce a ready-to-inject vial.
99mTc-DmsA labelling
The 99mTc-DMSA kit was purchased from Mallinckrodt (Petten, the Netherlands) and 
labelled according to the indicated procedure.
cell culture
The rat pancreatic tumour cell line CA20948 (derived from a rat pancreas tumour at our 
institute) with high SSTR2 expression, was cultured in DMEM (Gibco, Life technologies) 
supplemented with 10 % heat-inactivated fetal bovine serum. H69 tumour cells, human 
small cell lung carcinoma cells with SSTR2 expression (American Tissue Culture Collection, 
Wesel, Germany), were cultured in RPMI 1640 (Gibco, Life technologies) supplemented 
with 10 % heat-inactivated fetal bovine serum and 50 IU/ml penicillin/streptomycin. All 
cells were cultured at 37 °C in a 5 % CO2/humidified air atmosphere.
Animal models
All animal studies were in agreement with the Animal Welfare Committee requirements 
of Erasmus MC and conducted in accordance to accepted guidelines. Male 6–8-weeks-old 
BALB/c (nu/nu) nude mice were obtained from Charles River (Kißlegg, Germany). Sub-
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cutaneous tumours were established in mice by inoculation of approximately 5 × 106cells 
(CA20948 or H69), suspended in 200 µL sterile culture medium Hanks’ balanced salt solu-
tion (HBSS) in the case of CA20948 cells. Three days after inoculation of CA20948 cells, a 
tumour with a tumour size ~50 mm3 (used for the “smaller” tumour size group) was reached, 
and 2 weeks after inoculation, a tumour size ~200 mm3 (used for the “larger” tumour size 
group) was reached. For H69 cells, 200 µL, containing 1/3 Matrigel and 2/3 HBSS medium 
(Gibco, Life technologies), was used. The cells were injected subcutaneously (s.c.) into the 
right flank of the mice. One week after inoculation of tumour cells, tumours with a volume 
of ~50 mm3 (used for the “smaller” tumour size group) could be detected and after 3 weeks 
tumour volumes reached ~200 mm3 (used for the “larger” tumour size group). Tumour 
volumes were estimated using a calliper.
pharmacokinetics of 213Bi-DOTATATE as function of time in different 
tumour models
When tumour volumes reached ~120 mm3, animals were divided into five groups with seven 
animals in each group for both H69 and CA20948 tumour-bearing animals. Four groups of 
mice received a single intravenously (i.v.) injection of 213Bi-DOTATATE (200 µL) via the 
tail vein, 3.8 ± 0.6 MBq/0.3 nmol/200 µL for H69 tumour-bearing animals and 2.1 ± 0.2 
MBq/0.3 nmol/200 µL for CA20948 tumour-bearing animals. At 10, 30, 60 and 120 min 
post injection (p.i.), animals in the four groups were euthanized and tissues and organs of 
interest (including tumour, kidney, pancreas, spleen, liver, muscles, blood, femur, femur 
marrow and adrenals) were collected and counted using a gamma counter (Wallac Wizard 
3, PerkinElmer, USA). Control animals received a single injection of 213Bi-DOTA-TATE 
plus an excess of DOTATATE (10–6 M) i.v. via the tail vein (blocking dose) to determine the 
non-receptor-specific binding of 213Bi-DOTATATE. The animals of the control group were 
euthanized 60 min p.i.; tissues and organs of interest were harvested and counted using a 
gamma counter. Data was expressed in mean percentage of total injected radioactivity per 
gram tissue (%IA/g) ± SD.
Targeted Alpha Therapy
Tumour cells were inoculated into the right flank of the mice, and the tumours were al-
lowed to grow until tumour volumes of approximately 50 mm3 and 200 mm3 were reached, 
respectively. On the day of treatment (T = 0 days), the animals (H69-bearing animals: small 
tumour n = 10, large tumour n = 7; CA20948-bearing animals: small tumour n = 8, large 
tumour n = 5) were injected i.v. via the tail vein with 213Bi-DOTATATE (2–4 MBq/0.3 
nmol/200 µL) for three consecutive days. The control group (H69-bearing animals: small 
tumour n = 10, large tumour n = 9; CA20948-bearing animals; small tumour n = 5, large 
tumour n = 5) received i.v. via the tail vein three times 0.3 nmol/200 µL of unlabelled 
DOTATATE for three consecutive days.
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All animals were followed for 90 days after treatment. The behavior and the health status 
of the animals were observed daily, and the weight of the animals and the tumour volumes 
were monitored twice a week.
Determination of renal function by 99mTc-DmsA imaging
Renal function imaging was performed by a four-headed multi-pinhole SPECT/CT camera 
(Bioscan Inc., Washington D.C., USA). For 99mTc imaging, an energy peak at 140 keV was 
selected with an energy window width ± 10 %. A nine-pinhole aperture (diameter of each 
pinhole 1.4 mm) was used on each camera head. For the CT topogram, an axial length 
of 27 mm was used to cover the renal region. Animals were imaged under anesthesia by 
isoflurane and O2. The body temperature of the animals was maintained using a heated 
bed. Renal imaging of H69 (control n = 4, 213Bi-DOTATATE treated n = 8) and CA20948 
tumour-bearing animals (control n = 2, 213Bi-DOTATATE treated n = 4) was performed 2 h 
after i.p. administration of 99mTc-DMSA (25 MBq). 99mTc-DMSA images were acquired for 
12 min (20 projections, 60 s/projection) [16].
Absorbed dose in organs
The absorbed radiation dose (defined as the mean absorbed dose in Gy ) in organs and tu-
mours was estimated from the results obtained in the biodistribution studies as described by 
Konijnenberg et al. [17] in a spherical geometry using Monte Carlo code MCNP5 (Version 
1.4) for the electrons and γ-rays [18] and MCNPX (version 2.5) [19] for the α-particles, all 
energy emission spectra were taken from ICRP database [20], and particle histories of 1× 
107 was used for simulation to reduce the variation (< 5 %) in the data. The mean absorbed 
energies for 10 MBq 213Bi-DOTATATE injection were calculated for spheres of 1, 10, 100, 
200, 300 and 500 mg containing tissue with a mass density of 1g/mL to determine the 
spherical node S-values. A homogeneous activity distribution over the sphere was assumed. 
The absorbed dose Di was calculated for each volume i according to the MIRD-schema:
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model: (1) homogeneous in the cortex, (2) proximal tubular cell uptake and (3) glomerular cell uptake. 
Statistics  
with Ãi the time-integrated activity (TIA) in organ i and S(i←i) the absorbed dose rate per 
unit activity (S-value). Only the self-dose S-values were considered and were obtained 
by interpolation between the sphere S-values for the measured organs or tumour mass. 
For small tumours, a minimum tumour mass of 50 mg was used for the absorbed dose 
calculation. The Ãi in each organ was determined for 213Bi and its daughters taking the bio-
distribution into account according to the methods shown in Additional file 1. The absorbed 
dose to the kidneys was calculated both with the spherical S-values, as with the nephron 
model by Hobbs et al. [21]. Three hypothetical activity distributions were considered for 
this heterogeneous model: (1) homogeneous in the cortex, (2) proximal tubular cell uptake 
and (3) glomerular cell uptake.
4Tumour size-dependent efficacy | 79
statistics
Statistical analysis was performed using t-test and using the nonparametric Mann-Whitney 
test. P-values < 0.05 were considered statistically significant. For statistical significances 
in tumour growth patterns, one-way ANOVA was used. Values are presented as the mean 
and the standard deviation (SD).
rEsulTs
labelling
An incorporation yield of ≥ 99 % and a RCP ≥ 85 % were found for the radiopeptide, as 
determined by ITLC and HPLC, respectively.
pharmacokinetic studies
Biodistribution studies using 213Bi-DOTATATE in H69 tumour-bearing mice revealed 
relatively high tumour uptake. The highest tumour uptake was reached at 30 min p.i., 
9.8 ± 2.4 %IA/g. Tumour uptake T1/2 was 7 ± 2 min, and tumour clearance T1/2 was 2.3 ± 1.1 
h. An even higher renal activity compared to tumour uptake was found at all time points, 
the highest renal activity being found at 10 min p.i.: 44 ± 10 %IA/g. At 120 min p.i. the 
renal activity still was 25 ± 3 %IA/g. Blood clearance in H69 tumour-bearing animals was 
fast, and clearance T1/2 was 11 ± 2 min, see Fig. 1A-C. All other organs had relative low 
uptake at 120 min p.i., < 2 %IA/g, see Table 1.
figure 1A-f, Selected pharmacokinetics of 213Bi-DOTATATE from Tables 1 and 2. 213Bi-DOTATATE 
pharmacokinetics in H69 tumour-bearing mice, uptake in tumours (A) and kidney (B), and radioactivity in 
blood (C) are shown over time in H69 tumour-bearing animals. Same data are shown for CA20948 tumour-
bearing animals: uptake in tumours (D), and kidneys (E) and radioactivity in blood (F). Solid curves show 
the mean uptake value expressed in %IA/g ± SD. The dotted curves indicate the 95 % confidential interval.
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Tumour uptake of 213Bi-DOTATATE in CA20948 tumour-bearing mice was already highest 
at 10 min p.i., 19.6 ± 6.6 %IA/g, and the tumour uptake T1/2 was therefore unable to esti-
mate. A clearance T1/2 of 2.2 ± 0.9 h was found for CA20948 tumours. Similar renal activity 
was found in CA20948 tumour-bearing animals. Renal activity was highest at 10 min p.i., 
52 ± 17 %IA/g. Renal clearance T1/2 was 10 ± 3 min, whereas blood clearance T1/2 was 14 ± 1 
min, see Fig. 1D-F. At 120 min p.i., uptakes in other organs remained low, < 2 %IA/g, see 
Table 2.
Table 1, Pharmacokinetics of 213Bi-DOTATATE at 10, 30, 60 and 120 min post injection (p.i.) in H69 
tumour-bearing animals, expressed in mean %IA/g±SD, n = 7
uptake (%iA/g) 10 min p.i. 30 min p.i. 60 min p.i. 120 min p.i.
Tumour 7.5 ± 2.2 9.8 ± 2.4 9.8 ± 2.3 6.8 ± 3.2
muscle 2.1 ± 0.8 1.1 ± 0.2 1.0 ± 1.4 0.5 ± 0.4
kidney 44.0 ± 9.6 28.5 ± 3.7 26.2 ± 2.6 25.0 ± 3.8
pancreas 3.2 ± 0.3 2.8 ± 0.3 1.8 ± 0.2 1.4 ± 0.2
liver 2.1 ± 0.8 0.9 ± 0.09 0.4 ± 0.06 0.3 ± 0.05
Blood 8.1 ± 1.8 2.3 ± 1.1 0.6 ± 0.2 0.1 ± 0.06
spleen 2.3 ± 0.6 1.0 ± 0.09 0.4 ± 0.07 0.2 ± 0.07
Adrenal 3.6 ± 1.2 2.0 ± 0.6 0.9 ± 0.4 0.7 ± 0.4
femur 2.8 ± 0.4 1.5 ± 0.4 1.0 ± 0.5 0.4 ± 0.4
%IA/g = mean percentage of total injected radioactivity per gram tissue.
Table 2, Pharmacokinetics of 213Bi-DOTATATE at 10, 30, 60 and 120 min post injection (p.i.) in 
CA20948 tumour-bearing animals, expressed in mean %IA/g±SD, n = 7
uptake (%iA/g) 10 min p.i. 30 min p.i. 60 min p.i. 120 min p.i.
Tumour 19.6 ± 6.6 15.1 ± 6.6 12.7 ± 1.6 11.2 ± 5.4
muscle 3.1 ± 0.8 1.5 ± 0.8 1.4 ± 1.9 0.2 ± 0.2
kidney 51.5 ± 16.6 26.0 ± 3.3 15.0 ± 1.5 18.0 ± 1.9
pancreas 3.6 ± 0.2 3.1 ± 0.4 1.5 ± 0.3 1.2 ± 0.2
liver 2.0 ± 0.2 1.0 ± 0.1 0.2 ± 0.04 0.2 ± 0.03
Blood 7.1 ± 1.0 2.6 ± 0.4 0.3 ± 0.2 0.07 ± 0.04
spleen 2.0 ± 0.2 1.1 ± 0.4 0.2 ± 0.05 0.2 ± 0.04
Adrenal 3.4 ± 0.7 2.2 ± 0.8 0.6 ± 0.1 0.4 ± 0.1
femur 2.4 ± 0.2 1.4 ± 0.2 0.6 ± 0.1 0.2 ± 0.04
%IA/g = mean percentage of total injected radioactivity per gram tissue.
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Dosimetry
Dosimetry calculations in both tumour models were based on the data obtained from 
the biodistribution studies at 10, 30, 60 and 120 min p.i. In H69 tumour-bearing mice, 
a relatively high tumour absorbed radiation dose was estimated: 0.45 Gy/MBq injected 
213Bi-DOTATATE calculated for 100 mg tumour. The renal-absorbed dose was four times 
as high as the tumour-absorbed radiation dose: 2 Gy/MBq injected 213Bi-DOTATATE. The 
absorbed radiation dose of 213Bi-DOTATATE in pancreas, spleen and liver was low com-
pared to those in the tumour and kidney, 0.15, 0.06 and 0.06 Gy/MBq, respectively. Similar 
results were observed in CA20948 tumour-bearing animals. A lower tumour-absorbed 
radiation dose was found than that in  kidneys: 0.78 Gy/MBq in tumour vs 1.6 Gy/MBq. 
Absorbed radiation doses in pancreas, spleen and liver were 0.13, 0.05 and 0.06 Gy/MBq, 
respectively. For both tumour-bearing animal models, an absorbed dose of < 0.02 Gy/MBq 
was found in bone marrow.
figure 2, Calculated absorbed radiation dose rates in the tumour and kidney after 10 MBq 213Bi-DOTA-
TATE, based on the data obtained in the biodistribution study. Absorbed dose rate as function of time 
in H69 tumour-bearing animals; tumour (A) and kidney (B). Same data are shown of tumour (C) and 
kidney (D) for CA20948 tumour-bearing animals. Red lines indicate the absorbed dose rate contributed 
by all alpha particles and blue lines by all beta particles. The dotted lines indicate the individual absorbed 
dose rate of 213Bi, 213Po, 209Tl and 209Pb.
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Tumour- and kidney-absorbed radiation doses in H69 or CA20948 tumour-bearing ani-
mals were mainly caused by the α-particles emitted. The absorbed dose rate was higher in 
CA20948 than in H69 tumours, and the kidney-absorbed radiation dose was similar; see 
Fig. 2A-D. For an instantaneous uptake in the H69 tumour, its absorbed dose would rise by 
12 % to 0.50 Gy/MBq, whereas the absorbed dose to the CA20948 tumour is less dependent 
on the uptake kinetics: the dose is lowered by 2 % to 0.77 Gy/MBq when the same uptake 
kinetics as for the H69 tumour is assumed.
Targeted Alpha Therapy
Therapeutic anti-tumour effects were observed in all animals treated with 213Bi-DOTATATE, see 
Fig. 3. The tumour volume doubling time was 16 ± 6 days for the H69 and 10 ± 5 days for the 
CA20948 tumours, without any difference between the growth rate of small tumours and large 
tumours. The mean times to reach the end volume of 2000 mm3 of control and treated animals 
of both tumour models are indicated in Table 3. For small tumours, tumour sizes < 50 mm3 
could not be measured accurately; therefore, 50 mm3 was used as the minimum tumour sizes in 
our calculation and this was in three cases of H69 tumour-bearing animals with a small tumour 
and in all cases of CA20948 tumour-bearing animals with a small tumour. Overall calculated 
cumulative tumour-absorbed dose in small tumours was higher than large tumours. In CA20948 
tumours, the cumulative tumour-absorbed dose was higher than in H69 tumours.
Shrinkage of tumours was observed in H69 tumour-bearing animals with large tumours 
and a delay of tumour growth around 70 days after 213Bi-DOTATATE (cumulative injected 
activity of 9.4 ± 0.7 MBq) treatment. In CA20948 tumour-bearing animals with large 
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figure 3, Overview of mean tumour volumes ± standard deviation (SD) in mm3 per group after treat-
ment of 213Bi-DOTATATE (2–4 MBq per injection) or unlabelled DOTATATE (control) in H69 and 
CA20948 tumour-bearing mice for three consecutive days. V0 is the starting tumour volume. The dotted 
curves show the extrapolated growth curves of the tumours assuming 100 % survival of animals.
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tumours, the inhibition of tumour growth was initiated around 30 days after therapy (cu-
mulative injected activity 10.2 ± 0.4 MBq 213Bi-DOTATATE), leading to a tumour growth 
delay time of 50 days. Similar results were found in CA20948 tumour-bearing animals with 
small tumours after therapy (cumulative injected activity 7.7 ± 0.4 MBq); a delay in tumour 
growth of around 30 days was observed, and in one of the animals no tumour regrowth 
was observed. The delay time was estimated excluding animal with cure or stable disease. 
In H69 tumour-bearing animals with small tumours, a delay of tumour growth was found 
for around 30 days after therapy (cumulative injected activity 7.4 ± 0.5 MBq), and in two 
animals, no tumour regrowth was observed until the end of the study at day 90. Here, the 
two animals with cure/stable disease were excluded from the estimated delay time.
survival
All animals treated with 213Bi-DOTATATE showed a higher survival rate than control animals, 
see Fig. 4. In the control, non-TAT H69 tumour-bearing animals, a median survival of 34 days 
was found for animals bearing large tumours and 81 days for animals bearing small tumours. 
H69 tumour-bearing animals with small tumours had a median survival of > 90 days after 213Bi-
Table 3, An overview of mean time (days = d) to reach a tumour volume of 2000 mm3 after 213Bi-
DOTATATE therapy
h69 small h69 large cA20948 small cA20948 large
control 73 ± 19 d 38 ± 11 d 43 ± 20 d 27 ± 14 d
Therapy 102 ± 19 d 110 ± 19 d 76 ± 15 d 77 ± 25 d
Tumour dose (gy) 5 ± 1 Gy 2.0 ± 0.6 Gy 17 ± 1 Gy 10 ± 5 Gy
growth delay (control vs therapy) 28 ± 9 d*** 73 ± 24 d* 33 ± 17 d NS 50 ± 13 d**
NS = not significant
* =P value ≤ 0.05, **=P value ≤ 0.01 and ***=P value ≤ 0.001.
The tumour dose (Gy) ± SD was estimated based on the tumour size at T = 0 of therapy and the injected activ-
ity (MBq). Growth delay (days) was the ΔT for tumour to reach 2000 mm3 of therapy group vs control group.
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figure 4, Survival (percentage) after 213Bi-DOTATATE or DOTATATE treatment in A) H69 tumour-
bearing and B) CA20948 tumour-bearing mice.
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DOTATATE therapy (control vs treated, P-value = < 0.0001). Similar results were obtained in 
H69 tumour-bearing animals with large tumours after TAT; a median survival > 90 days was 
found (control vs treated, P-value = 0.0195). In the CA20948 tumour-bearing animals without 
TAT, a median survival of 29 days was found for animals bearing large tumours, whereas for 
animals bearing small tumours, this was 35 days. After 213Bi-DOTATATE, a median survival 
of 70 days was found in the large-tumour-animal group (control vs treated, P-value = not sig-
nificant) and > 90 days in the small-tumour-animal group (control vs treated, P-value = 0.005).
99mTc-DmsA uptake in kidney
Renal function was investigated in H69 and CA20948 tumour-bearing animals at day 90 after 
213Bi-DOTATATE therapy or unlabelled DOTATATE treatment. Renal function was determined 
by renal uptake of 99mTc-DMSA (25MBq). No significant differences in 99mTc-DMSA uptake 
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figure 5A-D, 99mTc-DMSA renal SPECT images in H69 control (A), 213Bi-DOTATATE-treated H69 
mice (B), CA20948 control (C) and 213Bi-DOTATATE-treated CA20948 mice (D). 5E, Renal uptake 
(in kBq) of 99mTc-DMSA (25 MBq) in H69 and CA20948 tumour-bearing mice after therapy with 213Bi-
DOTATATE or DOTATATE.
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in the kidneys were observed in 213Bi-DOTATATE-treated mice and control animals for both 
tumour models. In H69 tumour-bearing mice, a mean renal uptake of 2.6 ± 0.8 MBq (mean 
concentration of 2.9 ± 0.6 kBq/mm3) in the control group (n = 4) versus 2.1 ± 0.9 MBq (mean 
concentration of 2.9 ± 0.8 kBq/mm3) in 213Bi-DOTATATE-treated animals (n = 8) was found. 
Similar results were obtained in CA20948 tumour-bearing animals: mean uptake of 2.1 ± 0.2 
MBq (mean concentration of 3.1 ± 0.4 kBq/mm3) in 213Bi-DOTATATE treated animals (n = 4) 
and 2.1 ± 0.3 MBq (mean concentration 3.2 ± 0.3 kBq/mm3) in control (n = 2) were found. 
Figure 5A-E shows 99mTc-DMSA uptake in kidneys of both tumour models.
DiscussiOn
In this study, we compared the efficacy of 213Bi-DOTATATE TAT in tumours of different sizes 
in two different tumour models, both with expression of SSTR2. 213Bi-DOTATATE showed 
a very good therapeutic effect in both small and large tumours in the two different tumour 
models. Tumour-absorbed doses (Gy) in CA20948 tumour-bearing animals were higher 
compared to those in H69 tumour-bearing mice. Despite these findings, 213Bi-DOTATATE 
showed greater therapeutic effects in H69 tumour-bearing animals than in CA20948 tumour-
bearing animals; a higher survival rate was observed in H69 tumour-bearing animals at the 
end of the study. However, no significant difference in tumour (re)growth inhibition time 
between the two tumour models was found, even though the absorbed dose in tumour was 
higher in CA20948 tumour-bearing animals. In vitro, CA20948 cells appeared also more 
radioresistant than H69 cells; at external beam irradiation with 2 Gy, a survival fraction of 
H69 was 37 % [13] and for CA20498, 52 % was found [12].
In this study, we observed a higher anti-tumour effect in small tumours. In H69 tumour-
bearing mice with small tumours, two animals showed stable disease and in eight animals, 
a partial response was found after treatment. In the case of CA20948 tumour-bearing 
animals with small tumours, one animal showed stable disease till the end of the study and 
partial response was found in eight of the animals after 213Bi-DOTATATE therapy. In H69 
and CA20948 tumour-bearing animals with large tumours, a partial response was found. 
A longer tumour growth delay was found in animals with large tumours of both tumour 
models compared to small tumours. The time a tumour takes to reach 2000 mm3 in small 
tumours is longer than in large tumours; therefore, Δ delay time for tumour growth was 
used. Nevertheless, in animals showing regrowth, the small tumours were less responsive 
than the large tumours in both models.
The reason for partial remission can be explained as the distribution of the radiation-absorbed 
dose depends on the tumour size, the physical properties of the radionuclide and its possible 
inhomogeneous intratumoural distribution. In those cases where the tumour dimensions 
are smaller than the range of the ionizing particles, a large proportion of the absorbed 
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energy can “escape”, resulting in an suboptimal effect of 213Bi-DOTATATE TAT [22]. In 
larger tumours, also pronounced therapeutic effects were observed after 213Bi-DOTATATE 
therapies in both tumour models. However, no complete remissions were observed in these 
animals. Besides tumour perfusion [23] and inhomogeneous distribution of SSTR2, tumour 
size [17, 22], vessel density, permeability and tumour growth doubling time can play a criti-
cal role for the success of PRRT; this is especially true for α-emitters, where the penetration 
depth in tissue is relatively short (50–100 µm). In large tumours, often heterogeneity of 
receptor distribution [24] is observed, resulting in insufficient efficacy of the treatment 
and leading to probability survival of tumour cells. Therefore multiple fractions of therapy 
might improve the effect in larger tumours [25], especially in the case of TAT.
For somatostatin receptor-targeted PRRT, nephrotoxicity is often the dose-limiting factor, 
since reabsorption of radiolabelled somatostatin analogues by cells in the proximal tubule 
of the nephron occurs [26].
In this study the calculated renal absorbed dose using our simplified model was compared 
to the model described by Hobbs et al. [21]. We assumed all renal uptakes to be localized 
in the proximal tubular cells and took the glomerular cells as target. The absorbed dose in 
the glomeruli was 57 % lower than for the mean absorbed kidney dose. On the other hand, 
the dose to the glomeruli is almost a factor 20 higher when all activity was concentrated in 
the glomerular cells. The homogeneous mean absorbed dose we calculated with the sphere 
model was 24 % higher than when calculated with the cortex model from Hobbs et al. [21].
99mTc-DSMA can provide information on renal function after renal tubular damage and 
has been used as renal marker in PRRT [27]. In this study, we did not find any changes 
in renal function in animals after TAT (highest cumulative activity used was 11.5 MBq 
213Bi-DOTATATE). Kidney histology was performed in CA20948-bearing animals (data 
not shown), and no significant differences were observed in control vs treated animals. 
However, 213Bi-DOTATATE is known to accumulate in the kidney, leading to a high renal-
absorbed dose. In patients, the maximum tolerated dose in kidney is postulated to be 23–28 
Gy [28–30]. Kidney protectants during TAT are therefore advised [9, 31, 32], especially 
when higher treatment activities are used. In another study, we found a maximum tolerated 
activity of 21.2 ± 1.7 MBq in presence of i.p. L-lysine as kidney protectant prior to the 
213Bi-DOTATATE treatment; in absence of L-lysine, the maximum tolerated activity was 
< 13.1 ± 1.2 MBq (manuscript in preparation).
Even though we have not been able to achieve complete remission of all tumours, this 
study demonstrated that TAT can be effective for the treatment of both large and small 
tumours. These findings are in line with those of Kratochwil et al. [8] who demonstrated the 
effectiveness of TAT in eight patients refractory to PRRT with 177Lu and 90Y. We therefore 
believe that TAT is most promising for the treatment of NET. In combination with PRRT 
using 90Y- and 177Lu-peptides [33, 34], even greater therapeutic efficacy might be achieved, 
especially for in the treatment of patients with larger NET.
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cOnclusiOn
TAT with 213Bi-DOTATATE shows very good therapeutic efficacy for the treatment of both 
large and small tumours in these mouse models. In small tumours, 213Bi-DOTATATE dem-
onstrated greater anti-tumour effect by its higher probability for inducing stable disease. 
Furthermore, TAT using 213Bi-DOTATATE demonstrated to be safe in our experimental set-
ting, with kidneys as dose-limiting organs. 213Bi-DOTA-TATE therefore held great promise 
for targeted therapy for neuroendocrine tumours that express SSTR2.
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ADDiTiOnAl filE 1
1.  single compartment clearance model for 213Bi conjugates activity in 
organs or tumours.
The 213Bi activity in the volume is cleared with a biologic clearance constant lb (= ln(2)/Tb, with Tb the 
clearance half-life) and the kinetics follows an exponential decay function:
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1. Single compartment clearance model for 213Bi conjugates activity in organs or tumours. 
The 213Bi activity in the volume is cleared with a biologic clearance constant b (= ln(2)/Tb, with Tb the 
clearance half-life) and the kinetics follows an exponential decay function:  
𝐴𝐴𝐵𝐵𝐵𝐵(𝑡𝑡)=𝐴𝐴𝐵𝐵𝐵𝐵(0)𝑒𝑒−(𝜆𝜆𝐵𝐵𝐵𝐵+𝜆𝜆𝑏𝑏)𝑡𝑡 
The activity integration from time 0 to T of the 213Bi activity and time integrated activity ÃBi is then: 
 Ã𝐵𝐵𝐵𝐵(𝑇𝑇)=∫ 𝐴𝐴𝐵𝐵𝐵𝐵(𝑡𝑡) 𝑑𝑑𝑡𝑡= 𝐴𝐴𝐵𝐵𝐵𝐵(0)𝜆𝜆𝐵𝐵𝐵𝐵+𝜆𝜆𝑏𝑏(1− 𝑒𝑒−(𝜆𝜆𝐵𝐵𝐵𝐵+𝜆𝜆𝑏𝑏)𝑇𝑇)𝑇𝑇0    lim𝑇𝑇→∞Ã𝐵𝐵𝐵𝐵(𝑇𝑇)=Ã𝐵𝐵𝐵𝐵=𝐴𝐴𝐵𝐵𝐵𝐵(0)𝜆𝜆𝐵𝐵𝐵𝐵+𝜆𝜆𝑏𝑏 
213Bismuth decays with a branching ratio BR (=0.9791) to 213Po and the 213Po kinetics follows: 
𝐴𝐴𝑃𝑃𝑃𝑃(𝑡𝑡)=𝐵𝐵𝐵𝐵 𝜆𝜆𝑃𝑃𝑃𝑃𝜆𝜆𝑃𝑃𝑃𝑃−𝜆𝜆𝐵𝐵𝐵𝐵×𝐴𝐴𝐵𝐵𝐵𝐵(0)(𝑒𝑒−(𝜆𝜆𝐵𝐵𝐵𝐵+𝜆𝜆𝑏𝑏)𝑡𝑡 − 𝑒𝑒−(𝜆𝜆𝑃𝑃𝑃𝑃+𝜆𝜆𝑏𝑏)𝑡𝑡) 
The activity integration over time of the 213Po activity and time integrated activity ÃPo is then: 
Ã𝑃𝑃𝑃𝑃(𝑇𝑇)=𝐵𝐵𝐵𝐵 𝜆𝜆𝑃𝑃𝑃𝑃𝜆𝜆𝑃𝑃𝑃𝑃−𝜆𝜆𝐵𝐵𝐵𝐵 𝐴𝐴𝐵𝐵𝐵𝐵(0)(1−𝑒𝑒−(𝜆𝜆𝐵𝐵𝐵𝐵+𝜆𝜆𝑏𝑏)𝑇𝑇𝜆𝜆𝐵𝐵𝐵𝐵+𝜆𝜆𝑏𝑏 − 1−𝑒𝑒−(𝜆𝜆𝑃𝑃𝑃𝑃+𝜆𝜆𝑏𝑏)𝑇𝑇𝜆𝜆𝑃𝑃𝑃𝑃+𝜆𝜆𝑏𝑏 )  
 Ã𝑃𝑃𝑃𝑃=𝐵𝐵𝐵𝐵 𝜆𝜆𝑃𝑃𝑃𝑃𝜆𝜆𝑃𝑃𝑃𝑃−𝜆𝜆𝐵𝐵𝐵𝐵 𝐴𝐴𝐵𝐵𝐵𝐵(0)( 1𝜆𝜆𝐵𝐵𝐵𝐵+𝜆𝜆𝑏𝑏 − 1𝜆𝜆𝑃𝑃𝑃𝑃+𝜆𝜆𝑏𝑏)  
 Ã𝑃𝑃𝑃𝑃 ≈ 𝐵𝐵𝐵𝐵 𝐴𝐴𝐵𝐵𝐵𝐵(0)1𝜆𝜆𝐵𝐵𝐵𝐵+𝜆𝜆𝑏𝑏 
The decay and biodistribution of the other daughters 209Tl and 209Pb are described quite similarly: 
𝐴𝐴𝑇𝑇𝑇𝑇(𝑡𝑡)=(1−𝐵𝐵𝐵𝐵) 𝜆𝜆𝑇𝑇𝑇𝑇𝜆𝜆𝑇𝑇𝑇𝑇−𝜆𝜆𝐵𝐵𝐵𝐵×𝐴𝐴𝐵𝐵𝐵𝐵(0)(𝑒𝑒−(𝜆𝜆𝐵𝐵𝐵𝐵+𝜆𝜆𝑏𝑏)𝑡𝑡 − 𝑒𝑒−(𝜆𝜆𝑇𝑇𝑇𝑇+𝜆𝜆𝑏𝑏)𝑡𝑡) 
with: Ã𝑇𝑇𝑇𝑇(𝑇𝑇)=(1−𝐵𝐵𝐵𝐵) 𝜆𝜆𝑇𝑇𝑇𝑇𝜆𝜆𝑇𝑇𝑇𝑇−𝜆𝜆𝐵𝐵𝐵𝐵 𝐴𝐴𝐵𝐵𝐵𝐵(0)(1−𝑒𝑒−(𝜆𝜆𝐵𝐵𝐵𝐵+𝜆𝜆𝑏𝑏)𝑇𝑇𝜆𝜆𝐵𝐵𝐵𝐵+𝜆𝜆𝑏𝑏 − 1−𝑒𝑒−(𝜆𝜆𝑇𝑇𝑇𝑇+𝜆𝜆𝑏𝑏)𝑇𝑇𝜆𝜆𝑇𝑇𝑇𝑇+𝜆𝜆𝑏𝑏 )  
 Ã𝑇𝑇𝑇𝑇=(1−𝐵𝐵𝐵𝐵) 𝜆𝜆𝑇𝑇𝑇𝑇𝜆𝜆𝑇𝑇𝑇𝑇−𝜆𝜆𝐵𝐵𝐵𝐵 𝐴𝐴𝐵𝐵𝐵𝐵(0)( 1𝜆𝜆𝐵𝐵𝐵𝐵+𝜆𝜆𝑏𝑏 − 1𝜆𝜆𝑇𝑇𝑇𝑇+𝜆𝜆𝑏𝑏) 
𝐴𝐴𝑃𝑃𝑃𝑃(𝑡𝑡)=𝐵𝐵𝐵𝐵 𝜆𝜆𝑃𝑃𝑃𝑃 𝜆𝜆𝑃𝑃𝑏𝑏𝜆𝜆𝑃𝑃𝑃𝑃−𝜆𝜆𝐵𝐵𝐵𝐵×𝐴𝐴𝐵𝐵𝐵𝐵(0)(𝑒𝑒−(𝜆𝜆𝐵𝐵𝐵𝐵+𝜆𝜆𝑏𝑏)𝑡𝑡 − 𝑒𝑒−(𝜆𝜆𝑃𝑃𝑏𝑏+𝜆𝜆𝑏𝑏)𝑡𝑡𝜆𝜆𝑃𝑃𝑃𝑃 − 𝜆𝜆𝐵𝐵𝐵𝐵 − 𝑒𝑒−(𝜆𝜆𝑃𝑃𝑃𝑃+𝜆𝜆𝑏𝑏)𝑡𝑡 − 𝑒𝑒−(𝜆𝜆𝑃𝑃𝑏𝑏+𝜆𝜆𝑏𝑏)𝑡𝑡𝜆𝜆𝑃𝑃𝑃𝑃 − 𝜆𝜆𝑃𝑃𝑃𝑃 )+ 
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1. Single compartment clearance model for 213Bi conjugates activity in organs or tumours. 
The 213Bi activity in the volume is cleared with a biologic clearance constant b (= ln(2)/Tb, with Tb the 
clearance half-life) and the kinetics follows an exponential decay function:  
𝐴𝐴𝐵𝐵𝐵𝐵(𝑡𝑡)=𝐴𝐴𝐵𝐵𝐵𝐵(0)𝑒𝑒−(𝜆𝜆𝐵𝐵𝐵𝐵+𝜆𝜆𝑏𝑏)𝑡𝑡 
The activity integration fro  time 0 to T of the 213Bi activity and time integrated activity ÃBi is then: 
 Ã𝐵𝐵𝐵𝐵(𝑇𝑇)=∫ 𝐴𝐴𝐵𝐵𝐵𝐵(𝑡𝑡) 𝑑𝑑𝑡𝑡= 𝐴𝐴𝐵𝐵𝐵𝐵(0)𝜆𝜆𝐵𝐵𝐵𝐵+𝜆𝜆𝑏𝑏(1𝑒𝑒−(𝜆𝜆𝐵𝐵𝐵𝐵+𝜆𝜆𝑏𝑏 𝑇𝑇)𝑇𝑇0    lim𝑇𝑇→∞Ã𝐵𝐵𝐵𝐵(𝑇𝑇)=Ã𝐵𝐵𝐵𝐵=𝐴𝐴𝐵𝐵𝐵𝐵(0)𝜆𝜆𝐵𝐵𝐵𝐵+𝜆𝜆𝑏𝑏 
213Bismuth decays with  branching ratio BR (=0.9791) to 213Po and the 213Po kinetics follows: 
𝐴𝐴𝑃𝑃𝑃𝑃(𝑡𝑡)=𝐵𝐵𝐵𝐵 𝜆𝜆𝑃𝑃𝑃𝑃𝜆𝜆𝑃𝑃𝑃𝑃−𝜆𝜆𝐵𝐵𝐵𝐵×𝐴𝐴𝐵𝐵𝐵𝐵0)(𝑒𝑒−(𝜆𝜆𝐵𝐵𝐵𝐵+𝜆𝜆𝑏𝑏)𝑡𝑡 𝑒𝑒−(𝜆𝜆𝑃𝑃𝑃𝑃+𝜆𝜆𝑏𝑏 𝑡𝑡) 
The activity integration over time of the 213Po activity and time integrated activity ÃPo is then: 
Ã𝑃𝑃𝑃𝑃(𝑇𝑇)=𝐵𝐵𝐵𝐵 𝜆𝜆𝑃𝑃𝑃𝑃𝜆𝜆𝑃𝑃𝑃𝑃−𝜆𝜆𝐵𝐵𝐵𝐵 𝐴𝐴𝐵𝐵𝐵𝐵0)(1−𝑒𝑒−(𝜆𝜆𝐵𝐵𝐵𝐵+𝜆𝜆𝑏𝑏)𝑇𝑇𝜆𝜆𝐵𝐵𝐵𝐵+𝜆𝜆𝑏𝑏 − 1−𝑒𝑒−(𝜆𝜆𝑃𝑃𝑃𝑃+𝜆𝜆𝑏𝑏)𝑇𝑇𝜆𝜆𝑃𝑃𝑃𝑃+𝜆𝜆𝑏𝑏 )  
 Ã𝑃𝑃𝑃𝑃=𝐵𝐵𝐵𝐵 𝜆𝜆𝑃𝑃𝑃𝑃𝜆𝜆𝑃𝑃𝑃𝑃−𝜆𝜆𝐵𝐵𝐵𝐵 𝐴𝐴𝐵𝐵𝐵𝐵0)( 1𝜆𝜆𝐵𝐵𝐵𝐵+𝜆𝜆𝑏𝑏 − 1𝜆𝜆𝑃𝑃𝑃𝑃+𝜆𝜆𝑏𝑏)  
 Ã𝑃𝑃𝑃𝑃 ≈ 𝐵𝐵𝐵𝐵 𝐴𝐴𝐵𝐵𝐵𝐵(0)1𝜆𝜆𝐵𝐵𝐵𝐵+𝜆𝜆𝑏𝑏 
The decay and biodistributi n of the other daughters 209Tl and 209Pb are described quite similarly: 
𝐴𝐴𝑇𝑇𝑇𝑇(𝑡𝑡)=(1−𝐵𝐵𝐵𝐵) 𝜆𝜆𝑇𝑇𝑇𝑇𝜆𝜆𝑇𝑇𝑇𝑇−𝜆𝜆𝐵𝐵𝐵𝐵×𝐴𝐴𝐵𝐵𝐵𝐵0)(𝑒𝑒−(𝜆𝜆𝐵𝐵𝐵𝐵+𝜆𝜆𝑏𝑏)𝑡𝑡 𝑒𝑒−(𝜆𝜆𝑇𝑇𝑇𝑇+𝜆𝜆𝑏𝑏 𝑡𝑡) 
with: Ã𝑇𝑇𝑇𝑇(𝑇𝑇)=(1−𝐵𝐵𝐵𝐵) 𝜆𝜆𝑇𝑇𝑇𝑇𝜆𝜆𝑇𝑇𝑇𝑇−𝜆𝜆𝐵𝐵𝐵𝐵 𝐴𝐴𝐵𝐵𝐵𝐵0)(1−𝑒𝑒−(𝜆𝜆𝐵𝐵𝐵𝐵+𝜆𝜆𝑏𝑏)𝑇𝑇𝜆𝜆𝐵𝐵𝐵𝐵+𝜆𝜆𝑏𝑏 − 1−𝑒𝑒−(𝜆𝜆𝑇𝑇𝑇𝑇+𝜆𝜆𝑏𝑏)𝑇𝑇𝜆𝜆𝑇𝑇𝑇𝑇+𝜆𝜆𝑏𝑏 )  
 Ã𝑇𝑇𝑇𝑇=(1−𝐵𝐵𝐵𝐵) 𝜆𝜆𝑇𝑇𝑇𝑇𝜆𝜆𝑇𝑇𝑇𝑇−𝜆𝜆𝐵𝐵𝐵𝐵 𝐴𝐴𝐵𝐵𝐵𝐵0)( 1𝜆𝜆𝐵𝐵𝐵𝐵+𝜆𝜆𝑏𝑏 − 1𝜆𝜆𝑇𝑇𝑇𝑇+𝜆𝜆𝑏𝑏) 
𝐴𝐴𝑃𝑃𝑃𝑃(𝑡𝑡)=𝐵𝐵𝐵𝐵 𝜆𝜆𝑃𝑃𝑃𝑃 𝜆𝜆𝑃𝑃𝑏𝑏𝜆𝜆𝑃𝑃𝑃𝑃−𝜆𝜆𝐵𝐵𝐵𝐵×𝐴𝐴𝐵𝐵𝐵𝐵0)(𝑒𝑒−(𝜆𝜆𝐵𝐵𝐵𝐵+𝜆𝜆𝑏𝑏)𝑡𝑡 𝑒𝑒−(𝜆𝜆𝑃𝑃𝑏𝑏+𝜆𝜆𝑏𝑏)𝑡𝑡𝜆𝜆𝑃𝑃𝑃𝑃 − 𝜆𝜆𝐵𝐵𝐵𝐵 − 𝑒𝑒−(𝜆𝜆𝑃𝑃𝑃𝑃+𝜆𝜆𝑏𝑏)𝑡𝑡 𝑒𝑒−(𝜆𝜆𝑃𝑃𝑏𝑏+𝜆𝜆𝑏𝑏)𝑡𝑡𝜆𝜆𝑃𝑃𝑃𝑃 − 𝜆𝜆𝑃𝑃𝑃𝑃 )+ 
 
213Bismuth decays with a branching ratio BR ( = 0.9791) to 213Po and the 213Po kinetics follows:
 
 
dditional file 1 
1. Single compartment clearance model for 213Bi conjugates activity in organs or tumours. 
The 213Bi activity in the volume is cleared with a biologic clearance constant b (= ln(2)/Tb, with Tb the 
clearance half-life) and the kinetics follows an exponential decay function:  
𝐴𝐴𝐵𝐵𝐵𝐵 𝑡𝑡 𝐴𝐴𝐵𝐵𝐵𝐵 𝑒𝑒
−(𝜆𝜆𝐵𝐵𝐵𝐵+𝜆𝜆𝑏𝑏)𝑡𝑡 
The activity integration from time 0 to T of the 213Bi activity and time integrated activity ÃBi is then: 
 𝐵𝐵𝐵𝐵 𝑇𝑇 ∫ 𝐴𝐴𝐵𝐵𝐵𝐵 𝑡𝑡 𝑑𝑑𝑡𝑡
𝐴𝐴𝐵𝐵𝐵𝐵(0)
𝜆𝜆𝐵𝐵𝐵𝐵+𝜆𝜆𝑏𝑏
( − 𝑒𝑒−(𝜆𝜆𝐵𝐵𝐵𝐵+𝜆𝜆𝑏𝑏)𝑇𝑇)𝑇𝑇
0
   𝑇𝑇→∞ 𝐵𝐵𝐵𝐵 𝑇𝑇 𝐵𝐵𝐵𝐵
𝐴𝐴𝐵𝐵𝐵𝐵(0)
𝜆𝜆𝐵𝐵𝐵𝐵+𝜆𝜆𝑏𝑏
 
213Bismuth decays with a branching ratio BR (=0.9791) to 213Po and the 213Po kinetics follows: 
𝐴𝐴𝑃𝑃𝑃𝑃 𝑡𝑡
𝐵𝐵𝐵𝐵 𝜆𝜆𝑃𝑃𝑃𝑃
−𝜆𝜆𝐵𝐵𝐵𝐵
𝐴𝐴𝐵𝐵𝐵𝐵((𝑒𝑒−(𝜆𝜆𝐵𝐵𝐵𝐵+𝜆𝜆𝑏𝑏)𝑡𝑡 − 𝑒𝑒−(𝜆𝜆𝑃𝑃𝑃𝑃+𝜆𝜆𝑏𝑏)𝑡𝑡) 
The activity integration over time of the 213Po activity and time integrated activity ÃPo is then: 
𝑃𝑃𝑃𝑃 𝑇𝑇
𝐵𝐵𝐵𝐵 𝜆𝜆𝑃𝑃𝑃𝑃
𝜆𝜆𝑃𝑃𝑃𝑃−𝜆𝜆𝐵𝐵𝐵𝐵
𝐴𝐴𝐵𝐵𝐵𝐵((1−𝑒𝑒−(𝜆𝜆𝐵𝐵𝐵𝐵+𝜆𝜆𝑏𝑏)𝑇𝑇𝜆𝜆𝐵𝐵𝐵𝐵+𝜆𝜆𝑏𝑏 − 1−𝑒𝑒−(𝜆𝜆𝑃𝑃𝑃𝑃+𝜆𝜆𝑏𝑏)𝑇𝑇𝜆𝜆𝑃𝑃𝑃𝑃+𝜆𝜆𝑏𝑏 )  
 𝑃𝑃𝑃𝑃
𝐵𝐵𝐵𝐵 𝜆𝜆𝑃𝑃𝑃𝑃
𝜆𝜆𝑃𝑃𝑃𝑃−𝜆𝜆𝐵𝐵𝐵𝐵
𝐴𝐴𝐵𝐵𝐵𝐵 (
1
𝜆𝜆𝐵𝐵𝐵𝐵+𝜆𝜆𝑏𝑏
− 1
𝜆𝜆𝑃𝑃𝑃𝑃+𝜆𝜆𝑏𝑏
)  
 𝑃𝑃𝑃𝑃 ≈ 𝐵𝐵𝐵𝐵 𝐴𝐴𝐵𝐵𝐵𝐵
1
𝜆𝜆𝐵𝐵𝐵𝐵+𝜆𝜆𝑏𝑏
 
The decay and biodistribution of the other daughters 209Tl and 209Pb are described quite similarly: 
𝐴𝐴𝑇𝑇𝑇𝑇 𝑡𝑡
(1−𝐵𝐵𝐵𝐵) 𝜆𝜆𝑇𝑇𝑇𝑇
𝜆𝜆𝑇𝑇𝑇𝑇−𝜆𝜆𝐵𝐵𝐵𝐵
𝐴𝐴𝐵𝐵𝐵𝐵 (𝑒𝑒
−(𝜆𝜆𝐵𝐵𝐵𝐵+𝜆𝜆𝑏𝑏)𝑡𝑡 − 𝑒𝑒−(𝜆𝜆𝑇𝑇𝑇𝑇+𝜆𝜆𝑏𝑏)𝑡𝑡) 
with: 𝑇𝑇𝑇𝑇 𝑇𝑇
(1−𝐵𝐵𝐵𝐵) 𝜆𝜆𝑇𝑇𝑇𝑇
𝜆𝜆𝑇𝑇𝑇𝑇−𝜆𝜆𝐵𝐵𝐵𝐵
𝐴𝐴𝐵𝐵𝐵𝐵 (
1−𝑒𝑒−(𝜆𝜆𝐵𝐵𝐵𝐵+𝜆𝜆𝑏𝑏)𝑇𝑇
𝜆𝜆𝐵𝐵𝐵𝐵+𝜆𝜆𝑏𝑏
− 1−𝑒𝑒
−(𝜆𝜆𝑇𝑇𝑇𝑇+𝜆𝜆𝑏𝑏)𝑇𝑇
𝜆𝜆𝑇𝑇𝑇𝑇+𝜆𝜆𝑏𝑏
)  
 𝑇𝑇𝑇𝑇
(1−𝐵𝐵𝐵𝐵) 𝜆𝜆𝑇𝑇𝑇𝑇
𝜆𝜆𝑇𝑇𝑇𝑇−𝜆𝜆𝐵𝐵𝐵𝐵
𝐴𝐴𝐵𝐵𝐵𝐵 (
1
𝜆𝜆𝐵𝐵𝐵𝐵+𝜆𝜆𝑏𝑏
− 1
𝜆𝜆𝑇𝑇𝑇𝑇+𝜆𝜆𝑏𝑏
) 
𝐴𝐴𝑃𝑃𝑃𝑃 𝑡𝑡
𝐵𝐵𝐵𝐵 𝜆𝜆𝑃𝑃𝑃𝑃 𝜆𝜆𝑃𝑃𝑏𝑏
𝜆𝜆𝑃𝑃𝑃𝑃−𝜆𝜆𝐵𝐵𝐵𝐵
𝐴𝐴𝐵𝐵𝐵𝐵 (
𝑒𝑒−(𝜆𝜆𝐵𝐵𝐵𝐵+𝜆𝜆𝑏𝑏)𝑡𝑡 − 𝑒𝑒−(𝜆𝜆𝑃𝑃𝑏𝑏+𝜆𝜆𝑏𝑏)𝑡𝑡
𝜆𝜆𝑃𝑃𝑃𝑃 − 𝜆𝜆𝐵𝐵𝐵𝐵
−
𝑒𝑒−(𝜆𝜆𝑃𝑃𝑃𝑃+𝜆𝜆𝑏𝑏)𝑡𝑡 − 𝑒𝑒−(𝜆𝜆𝑃𝑃𝑏𝑏+𝜆𝜆𝑏𝑏)𝑡𝑡
𝜆𝜆𝑃𝑃𝑃𝑃 − 𝜆𝜆𝑃𝑃𝑃𝑃
)  
 
 ti ity integration over time of the 213Po activity and time integrated activity ÃPo is then:
 
 
Additional file 1 
1. Single compartment clearance model for 213Bi conjugates activity in organs or tumours. 
The 213Bi activity in e volume is cleared with a biologic clearance constant b (= ln(2)/Tb, with Tb the 
clearance half-life) d the ki etics follows an exponential decay function:  
𝐴𝐴𝐵𝐵𝐵𝐵(𝑡𝑡=𝐴𝐴𝐵𝐵𝐵𝐵(0)𝑒𝑒−(𝜆𝜆𝐵𝐵𝐵𝐵+𝜆𝜆𝑏𝑏)𝑡𝑡 
The activity integra ion from time 0 to T of the 213Bi activi y and time integrated activity ÃBi is then: 
 Ã𝐵𝐵𝐵𝐵(𝑇𝑇)=∫ 𝐴𝐴𝐵𝐵𝐵𝐵 𝑡𝑡) 𝑑𝑑𝑡𝑡=𝐴𝐴𝐵𝐵𝐵𝐵(0𝜆𝜆𝐵𝐵𝐵𝐵+𝜆𝜆𝑏𝑏(1− 𝑒𝑒−(𝜆𝜆𝐵𝐵𝐵𝐵+𝜆𝜆𝑏𝑏)𝑇𝑇)𝑇𝑇0    lim𝑇𝑇→∞Ã𝐵𝐵𝐵𝐵 𝑇𝑇=Ã𝐵𝐵𝐵𝐵=𝐴𝐴𝐵𝐵𝐵𝐵(0)𝜆𝜆𝐵𝐵𝐵𝐵+𝜆𝜆𝑏𝑏 
213Bismuth decays with a branching ratio BR (=0.9791) to 213P  and the 213Po kinetics follows: 
𝐴𝐴𝑃𝑃𝑃𝑃 𝑡𝑡=𝐵𝐵𝐵𝐵 𝜆𝜆𝑃𝑃𝑃𝑃𝜆𝜆𝑃𝑃𝑃𝑃−𝜆𝜆𝐵𝐵𝐵𝐵×𝐴𝐴𝐵𝐵𝐵𝐵0)(𝑒𝑒−(𝜆𝜆𝐵𝐵𝐵𝐵+𝜆𝜆𝑏𝑏)𝑡𝑡 − 𝑒𝑒−(𝜆𝜆𝑃𝑃𝑃𝑃+𝜆𝜆𝑏𝑏)𝑡𝑡) 
The activity integration o er time of the 213Po activity and time int grated activity ÃPo is then: 
Ã𝑃𝑃𝑃𝑃 𝑇𝑇=𝐵𝐵𝐵𝐵 𝜆𝜆𝑃𝑃𝑃𝑃𝜆𝜆𝑃𝑃𝑃𝑃−𝜆𝜆𝐵𝐵𝐵𝐵 𝐴𝐴𝐵𝐵𝐵𝐵0)(1−𝑒𝑒−(𝜆𝜆𝐵𝐵𝐵𝐵+𝜆𝜆𝑏𝑏)𝑇𝑇𝜆𝜆𝐵𝐵𝐵𝐵+𝜆𝜆𝑏𝑏 − 1−𝑒𝑒−(𝜆𝜆𝑃𝑃𝑃𝑃+𝜆𝜆𝑏𝑏)𝑇𝑇𝜆𝜆𝑃𝑃𝑃𝑃+𝜆𝜆𝑏𝑏 )  
 Ã𝑃𝑃𝑃𝑃=𝐵𝐵𝐵𝐵 𝜆𝜆𝑃𝑃𝑃𝑃𝜆𝜆𝑃𝑃𝑃𝑃−𝜆𝜆𝐵𝐵𝐵𝐵 𝐴𝐴𝐵𝐵𝐵𝐵(0( 1𝜆𝜆𝐵𝐵𝐵𝐵+𝜆𝜆𝑏𝑏 − 1𝜆𝜆𝑃𝑃𝑃𝑃+𝜆𝜆𝑏𝑏)  
 Ã𝑃𝑃𝑃𝑃 ≈ 𝐵𝐵𝐵𝐵 𝐴𝐴𝐵𝐵𝐵𝐵(0)1𝜆𝜆𝐵𝐵𝐵𝐵+𝜆𝜆𝑏𝑏 
The decay and biodistribution of the other daughters 209Tl and 209Pb are described quite similarly: 
𝐴𝐴𝑇𝑇𝑇𝑇 𝑡𝑡=1−𝐵𝐵𝐵𝐵) 𝜆𝜆𝑇𝑇𝑇𝑇𝜆𝜆𝑇𝑇𝑇𝑇−𝜆𝜆𝐵𝐵𝐵𝐵×𝐴𝐴𝐵𝐵𝐵𝐵0)(𝑒𝑒−(𝜆𝜆𝐵𝐵𝐵𝐵+𝜆𝜆𝑏𝑏)𝑡𝑡 − 𝑒𝑒−(𝜆𝜆𝑇𝑇𝑇𝑇+𝜆𝜆𝑏𝑏)𝑡𝑡) 
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 𝐴𝐴𝑃𝑃𝑃𝑃(𝑡𝑡)=𝜆𝜆𝑃𝑃𝑃𝑃𝜆𝜆𝑢𝑢𝐵𝐵𝐵𝐵(𝜆𝜆𝑢𝑢−𝜆𝜆𝑏𝑏)(𝜆𝜆𝑃𝑃𝑃𝑃−𝜆𝜆𝐵𝐵𝐵𝐵)𝐴𝐴𝐵𝐵𝐵𝐵 (0)(𝑒𝑒−(𝜆𝜆𝐵𝐵𝐵𝐵+𝜆𝜆𝑏𝑏)𝑡𝑡−𝑒𝑒−(𝜆𝜆𝐵𝐵𝐵𝐵+𝜆𝜆𝑢𝑢)𝑡𝑡 − 𝑒𝑒−(𝜆𝜆𝑃𝑃𝑃𝑃+𝜆𝜆𝑏𝑏)𝑡𝑡+𝑒𝑒−(𝜆𝜆𝑃𝑃𝑃𝑃+𝜆𝜆𝑢𝑢)𝑡𝑡) 
 
 Ã𝑃𝑃𝑃𝑃(𝑇𝑇)=𝜆𝜆𝑃𝑃𝑃𝑃𝜆𝜆𝑢𝑢𝐵𝐵𝐵𝐵𝜆𝜆𝑃𝑃𝑃𝑃−𝜆𝜆𝐵𝐵𝐵𝐵 𝐴𝐴𝐵𝐵𝐵𝐵(0)(1−𝑒𝑒−(𝜆𝜆𝐵𝐵𝐵𝐵+𝜆𝜆𝑏𝑏)𝑇𝑇𝜆𝜆𝐵𝐵𝐵𝐵+𝜆𝜆𝑏𝑏  − 1−𝑒𝑒−(𝜆𝜆𝐵𝐵𝐵𝐵+𝜆𝜆𝑢𝑢)𝑇𝑇𝜆𝜆𝐵𝐵𝐵𝐵+𝜆𝜆𝑢𝑢 − 1−𝑒𝑒−(𝜆𝜆𝑃𝑃𝑃𝑃+𝜆𝜆𝑏𝑏)𝑇𝑇𝜆𝜆𝑃𝑃𝑃𝑃+𝜆𝜆𝑏𝑏 +1−𝑒𝑒−(𝜆𝜆𝑃𝑃𝑃𝑃+𝜆𝜆𝑢𝑢)𝑇𝑇𝜆𝜆𝑃𝑃𝑃𝑃+𝜆𝜆𝑢𝑢 ) 
 Ã𝑃𝑃𝑃𝑃=𝜆𝜆𝑃𝑃𝑃𝑃𝜆𝜆𝑢𝑢𝜆𝜆𝑃𝑃𝑃𝑃−𝜆𝜆𝐵𝐵𝐵𝐵 𝐵𝐵𝐵𝐵 𝐴𝐴𝐵𝐵𝐵𝐵(0)( 1𝜆𝜆𝐵𝐵𝐵𝐵+𝜆𝜆𝑏𝑏)(𝜆𝜆𝐵𝐵𝐵𝐵+𝜆𝜆𝑢𝑢)− 1(𝜆𝜆𝑃𝑃𝑃𝑃+𝜆𝜆𝑏𝑏)(𝜆𝜆𝑃𝑃𝑃𝑃+𝜆𝜆𝑢𝑢)) 
2.  single compartment uptake and clearance model for 213Bi conjugates 
activity.
Uptake kinetics in organ or tumour with rate constant lu (= ln(2)/Tu, with Tu the uptake half-life) and 
clearance back to plasma with rate constant lb
213Bi kinetics: 
 
 
(1− 𝐵𝐵𝐵𝐵) 𝜆𝜆𝑇𝑇𝑇𝑇 𝜆𝜆𝑃𝑃𝑃𝑃
𝜆𝜆𝑇𝑇𝑇𝑇 − 𝜆𝜆𝐵𝐵𝐵𝐵
×𝐴𝐴𝐵𝐵𝐵𝐵(0)(𝑒𝑒−(𝜆𝜆𝐵𝐵𝐵𝐵+𝜆𝜆𝑏𝑏)𝑡𝑡 − 𝑒𝑒−(𝜆𝜆𝑃𝑃𝑏𝑏+𝜆𝜆𝑏𝑏)𝑡𝑡𝜆𝜆𝑃𝑃𝑃𝑃 − 𝜆𝜆𝐵𝐵𝐵𝐵 − 𝑒𝑒−(𝜆𝜆𝑇𝑇𝑇𝑇+𝜆𝜆𝑏𝑏)𝑡𝑡 − 𝑒𝑒−(𝜆𝜆𝑃𝑃𝑏𝑏+𝜆𝜆𝑏𝑏)𝑡𝑡𝜆𝜆𝑃𝑃𝑃𝑃 − 𝜆𝜆𝑇𝑇𝑇𝑇 ) 
 Ã𝑃𝑃𝑃𝑃(𝑇𝑇)=𝐵𝐵𝐵𝐵 𝜆𝜆𝑃𝑃𝑃𝑃 𝜆𝜆𝑃𝑃𝑏𝑏𝜆𝜆𝑃𝑃𝑃𝑃−𝜆𝜆𝐵𝐵𝐵𝐵×𝐴𝐴𝐵𝐵𝐵𝐵(0)(1−𝑒𝑒−(𝜆𝜆𝐵𝐵𝐵𝐵+𝜆𝜆𝑏𝑏)𝑇𝑇𝜆𝜆𝐵𝐵𝐵𝐵+𝜆𝜆𝑏𝑏 −1−𝑒𝑒−(𝜆𝜆𝑃𝑃𝑏𝑏+𝜆𝜆𝑏𝑏)𝑇𝑇𝜆𝜆𝑃𝑃𝑏𝑏+𝜆𝜆𝑏𝑏𝜆𝜆𝑃𝑃𝑏𝑏−𝜆𝜆𝐵𝐵𝐵𝐵 − 1−𝑒𝑒−(𝜆𝜆𝑃𝑃𝑃𝑃+𝜆𝜆𝑏𝑏)𝑇𝑇𝜆𝜆𝑃𝑃𝑃𝑃+𝜆𝜆𝑏𝑏 −1−𝑒𝑒−(𝜆𝜆𝑃𝑃𝑏𝑏+𝜆𝜆𝑏𝑏)𝑇𝑇𝜆𝜆𝑃𝑃𝑏𝑏+𝜆𝜆𝑏𝑏𝜆𝜆𝑃𝑃𝑏𝑏−𝜆𝜆𝑃𝑃𝑃𝑃 )+ 
(1− 𝐵𝐵𝐵𝐵) 𝜆𝜆𝑇𝑇𝑇𝑇 𝜆𝜆𝑃𝑃𝑃𝑃
𝜆𝜆𝑇𝑇𝑇𝑇 − 𝜆𝜆𝐵𝐵𝐵𝐵
×𝐴𝐴𝐵𝐵𝐵𝐵(0)(1−𝑒𝑒−(𝜆𝜆𝐵𝐵𝐵𝐵+𝜆𝜆𝑏𝑏)𝑇𝑇𝜆𝜆𝐵𝐵𝐵𝐵+𝜆𝜆𝑏𝑏 − 1−𝑒𝑒−(𝜆𝜆𝑃𝑃𝑏𝑏+𝜆𝜆𝑏𝑏)𝑇𝑇𝜆𝜆𝑃𝑃𝑏𝑏+𝜆𝜆𝑏𝑏𝜆𝜆𝑃𝑃𝑃𝑃 − 𝜆𝜆𝐵𝐵𝐵𝐵 − 1−𝑒𝑒−(𝜆𝜆𝑇𝑇𝑇𝑇+𝜆𝜆𝑏𝑏)𝑇𝑇𝜆𝜆𝑇𝑇𝑇𝑇+𝜆𝜆𝑏𝑏 − 1−𝑒𝑒−(𝜆𝜆𝑃𝑃𝑏𝑏+𝜆𝜆𝑏𝑏)𝑇𝑇𝜆𝜆𝑃𝑃𝑏𝑏+𝜆𝜆𝑏𝑏𝜆𝜆𝑃𝑃𝑃𝑃 − 𝜆𝜆𝑇𝑇𝑇𝑇 ) 
 Ã𝑃𝑃𝑃𝑃=𝐵𝐵𝐵𝐵 𝜆𝜆𝑃𝑃𝑃𝑃 𝜆𝜆𝑃𝑃𝑏𝑏𝜆𝜆𝑃𝑃𝑃𝑃−𝜆𝜆𝐵𝐵𝐵𝐵×𝐴𝐴𝐵𝐵𝐵𝐵(0)( 1𝜆𝜆𝐵𝐵𝐵𝐵+𝜆𝜆𝑏𝑏 − 1𝜆𝜆𝑃𝑃𝑏𝑏+𝜆𝜆𝑏𝑏𝜆𝜆𝑃𝑃𝑃𝑃 − 𝜆𝜆𝐵𝐵𝐵𝐵 − 1𝜆𝜆𝑃𝑃𝑃𝑃+𝜆𝜆𝑏𝑏 − 1𝜆𝜆𝑃𝑃𝑏𝑏+𝜆𝜆𝑏𝑏𝜆𝜆𝑃𝑃𝑃𝑃 − 𝜆𝜆𝑃𝑃𝑃𝑃 )+ 
(1− 𝐵𝐵𝐵𝐵) 𝜆𝜆𝑇𝑇𝑇𝑇 𝜆𝜆𝑃𝑃𝑃𝑃
𝜆𝜆𝑇𝑇𝑇𝑇 − 𝜆𝜆𝐵𝐵𝐵𝐵
×𝐴𝐴𝐵𝐵𝐵𝐵(0)( 1𝜆𝜆𝐵𝐵𝐵𝐵+𝜆𝜆𝑏𝑏 − 1𝜆𝜆𝑃𝑃𝑏𝑏+𝜆𝜆𝑏𝑏𝜆𝜆𝑃𝑃𝑃𝑃 − 𝜆𝜆𝐵𝐵𝐵𝐵 − 1𝜆𝜆𝑇𝑇𝑇𝑇+𝜆𝜆𝑏𝑏 − 1𝜆𝜆𝑃𝑃𝑏𝑏+𝜆𝜆𝑏𝑏𝜆𝜆𝑃𝑃𝑃𝑃 − 𝜆𝜆𝑇𝑇𝑇𝑇 ) 
2. Single compartment uptake and clearance model for 213Bi conjugates activity. 
 kinetics in organ or tumour with rate constant u (= ln(2)/Tu, with Tu t e ptake half-life) and 
clearance back to plasma with rate constant b  
213Bi kinetics:  𝐴𝐴𝐵𝐵𝐵𝐵(𝑡𝑡)=𝜆𝜆𝑢𝑢𝜆𝜆𝑢𝑢−𝜆𝜆𝑏𝑏 𝐴𝐴𝐵𝐵𝐵𝐵(0)𝑒𝑒−𝜆𝜆𝐵𝐵𝐵𝐵𝑡𝑡(𝑒𝑒−𝜆𝜆𝑏𝑏𝑡𝑡 − 𝑒𝑒−𝜆𝜆𝑢𝑢𝑡𝑡)  
Ã𝐵𝐵𝐵𝐵(𝑇𝑇)=𝜆𝜆𝑢𝑢𝜆𝜆𝑢𝑢 − 𝜆𝜆𝑃𝑃 𝐴𝐴𝐵𝐵𝐵𝐵(0)1−𝑒𝑒−(𝜆𝜆𝐵𝐵𝐵𝐵+𝜆𝜆𝑏𝑏)𝑇𝑇𝜆𝜆𝐵𝐵𝐵𝐵+𝜆𝜆𝑏𝑏 − 1−𝑒𝑒−(𝜆𝜆𝐵𝐵𝐵𝐵+𝜆𝜆𝑢𝑢)𝑇𝑇𝜆𝜆𝐵𝐵𝐵𝐵+𝜆𝜆𝑢𝑢  
 Ã𝐵𝐵𝐵𝐵=𝐴𝐴𝐵𝐵𝐵𝐵(0)𝜆𝜆𝑢𝑢(𝜆𝜆𝐵𝐵𝐵𝐵+𝜆𝜆𝑏𝑏)(𝜆𝜆𝐵𝐵𝐵𝐵+𝜆𝜆𝑢𝑢) 
213Po kinetics:   
 𝐴𝐴𝑃𝑃𝑃𝑃(𝑡𝑡)=𝜆𝜆𝑃𝑃𝑃𝑃𝜆𝜆𝑢𝑢𝐵𝐵𝐵𝐵(𝜆𝜆𝑢𝑢−𝜆𝜆𝑏𝑏)(𝜆𝜆𝑃𝑃𝑃𝑃−𝜆𝜆𝐵𝐵𝐵𝐵)𝐴𝐴𝐵𝐵𝐵𝐵 (0)(𝑒𝑒−(𝜆𝜆𝐵𝐵𝐵𝐵+𝜆𝜆𝑏𝑏)𝑡𝑡−𝑒𝑒−(𝜆𝜆𝐵𝐵𝐵𝐵+𝜆𝜆𝑢𝑢)𝑡𝑡 − 𝑒𝑒−(𝜆𝜆𝑃𝑃𝑃𝑃+𝜆𝜆𝑏𝑏)𝑡𝑡+𝑒𝑒−(𝜆𝜆𝑃𝑃𝑃𝑃+𝜆𝜆𝑢𝑢)𝑡𝑡) 
 
 𝑃𝑃𝑃𝑃(𝑇𝑇)=𝜆𝜆𝑃𝑃𝑃𝑃𝜆𝜆𝑢𝑢𝐵𝐵𝐵𝐵𝜆𝜆𝑃𝑃𝑃𝑃−𝜆𝜆𝐵𝐵𝐵𝐵 𝐴𝐴𝐵𝐵𝐵𝐵0)(1−𝑒𝑒−(𝜆𝜆𝐵𝐵𝐵𝐵+𝜆𝜆𝑏𝑏)𝑇𝑇𝜆𝜆𝐵𝐵𝐵𝐵+𝜆𝜆𝑏𝑏  − 1−𝑒𝑒−(𝜆𝜆𝐵𝐵𝐵𝐵+𝜆𝜆𝑢𝑢)𝑇𝑇𝜆𝜆𝐵𝐵𝐵𝐵+𝜆𝜆𝑢𝑢 − 1−𝑒𝑒−(𝜆𝜆𝑃𝑃𝑃𝑃+𝜆𝜆𝑏𝑏)𝑇𝑇𝜆𝜆𝑃𝑃𝑃𝑃+𝜆𝜆𝑏𝑏 +1−𝑒𝑒−(𝜆𝜆𝑃𝑃𝑃𝑃+𝜆𝜆𝑢𝑢)𝑇𝑇𝜆𝜆𝑃𝑃𝑃𝑃+𝜆𝜆𝑢𝑢 ) 
 Ã𝑃𝑃𝑃𝑃=𝜆𝜆𝑃𝑃𝑃𝑃𝜆𝜆𝑢𝑢𝜆𝜆𝑃𝑃𝑃𝑃−𝜆𝜆𝐵𝐵𝐵𝐵 𝐵𝐵𝐵𝐵 𝐴𝐴𝐵𝐵𝐵𝐵(0)( 1𝜆𝜆𝐵𝐵𝐵𝐵+𝜆𝜆𝑏𝑏)(𝜆𝜆𝐵𝐵𝐵𝐵+𝜆𝜆𝑢𝑢)− 1(𝜆𝜆𝑃𝑃𝑃𝑃+𝜆𝜆𝑏𝑏)(𝜆𝜆𝑃𝑃𝑃𝑃+𝜆𝜆𝑢𝑢)) 
213Po kinetics: 
 
 
− 𝐵𝐵𝐵𝐵 𝜆𝜆𝑇𝑇𝑇𝑇 𝜆𝜆𝑃𝑃𝑃𝑃
𝜆𝜆𝑇𝑇𝑇𝑇 − 𝜆𝜆𝐵𝐵𝐵𝐵
𝐴𝐴𝐵𝐵𝐵𝐵 (
𝑒𝑒− 𝜆𝜆𝐵𝐵𝐵𝐵+𝜆𝜆𝑏𝑏)𝑡𝑡 − 𝑒𝑒−(𝜆𝜆𝑃𝑃𝑏𝑏+𝜆𝜆𝑏𝑏)𝑡𝑡
𝜆𝜆𝑃𝑃𝑃𝑃 − 𝜆𝜆𝐵𝐵𝐵𝐵
−
𝑒𝑒−(𝜆𝜆𝑇𝑇𝑇𝑇+𝜆𝜆𝑏𝑏)𝑡𝑡 − 𝑒𝑒−(𝜆𝜆𝑃𝑃𝑏𝑏+𝜆𝜆𝑏𝑏)𝑡𝑡
𝜆𝜆𝑃𝑃𝑃𝑃 − 𝜆𝜆𝑇𝑇𝑇𝑇
) 
 𝑃𝑃𝑃𝑃 𝑇𝑇
𝐵𝐵𝐵𝐵 𝜆𝜆𝑃𝑃𝑃𝑃 𝜆𝜆𝑃𝑃𝑏𝑏
𝜆𝜆𝑃𝑃𝑃𝑃−𝜆𝜆𝐵𝐵𝐵𝐵
𝐴𝐴𝐵𝐵𝐵𝐵 (
1−𝑒𝑒−(𝜆𝜆𝐵𝐵𝐵𝐵+𝜆𝜆𝑏𝑏)𝑇𝑇
𝜆𝜆𝐵𝐵𝐵𝐵+𝜆𝜆𝑏𝑏
−1−𝑒𝑒
−(𝜆𝜆𝑃𝑃𝑏𝑏+𝜆𝜆𝑏𝑏)𝑇𝑇
𝜆𝜆𝑃𝑃𝑏𝑏+𝜆𝜆𝑏𝑏
𝜆𝜆𝑃𝑃𝑏𝑏−𝜆𝜆𝐵𝐵𝐵𝐵
−
1−𝑒𝑒−(𝜆𝜆𝑃𝑃𝑃𝑃+𝜆𝜆𝑏𝑏)𝑇𝑇
𝜆𝜆𝑃𝑃𝑃𝑃+𝜆𝜆𝑏𝑏
−1−𝑒𝑒
−(𝜆𝜆𝑃𝑃𝑏𝑏+𝜆𝜆𝑏𝑏)𝑇𝑇
𝜆𝜆𝑃𝑃𝑏𝑏+𝜆𝜆𝑏𝑏
𝜆𝜆𝑃𝑃𝑏𝑏−𝜆𝜆𝑃𝑃𝑃𝑃
)  
− 𝐵𝐵𝐵𝐵 𝜆𝜆𝑇𝑇𝑇𝑇 𝜆𝜆𝑃𝑃𝑃𝑃
𝜆𝜆𝑇𝑇𝑇𝑇 − 𝜆𝜆𝐵𝐵𝐵𝐵
𝐴𝐴𝐵𝐵𝐵𝐵 (
1−𝑒𝑒−(𝜆𝜆𝐵𝐵𝐵𝐵+𝜆𝜆𝑏𝑏)𝑇𝑇
𝜆𝜆𝐵𝐵𝐵𝐵+𝜆𝜆𝑏𝑏
− 1−𝑒𝑒
−(𝜆𝜆𝑃𝑃𝑏𝑏+𝜆𝜆𝑏𝑏)𝑇𝑇
𝜆𝜆𝑃𝑃𝑏𝑏+𝜆𝜆𝑏𝑏
𝜆𝜆𝑃𝑃𝑃𝑃 − 𝜆𝜆𝐵𝐵𝐵𝐵
−
1−𝑒𝑒−(𝜆𝜆𝑇𝑇𝑇𝑇+𝜆𝜆𝑏𝑏)𝑇𝑇
𝜆𝜆𝑇𝑇𝑇𝑇+𝜆𝜆𝑏𝑏
− 1−𝑒𝑒
−(𝜆𝜆𝑃𝑃𝑏𝑏+𝜆𝜆𝑏𝑏)𝑇𝑇
𝜆𝜆𝑃𝑃𝑏𝑏+𝜆𝜆𝑏𝑏
𝜆𝜆𝑃𝑃𝑃𝑃 − 𝜆𝜆𝑇𝑇𝑇𝑇
) 
 𝑃𝑃𝑃𝑃
𝐵𝐵𝐵𝐵 𝜆𝜆𝑃𝑃𝑃𝑃 𝜆𝜆𝑃𝑃𝑏𝑏
𝜆𝜆𝑃𝑃𝑃𝑃−𝜆𝜆𝐵𝐵𝐵𝐵
𝐴𝐴𝐵𝐵𝐵𝐵 (
1
𝜆𝜆𝐵𝐵𝐵𝐵+𝜆𝜆𝑏𝑏
− 1
𝜆𝜆𝑃𝑃𝑏𝑏+𝜆𝜆𝑏𝑏
𝜆𝜆𝑃𝑃𝑃𝑃 − 𝜆𝜆𝐵𝐵𝐵𝐵
−
1
𝜆𝜆𝑃𝑃𝑃𝑃+𝜆𝜆𝑏𝑏
− 1
𝜆𝜆𝑃𝑃𝑏𝑏+𝜆𝜆𝑏𝑏
𝜆𝜆𝑃𝑃𝑃𝑃 − 𝜆𝜆𝑃𝑃𝑃𝑃
)  
− 𝐵𝐵𝐵𝐵 𝜆𝜆𝑇𝑇𝑇𝑇 𝜆𝜆𝑃𝑃𝑃𝑃
𝜆𝜆𝑇𝑇𝑇𝑇 − 𝜆𝜆𝐵𝐵𝐵𝐵
𝐴𝐴𝐵𝐵𝐵𝐵 (
1
𝜆𝜆𝐵𝐵𝐵𝐵+𝜆𝜆𝑏𝑏
− 1
𝜆𝜆𝑃𝑃𝑏𝑏+𝜆𝜆𝑏𝑏
𝜆𝜆𝑃𝑃𝑃𝑃 − 𝜆𝜆𝐵𝐵𝐵𝐵
−
1
𝜆𝜆𝑇𝑇𝑇𝑇+𝜆𝜆𝑏𝑏
− 1
𝜆𝜆𝑃𝑃𝑏𝑏+𝜆𝜆𝑏𝑏
𝜆𝜆𝑃𝑃𝑃𝑃 − 𝜆𝜆𝑇𝑇𝑇𝑇
) 
2. Single compartment up ake and clearance model for 213Bi conjugates activi y. 
Uptake kinetics in organ or tumour with rate constant u (= ln(2)/Tu, with Tu the uptake half-life) and 
clearance back to plasma with rate constant b  
213Bi kinetics:  𝐴𝐴𝐵𝐵𝐵𝐵 𝑡𝑡
𝜆𝜆𝑢𝑢
𝜆𝜆𝑢𝑢−𝜆𝜆𝑏𝑏
𝐴𝐴𝐵𝐵𝐵𝐵 𝑒𝑒
−𝜆𝜆𝐵𝐵𝐵𝐵𝑡𝑡 𝑒𝑒−𝜆𝜆𝑏𝑏𝑡𝑡 − 𝑒𝑒−𝜆𝜆𝑢𝑢𝑡𝑡   
𝐵𝐵𝐵𝐵 𝑇𝑇
𝜆𝜆𝑢𝑢
𝜆𝜆𝑢𝑢 − 𝜆𝜆𝑃𝑃
𝐴𝐴𝐵𝐵𝐵𝐵
1−𝑒𝑒−(𝜆𝜆𝐵𝐵𝐵𝐵+𝜆𝜆𝑏𝑏)𝑇𝑇
𝜆𝜆𝐵𝐵𝐵𝐵+𝜆𝜆𝑏𝑏
−
1−𝑒𝑒−(𝜆𝜆𝐵𝐵𝐵𝐵+𝜆𝜆𝑢𝑢)𝑇𝑇
𝜆𝜆𝐵𝐵𝐵𝐵+𝜆𝜆𝑢𝑢
 
 𝐵𝐵𝐵𝐵
𝐴𝐴𝐵𝐵𝐵𝐵(0)𝜆𝜆𝑢𝑢(𝜆𝜆𝐵𝐵𝐵𝐵+𝜆𝜆𝑏𝑏)𝜆𝜆𝐵𝐵𝐵𝐵+𝜆𝜆𝑢𝑢) 
213Po kinetics:   
 𝐴𝐴𝑃𝑃𝑃𝑃 𝑡𝑡
𝜆𝜆𝑃𝑃𝑃𝑃𝜆𝜆𝑢𝑢𝐵𝐵𝐵𝐵(𝜆𝜆𝑢𝑢−𝜆𝜆𝑏𝑏)(𝜆𝜆𝑃𝑃𝑃𝑃−𝜆𝜆𝐵𝐵𝐵𝐵)𝐴𝐴𝐵𝐵𝐵𝐵 (𝑒𝑒−(𝜆𝜆𝐵𝐵𝐵𝐵+𝜆𝜆𝑏𝑏)𝑡𝑡−𝑒𝑒−(𝜆𝜆𝐵𝐵𝐵𝐵+𝜆𝜆𝑢𝑢)𝑡𝑡 − 𝑒𝑒−(𝜆𝜆𝑃𝑃𝑃𝑃+𝜆𝜆𝑏𝑏)𝑡𝑡 𝑒𝑒−(𝜆𝜆𝑃𝑃𝑃𝑃+𝜆𝜆𝑢𝑢)𝑡𝑡) 
 
 Ã𝑃𝑃𝑃𝑃 𝑇𝑇 𝜆𝜆𝑃𝑃𝑃𝑃𝜆𝜆𝑢𝑢𝐵𝐵𝐵𝐵𝜆𝜆𝑃𝑃𝑃𝑃−𝜆𝜆𝐵𝐵𝐵𝐵 𝐴𝐴𝐵𝐵𝐵𝐵((1−𝑒𝑒−(𝜆𝜆𝐵𝐵𝐵𝐵+𝜆𝜆𝑏𝑏)𝑇𝑇𝜆𝜆𝐵𝐵𝐵𝐵+𝜆𝜆𝑏𝑏  − 1−𝑒𝑒−(𝜆𝜆𝐵𝐵𝐵𝐵+𝜆𝜆𝑢𝑢)𝑇𝑇𝜆𝜆𝐵𝐵𝐵𝐵+𝜆𝜆𝑢𝑢 − 1−𝑒𝑒−(𝜆𝜆𝑃𝑃𝑃𝑃+𝜆𝜆𝑏𝑏)𝑇𝑇𝜆𝜆𝑃𝑃𝑃𝑃+𝜆𝜆𝑏𝑏 1−𝑒𝑒−(𝜆𝜆𝑃𝑃𝑃𝑃+𝜆𝜆𝑢𝑢)𝑇𝑇𝜆𝜆𝑃𝑃𝑃𝑃+𝜆𝜆𝑢𝑢  
 𝑃𝑃𝑃𝑃
𝜆𝜆𝑃𝑃𝑃𝑃𝜆𝜆𝑢𝑢
𝜆𝜆𝑃𝑃𝑃𝑃−𝜆𝜆𝐵𝐵𝐵𝐵
𝐵𝐵𝐵𝐵 𝐴𝐴𝐵𝐵𝐵𝐵 (
1
𝜆𝜆𝐵𝐵𝐵𝐵+𝜆𝜆𝑏𝑏)(𝜆𝜆𝐵𝐵𝐵𝐵+𝜆𝜆𝑢𝑢)− 1(𝜆𝜆𝑃𝑃𝑃𝑃+𝜆𝜆𝑏𝑏)(𝜆𝜆𝑃𝑃𝑃𝑃+𝜆𝜆𝑢𝑢)) 
 
 
(1− 𝐵𝐵𝐵𝐵) 𝜆𝜆𝑇𝑇𝑇𝑇 𝜆𝜆𝑃𝑃𝑃𝑃
𝜆𝜆𝑇𝑇𝑇𝑇 − 𝜆𝜆𝐵𝐵𝐵𝐵
×𝐴𝐴𝐵𝐵𝐵𝐵(0)(𝑒𝑒−(𝜆𝜆𝐵𝐵𝐵𝐵+𝜆𝜆𝑏𝑏)𝑡𝑡 − 𝑒𝑒−(𝜆𝜆𝑃𝑃𝑏𝑏+𝜆𝜆𝑏𝑏)𝑡𝑡𝜆𝜆𝑃𝑃𝑃𝑃 − 𝜆𝜆𝐵𝐵𝐵𝐵 − 𝑒𝑒−(𝜆𝜆𝑇𝑇𝑇𝑇+𝜆𝜆𝑏𝑏)𝑡𝑡 − 𝑒𝑒−(𝜆𝜆𝑃𝑃𝑏𝑏+𝜆𝜆𝑏𝑏)𝑡𝑡𝜆𝜆𝑃𝑃𝑃𝑃 − 𝜆𝜆𝑇𝑇𝑇𝑇 ) 
 Ã𝑃𝑃𝑃𝑃(𝑇𝑇)=𝐵𝐵𝐵𝐵 𝜆𝜆𝑃𝑃𝑃𝑃 𝜆𝜆𝑃𝑃𝑏𝑏𝜆𝜆𝑃𝑃𝑃𝑃−𝜆𝜆𝐵𝐵𝐵𝐵×𝐴𝐴𝐵𝐵𝐵𝐵(0)(1−𝑒𝑒−(𝜆𝜆𝐵𝐵𝐵𝐵+𝜆𝜆𝑏𝑏)𝑇𝑇𝜆𝜆𝐵𝐵𝐵𝐵+𝜆𝜆𝑏𝑏 −1−𝑒𝑒−(𝜆𝜆𝑃𝑃𝑏𝑏+𝜆𝜆𝑏𝑏)𝑇𝑇𝜆𝜆𝑃𝑃𝑏𝑏+𝜆𝜆𝑏𝑏𝜆𝜆𝑃𝑃𝑏𝑏−𝜆𝜆𝐵𝐵𝐵𝐵 − 1−𝑒𝑒−(𝜆𝜆𝑃𝑃𝑃𝑃+𝜆𝜆𝑏𝑏)𝑇𝑇𝜆𝜆𝑃𝑃𝑃𝑃+𝜆𝜆𝑏𝑏 −1−𝑒𝑒−(𝜆𝜆𝑃𝑃𝑏𝑏+𝜆𝜆𝑏𝑏)𝑇𝑇𝜆𝜆𝑃𝑃𝑏𝑏+𝜆𝜆𝑏𝑏𝜆𝜆𝑃𝑃𝑏𝑏−𝜆𝜆𝑃𝑃𝑃𝑃 )+ 
(1− 𝐵𝐵𝐵𝐵) 𝜆𝜆𝑇𝑇𝑇𝑇 𝜆𝜆𝑃𝑃𝑃𝑃
𝜆𝜆𝑇𝑇𝑇𝑇 − 𝜆𝜆𝐵𝐵𝐵𝐵
×𝐴𝐴𝐵𝐵𝐵𝐵(0)(1−𝑒𝑒−(𝜆𝜆𝐵𝐵𝐵𝐵+𝜆𝜆𝑏𝑏)𝑇𝑇𝜆𝜆𝐵𝐵𝐵𝐵+𝜆𝜆𝑏𝑏 − 1−𝑒𝑒−(𝜆𝜆𝑃𝑃𝑏𝑏+𝜆𝜆𝑏𝑏)𝑇𝑇𝜆𝜆𝑃𝑃𝑏𝑏+𝜆𝜆𝑏𝑏𝜆𝜆𝑃𝑃𝑃𝑃 − 𝜆𝜆𝐵𝐵𝐵𝐵 − 1−𝑒𝑒−(𝜆𝜆𝑇𝑇𝑇𝑇+𝜆𝜆𝑏𝑏)𝑇𝑇𝜆𝜆𝑇𝑇𝑇𝑇+𝜆𝜆𝑏𝑏 − 1−𝑒𝑒−(𝜆𝜆𝑃𝑃𝑏𝑏+𝜆𝜆𝑏𝑏)𝑇𝑇𝜆𝜆𝑃𝑃𝑏𝑏+𝜆𝜆𝑏𝑏𝜆𝜆𝑃𝑃𝑃𝑃 − 𝜆𝜆𝑇𝑇𝑇𝑇 ) 
 Ã𝑃𝑃𝑃𝑃=𝐵𝐵𝐵𝐵 𝜆𝜆𝑃𝑃𝑃𝑃 𝜆𝜆𝑃𝑃𝑏𝑏𝜆𝜆𝑃𝑃𝑃𝑃−𝜆𝜆𝐵𝐵𝐵𝐵×𝐴𝐴𝐵𝐵𝐵𝐵(0)( 1𝜆𝜆𝐵𝐵𝐵𝐵+𝜆𝜆𝑏𝑏 − 1𝜆𝜆𝑃𝑃𝑏𝑏+𝜆𝜆𝑏𝑏𝜆𝜆𝑃𝑃𝑃𝑃 − 𝜆𝜆𝐵𝐵𝐵𝐵 − 1𝜆𝜆𝑃𝑃𝑃𝑃+𝜆𝜆𝑏𝑏 − 1𝜆𝜆𝑃𝑃𝑏𝑏+𝜆𝜆𝑏𝑏𝜆𝜆𝑃𝑃𝑃𝑃 − 𝜆𝜆𝑃𝑃𝑃𝑃 )+ 
(1− 𝐵𝐵𝐵𝐵) 𝜆𝜆𝑇𝑇𝑇𝑇 𝜆𝜆𝑃𝑃𝑃𝑃
𝜆𝜆𝑇𝑇𝑇𝑇 − 𝜆𝜆𝐵𝐵𝐵𝐵
×𝐴𝐴𝐵𝐵𝐵𝐵(0)( 1𝜆𝜆𝐵𝐵𝐵𝐵+𝜆𝜆𝑏𝑏 − 1𝜆𝜆𝑃𝑃𝑏𝑏+𝜆𝜆𝑏𝑏𝜆𝜆𝑃𝑃𝑃𝑃 − 𝜆𝜆𝐵𝐵𝐵𝐵 − 1𝜆𝜆𝑇𝑇𝑇𝑇+𝜆𝜆𝑏𝑏 − 1𝜆𝜆𝑃𝑃𝑏𝑏+𝜆𝜆𝑏𝑏𝜆𝜆𝑃𝑃𝑃𝑃 − 𝜆𝜆𝑇𝑇𝑇𝑇 ) 
2. Single compartment uptake and clearance model for 213Bi conjugates activity. 
Uptake kinetics in organ or tumour with rate constant u (= ln(2)/Tu, with Tu the uptake half-life) and 
clearance back to plasma with rate constant b  
213Bi kinetics:  𝐴𝐴𝐵𝐵𝐵𝐵(𝑡𝑡)=𝜆𝜆𝑢𝑢𝜆𝜆𝑢𝑢−𝜆𝜆𝑏𝑏 𝐴𝐴𝐵𝐵𝐵𝐵(0)𝑒𝑒−𝜆𝜆𝐵𝐵𝐵𝐵𝑡𝑡(𝑒𝑒−𝜆𝜆𝑏𝑏𝑡𝑡 − 𝑒𝑒−𝜆𝜆𝑢𝑢𝑡𝑡)  
Ã𝐵𝐵𝐵𝐵(𝑇𝑇)=𝜆𝜆𝑢𝑢𝜆𝜆𝑢𝑢 − 𝜆𝜆𝑃𝑃 𝐴𝐴𝐵𝐵𝐵𝐵(0)(1−𝑒𝑒−(𝜆𝜆𝐵𝐵𝐵𝐵+𝜆𝜆𝑏𝑏)𝑇𝑇𝜆𝜆𝐵𝐵𝐵𝐵+𝜆𝜆𝑏𝑏 − 1−𝑒𝑒−(𝜆𝜆𝐵𝐵𝐵𝐵+𝜆𝜆𝑢𝑢)𝑇𝑇𝜆𝜆𝐵𝐵𝐵𝐵+𝜆𝜆𝑢𝑢  
 Ã𝐵𝐵𝐵𝐵=𝐴𝐴𝐵𝐵𝐵𝐵(0)𝜆𝜆𝑢𝑢(𝜆𝜆𝐵𝐵𝐵𝐵+𝜆𝜆𝑏𝑏)(𝜆𝜆𝐵𝐵𝐵𝐵+𝜆𝜆𝑢𝑢) 
213Po kinetics:   
 𝐴𝐴𝑃𝑃𝑃𝑃(𝑡𝑡)=𝜆𝜆𝑃𝑃𝑃𝑃𝜆𝜆𝑢𝑢𝐵𝐵𝐵𝐵(𝜆𝜆𝑢𝑢−𝜆𝜆𝑏𝑏)(𝜆𝜆𝑃𝑃𝑃𝑃−𝜆𝜆𝐵𝐵𝐵𝐵)𝐴𝐴𝐵𝐵𝐵𝐵 (0)(𝑒𝑒−(𝜆𝜆𝐵𝐵𝐵𝐵+𝜆𝜆𝑏𝑏)𝑡𝑡−𝑒𝑒−(𝜆𝜆𝐵𝐵𝐵𝐵+𝜆𝜆𝑢𝑢)𝑡𝑡 − 𝑒𝑒−(𝜆𝜆𝑃𝑃𝑃𝑃+𝜆𝜆𝑏𝑏)𝑡𝑡+𝑒𝑒−(𝜆𝜆𝑃𝑃𝑃𝑃+𝜆𝜆𝑢𝑢)𝑡𝑡) 
 
 Ã𝑃𝑃𝑃𝑃(𝑇𝑇)=𝜆𝜆𝑃𝑃𝑃𝑃𝜆𝜆𝑢𝑢𝐵𝐵𝐵𝐵𝜆𝜆𝑃𝑃𝑃𝑃−𝜆𝜆𝐵𝐵𝐵𝐵 𝐴𝐴𝐵𝐵𝐵𝐵(0)(1−𝑒𝑒−(𝜆𝜆𝐵𝐵𝐵𝐵+𝜆𝜆𝑏𝑏)𝑇𝑇𝜆𝜆𝐵𝐵𝐵𝐵+𝜆𝜆𝑏𝑏  − 1−𝑒𝑒−(𝜆𝜆𝐵𝐵𝐵𝐵+𝜆𝜆𝑢𝑢)𝑇𝑇𝜆𝜆𝐵𝐵𝐵𝐵+𝜆𝜆𝑢𝑢 − 1−𝑒𝑒−(𝜆𝜆𝑃𝑃𝑃𝑃+𝜆𝜆𝑏𝑏)𝑇𝑇𝜆𝜆𝑃𝑃𝑃𝑃+𝜆𝜆𝑏𝑏 +1−𝑒𝑒−(𝜆𝜆𝑃𝑃𝑃𝑃+𝜆𝜆𝑢𝑢)𝑇𝑇𝜆𝜆𝑃𝑃𝑃𝑃+𝜆𝜆𝑢𝑢 ) 
 Ã𝑃𝑃𝑃𝑃=𝜆𝜆𝑃𝑃𝑃𝑃𝜆𝜆𝑢𝑢𝜆𝜆𝑃𝑃𝑃𝑃−𝜆𝜆𝐵𝐵𝐵𝐵 𝐵𝐵𝐵𝐵 𝐴𝐴𝐵𝐵𝐵𝐵(0)( 1𝜆𝜆𝐵𝐵𝐵𝐵+𝜆𝜆𝑏𝑏)(𝜆𝜆𝐵𝐵𝐵𝐵+𝜆𝜆𝑢𝑢)− 1(𝜆𝜆𝑃𝑃𝑃𝑃+𝜆𝜆𝑏𝑏)(𝜆𝜆𝑃𝑃𝑃𝑃+𝜆𝜆𝑢𝑢)) 
 
 
(1− 𝐵𝐵𝐵𝐵) 𝜆𝜆𝑇𝑇𝑇𝑇 𝜆𝜆𝑃𝑃𝑃𝑃
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𝑒𝑒− 𝜆𝜆𝑇𝑇𝑇𝑇+𝜆𝜆𝑏𝑏 𝑡𝑡 − 𝑒𝑒−(𝜆𝜆𝑇𝑇𝑇𝑇+𝜆𝜆𝑢𝑢)𝑡𝑡 − 𝑒𝑒−(𝜆𝜆𝑃𝑃𝑏𝑏+𝜆𝜆𝑏𝑏)𝑡𝑡+𝑒𝑒−(𝜆𝜆𝑃𝑃𝑏𝑏+𝜆𝜆𝑢𝑢 𝑡𝑡
𝜆𝜆𝑇𝑇𝑇𝑇 − 𝜆𝜆𝑃𝑃𝑃𝑃
)} 
 Ã𝑃𝑃𝑃𝑃 = 𝜆𝜆𝑃𝑃𝑃𝑃𝐴𝐴𝐵𝐵𝐵𝐵(0)𝜆𝜆𝑢𝑢×
{
  
 
  
 𝜆𝜆𝑃𝑃𝑃𝑃𝐵𝐵𝐵𝐵𝑃𝑃𝑃𝑃(𝜆𝜆𝑃𝑃𝑃𝑃−𝜆𝜆𝐵𝐵𝐵𝐵)(
1(𝜆𝜆𝐵𝐵𝐵𝐵−𝜆𝜆𝑃𝑃𝑏𝑏)(𝜆𝜆𝑃𝑃𝑏𝑏+𝜆𝜆𝑏𝑏)(𝜆𝜆𝑃𝑃𝑏𝑏+𝜆𝜆𝑢𝑢) 1(𝜆𝜆𝐵𝐵𝐵𝐵−𝜆𝜆𝑃𝑃𝑏𝑏)(𝜆𝜆𝐵𝐵𝐵𝐵+𝜆𝜆𝑏𝑏)(𝜆𝜆𝐵𝐵𝐵𝐵+𝜆𝜆𝑢𝑢+ 1(𝜆𝜆𝑃𝑃𝑃𝑃−𝜆𝜆𝑃𝑃𝑏𝑏)(𝜆𝜆𝑃𝑃𝑃𝑃+𝜆𝜆𝑏𝑏)(𝜆𝜆𝑃𝑃𝑃𝑃+𝜆𝜆𝑢𝑢)– 1(𝜆𝜆𝑃𝑃𝑃𝑃−𝜆𝜆𝑃𝑃𝑏𝑏)(𝜆𝜆𝑃𝑃𝑏𝑏+𝜆𝜆𝑏𝑏)(𝜆𝜆𝑃𝑃𝑏𝑏+𝜆𝜆𝑢𝑢)) +𝜆𝜆𝑇𝑇𝑇𝑇𝐵𝐵𝐵𝐵𝑇𝑇𝑇𝑇(𝜆𝜆𝑇𝑇𝑇𝑇−𝜆𝜆𝐵𝐵𝐵𝐵)( 1(𝜆𝜆𝐵𝐵𝐵𝐵−𝜆𝜆𝑃𝑃𝑏𝑏)(𝜆𝜆𝑃𝑃𝑏𝑏+𝜆𝜆𝑏𝑏)(𝜆𝜆𝑃𝑃𝑏𝑏+𝜆𝜆𝑢𝑢) 1𝜆𝜆𝐵𝐵𝐵𝐵−𝜆𝜆𝑃𝑃𝑏𝑏 𝜆𝜆𝐵𝐵𝐵𝐵+𝜆𝜆𝑏𝑏 𝜆𝜆𝐵𝐵𝐵𝐵+𝜆𝜆𝑢𝑢+ 1(𝜆𝜆𝑇𝑇𝑇𝑇−𝜆𝜆𝑃𝑃𝑏𝑏)(𝜆𝜆𝑇𝑇𝑇𝑇+𝜆𝜆𝑏𝑏)(𝜆𝜆𝑇𝑇𝑇𝑇+𝜆𝜆𝑢𝑢)− 1 (𝜆𝜆𝑇𝑇𝑇𝑇−𝜆𝜆𝑃𝑃𝑏𝑏)(𝜆𝜆𝑃𝑃𝑏𝑏+𝜆𝜆𝑏𝑏)(𝜆𝜆𝑃𝑃𝑏𝑏+𝜆𝜆𝑢𝑢))}   
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ABsTrAcT
Absorbed doses for α-emitters are different from those for β-emitters, as the high linear 
energy transfer (LET) nature of α-particles results in a very dense energy deposition over a 
relatively short path length near the point of emission. This highly localized and therefore 
high energy deposition can lead to enhanced cell-killing effects at absorbed doses that are 
non-lethal in low-LET type of exposure. Affinities of DOTA-DPhe1-Tyr3-octreotate (DOTA-
TATE), 115In-DOTATATE, 175Lu-DOTATATE and 209Bi-DOTATATE were determined in the 
K562-SST2 cell line. Two other cell lines were used for radiation response assessment; 
BON and CA20948, with a low and high expression of somatostatin receptors, respectively. 
Cellular uptake kinetics of 111In-DOTATATE were determined in CA20948 cells. CA20948 
and BON were irradiated with 137Cs, 177Lu-DTPA, 177Lu-DOTATATE, 213Bi-DTPA and 
213Bi-DOTATATE. Absorbed doses were calculated using the MIRDcell dosimetry method 
for the specific binding and a Monte Carlo model of a cylindrical 6-well plate geometry 
for the exposure by the radioactive incubation medium. Absorbed doses were compared to 
conventional irradiation of cells with 137Cs and the relative biological effect (RBE) at 10 % 
survival was calculated.
results:
IC50 of (labelled) DOTATATE was in the nM range. Absorbed doses up to 7 Gy were 
obtained by 5.2 MBq 213Bi-DOTATATE, in majority the dose was caused by α-particle 
radiation. Cellular internalization determined with 111In-DOTATATE showed a linear rela-
tion with incubation time. Cell survival after exposure of 213Bi-DTPA and 213Bi-DOTATATE 
to BON or CA20948 cells showed a linear-exponential relation with the absorbed dose, 
confirming the high LET character of 213Bi. The survival of CA20948 after exposure to 
177Lu-DOTATATE and the reference 137Cs irradiation showed the typical curvature of the 
linear-quadratic model. 10 % Cell survival of CA20948 was reached at 3 Gy with 213Bi-
DOTATATE, a factor 6 lower than the 18 Gy found for 177Lu-DOTATATE and also below 
the 5 Gy after 137Cs external exposure.
conclusion:
213Bi-DTPA and 213Bi-DOTATATE lead to a factor 6 advantage in cell killing compared to 
177Lu-DOTATATE. The RBE at 10 % survival by 213Bi-ligand compared to 137Cs was 2.0 
whereas the RBE for 177Lu-DOTATATE was 0.3 in the CA20948 in vitro model.
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inTrODucTiOn
The receptor-mediated endocytosis pathway is one of the main pathways to deliver 
biomolecules in cells. Peptide receptor radionuclide therapy (PRRT) uses this process to 
deliver cytotoxic dose by the emission of β-particles to neuroendocrine tumours (NET). 
Somatostatin peptide analogues, such as DOTA-DPhe1-Tyr3-octreotide (DOTATOC) and 
DOTA-DPhe1-Tyr3-octreotate (DOTATATE), are the most common delivery systems for 
treatment of NET. By radiolabelling these analogues with β-emitting radionuclide such 
as 90Y (T1/2 = 64.1 h) or 177Lu (T1/2 = 6.6 d), high radiation doses can be delivered to tumour 
cells, causing mostly single-strand breaks (SSB) in the DNA of the tumour cells. Dependent 
on the number of SSB, cells can undergo cell arrest, with either activation of the cellular 
repair mechanism for repair or apoptosis as a consequence [1]. Combination of several 
repairable SSB lesions may lead to additional cell kill.
α-Emitters (e.g. 213Bi, T1/2 = 46 min;225Ac, T1/2 = 9.9 d; 211At, T1/2 = 7.2 h) are increasingly 
used for targeted alpha therapy (TAT) because of their emission of high linear energy trans-
fer (LET) particles with a relative short path length. Labelled 213Bi-peptides have already 
been proven to be promising in PRRT with NETs in preclinical as well in clinical studies 
[2–5]. α-Emitters emit high LET particles, causing double-strand breaks (DSB) in DNA 
when targeted to the tumour cells [6]. Therefore, the cytotoxic property in cells is found to 
be greater for α-emitters than for β-emitters [6, 7].
The cytotoxic response of the cells is related to the absorbed dose delivered to the cells. 
Several studies have been investigating the absorbed dose caused in cells by α-emitters 
[8–10]. Those studies showed the challenge involved in describing dose-related survival in 
cells with α-particles radiation. Huang and co-workers distinguished three clear differences 
in cell dosimetry calculations for α-emitters compared to β-emitters or to external beam 
therapy; 1) short path length, 2) small target volume and 3) non-uniform distribution of 
radionuclides [11]. For β-emitters and external γ-beams, hundreds to thousands of ioniza-
tions are required for a cell-killing effect, whereas using α-emitters, this can be reached 
with 4–10 ionizations. Due to the low number of ionizations, leading to large variations 
in the number of α-particle tracks traversing the cells, the validity of the mean absorbed 
dose which assumes Poisson statistics, was not always given for α-emitters [12]. Moreover, 
variability in experiments strongly influenced the calculated absorbed dose, for example 
the models in which the absorbed dose was calculated; single cells, clusters of cells or 
whole organs. Furthermore, inhomogeneous uptake can also influence the calculated ab-
sorbed dose. The dose limits for α-emitters showed a high model dependence for selected 
survival endpoints, and therefore, the relative biological effect (RBE) should be considered 
within the same model and using the same endpoint. As mentioned, the calculation of the 
absorbed dose in vitro for α-emitters can be quite complicated. Many studies only mention 
the radioactivity administered to the cells instead of using absorbed dose. Therefore, the 
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effective cytotoxic properties of α-emitters as published cannot easily be compared to each 
other on an absorbed dose level.
In this study we calculated the average absorbed dose delivered to single cells using non-
specific and receptor-specific binding absorbed dose calculation methods. The non-specific 
binding method describes the homogeneous irradiation from medium without specific bind-
ing of labelled peptide to the receptors on the cell, whereas the specific binding method 
describes the specific binding of the labelled peptide to the receptor on the cell and the addi-
tion of homogeneous irradiation from medium to the cells. Affinity studies in K562-SSTR2 
(transgenic human erythroleukemic cells transfected with somatostatin receptor subtype 
2 (SSTR2)) cells were performed to determine the IC50 of DOTATATE, 115In-DOTATATE, 
175Lu-DOTATATE, and 209Bi-DOTATATE. An internalization assay with CA20948 (rat 
pancreatic tumour) cell using 111In-DOTATATE was performed to obtain information of the 
kinetics of cell uptake. Based on results obtained from cell uptake, small-scale dosimetry 
calculations were performed to provide the additional absorbed dose caused by specific 
binding to the cells to obtain the correlation between absorbed dose and cell survival. 
We evaluated the RBE at the absorbed dose of 10 % survival (D10) of 213Bi-DTPA, 213Bi-
DOTATATE, 177Lu-DTPA, 177Lu-DOTATATE and external radiation using 137Cs using two 
different cell lines; CA20948 [13] with high and BON (human carcinoid) with low SSTR2 
expression [14]. The aim of the study was to compare the effective cytotoxic properties 
of different irradiation methods i.e. external photon irradiation and targeted radionuclide 
therapy in the same study.
mATEriAls AnD mEThODs
All chemicals were purchased from Sigma Aldrich, culture media for cell culture and in 
vitro assays were purchased from Gibco, Life Technologies, unless otherwise indicated.
cell culture
K562-SST2 is a human erythroleukemic transgenic cell line with an overexpression of 
SSTR2 [15] and was a gift of prof. L. Hofland and prof. P.M. van Hagen (Erasmus MC, 
Rotterdam, the Netherlands). Cells were cultured in RPMI 1640 supplemented with 10 % 
of fetal calf serum (Gibco, Life Technologies). CA20948 tumour cells [16] were cultured in 
DMEM supplemented with 10 % fetal calf serum. Human carcinoid BON cells (American 
Tissue Culture Collection, Wesel, Germany) were cultured in F12-DMEM. The medium 
was supplemented with 10 % fetal calf serum. All cells were cultured in T175 tissue culture 
flasks at 37°C in a humidified atmosphere of 5 % CO2.
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radiolabelling and radioiodination of peptides
111In-DOTATATE with a molar activity (MA) of 15 MBq/nmol was prepared by incubation 
of 15 MBq 111InCl3 (T1/2 = 2.8 d, γ of 171 and 245 keV, Covidien), DOTATATE (Mw 1436 
g/mol, Biosynthema, St. Louis, MO, USA), sodium acetate 2.5 M, ethanol and a mixture 
of gentisic acid/ascorbic acid 50 mM in a volume of 140 µL at 80°C for 20 min. After 
incubation, 5 µL 10 mM DTPA (diethylenetriaminepentaacetic acid) was added to stop the 
reaction and to chelate any “unbound” or “free” 111In. MA is expressed in MBq per nmol 
peptide.
177Lu-DOTATATE (at MA 53 MBq/nmol) was prepared under the same labelling condi-
tions as 111In-DOTATATE described above. 177LuCl3 was purchased from IDB Holland B.V 
(Baarle Nassau, the Netherlands).
For the labelling of 213Bi, an 225Ac/213Bi generator (≤ 222 MBq) was eluted with a fixed 
elution volume of 600 µL 0.1M/0.1M NaI/HCl [17]. The 213Bi containing elution was added 
to a mixture of 7 nmol DOTATATE, 60 µL TRIS 2M, 1.85 µL ascorbic acid 20 % and MQ 
(final volume 800 µL). The reaction was performed at 95°C for 5 min and cooled on ice 
for 2 min afterwards. 5 µL of DTPA 10 mM was added to stop the labelling and chelate 
“unbound”/”free” 213Bi [18].
To determine the incorporation of the radioactivity, ITLC (Instant Thin-Layer Chromato-
graphy) was performed after each labelling. HPLC (High Performance Liquid Chromato-
graphy) was performed to determine the radiochemical purity (RCP) of the radiopeptides as 
described by the Blois et al. [19]. RCP of the labelled peptide was expressed as percentage 
of intact labelled peptide of interest versus of all other radioactive detectable compounds.
Tyr3-octreotide (Mw = 1034 g/mol, Biosynthema, St. Louis, MO, USA) was used to prepare 
125I-Tyr3-octreotide using chloramine-T as described elsewhere [20]. Analysis and purifica-
tion of the radioiodinated peptide were performed using HPLC as described by de Blois et 
al [19].
labelling of non-radio-peptide
The labelling of 115In-DOTATATE was performed by addition of 115InHNO3 (ICP standard, 
1 g/L) to DOTATATE at a molar ratio of 5:1. The pH was adjusted to a pH of 4 by 
adding sodium acetate (2.5 M) and the labelling mixture was heated for 30 min at 80°C. 
Quality control was performed using HPLC as described previously [19]. UV-detection 
was performed at 278 nm. Under these conditions, DOTATATE was fully incorporated 
with 115In. After quality control the labelled peptide was purified and collected using the 
same HPLC method. The concentration of the labelled peptide was determined by UV 
spectro photometer at 278 nm. This procedure was also performed for the labelling of 175Lu-
DOTATATE and 209Bi-DOTATATE.
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ic50
IC50 values of DOTATATE, 115In-DOTATATE, 175Lu-DOTATATE or 209Bi-DOTATATE were 
determined using K562-SST2 membranes [21]. In short, cell membranes were isolated as 
described by Reubi [22]. Freshly dispersed membrane preparations (corresponding to 25 
µg protein) were incubated at room temperature for 60 min with 125I-Tyr3-octreotide (40k 
cpm) with or without increasing concentrations of DOTATATE, 115In-DOTATATE, 175Lu-
DOTATATE, or 209Bi-DOTATATE in HEPES buffer (10 mM HEPES, 5mM MgCl2 and 
0.02 g/L bacitracin, pH 7.6) containing 0.2 % BSA. After incubation for 1 h, 1 mL HEPES 
(4°C) was added to stop the reaction. Non-bound radioligand was separated from the 
membrane-bound radioligand by centrifugation for 2 min at 10000 g. The remaining pellet 
was washed twice with ice-cold HEPES buffer and counted in a γ-counter (Wallac Wizard 
3, Perkin Elmer, Groningen, the Netherlands) [21]. One-way ANOVA was used to calculate 
significant differences of IC50 values of DOTATATE, 115In-DOTATATE, 175Lu-DOTATATE, 
and 209Bi-DOTATATE.
internalisation as function of peptide amount in ssTr2 positive cA20948 
cell line
0.5x106 CA20948 cells were incubated with 111In-DOTATATE, ranging from 1 nM to 390 
nM, for 1 h at 37°C. After incubation, 111In-DOTATATE was removed from the cells by 
washing the cells twice with 1 mL ice-cold PBS. Ice-cold strip medium (1 mL, HBSS 
containing 20 mM sodium acetate, pH 5) was added to the cells and incubated for 10 min to 
remove membrane-bound (ƒmem) 111In-DOTATATE from the receptor. The strip medium was 
collected and 1 mL of ice-cold strip medium was added to the cells for 10 min incubation 
and collected again. Sodium hydroxide (1 mL, 1M) was added to the cells to detach the 
cells from the well and to determine the radioactivity inside the cells, this is the internal-
ized fraction (ƒint). The ƒint was collected separately from the ƒmem. The collected fractions 
were measured by the γ-counter. The results were plotted as % activity (%A) compared 
to total applied activity. To determine the non-specific binding, an excess of DOTATATE 
(1x10–6M) was added to 111In-DOTATATE and incubated for 1 h. The ƒmem and ƒint fractions 
were measured on the γ-counter. No internalization assays were performed with BON cell 
line due to the low expression of SSTR2 receptors. The specific binding of ƒmem and ƒint is 
the binding in 0.5x106 CA20948 cells minus the non-specific binding. The specific binding 
for 0.5x106 CA20948 cells were extrapolated to an uptake in 500 cells, these extrapolated 
uptakes were used to calculate the binding of 500 cells used for clonogenic assay. 111In-
DOTATATE was only used to investigate the cell uptake kinetics, in this study potential 
cytotoxic effects caused by absorbed dose were neglected.
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clonogenic assay
Survival curves of BON and CA20948 cells were determined by clonogenic assay after 
irradiation with 137Cs, 177Lu-DTPA, 177Lu-DOTATATE, 213Bi-DTPA or 213Bi-DOTATATE. 
Before irradiation of the cells, 500 cells were seeded in 6-well plates (pre-coated with 
poly-l-lysine) 24 h before the experiment. The cells were treated with increasing doses 
of radioligand, diluted in internalization medium (30 mM HEPES and 0.25 % BSA), and 
incubated for 1 h at 37°C in a humidified atmosphere of 5 % CO2. After irradiation, inter-
nalization medium containing radioligand was removed. Cells were washed twice with 
PBS and incubated with medium containing 10 % FBS for 12 d. Every 2 or 3 d, medium 
was replaced by fresh culture medium. In order to be able to compare the cytotoxic effect 
of 213Bi-DOTATATE vs 177Lu-DOTATATE, the starting amount of labelled peptide was kept 
constant, therefore excess peptide was added to the 177Lu-DOTATATE to a start concentra-
tion of 390 nM. Similarly, clonogenic assay was performed with different doses of external 
irradiation with 137Cs (dose-rate of 0.6 Gy/min): 0.5, 1, 2, 4, 5, 6, 8 and 10 Gy.
After incubation over a period of 12 days at 37°C in a humidified atmosphere of 5 % CO2, 
cells were washed twice with PBS, fixed with 1 mL 100 % ethanol and stained with 1 mL 
hematoxylin. The 6-well plates containing colonies were scanned with a HP-scanner at 200 
dpi. The colonies in each well were counted by a clonocounter [23]. The survival was plot-
ted as a function of absorbed dose and fitted to linear-quadratic (LQ) or linear-exponential 
curves.
Non-specific binding absorbed dose
The cell absorbed dose during the incubation period was calculated with a dosimetry model 
of the 6-well plate, as described by Verwijnen et al. [24]. The 3.5 cm diameter well cavity 
was modeled in the Monte Carlo radiation transport code Monte Carlo N-Particle eXtended 
MCNPX (version 2.5.0, Los Alamos National Laboratory, USA) with homogeneously dis-
tributed radioactivity over the 2 mL volume aqueous liquid within the cavity. Dose scoring 
regions of 25 μm were used to calculate the absorbed fractions of energy as a function of 
depth in the bottom 200 μm of the well, see Fig. 1. The division the layers of the well were 
as followed; 18 layers of 100 µm and 8 layers of 25 µm at the bottom of the well.
Radiation energy spectra for 177Lu, 213Bi and its daughters were derived from the MIRD 
radionuclide data handbook [25]. For each emission (α-, β- particles, low energy Auger- 
and internal conversion electrons and γ-rays) 10 million particle histories were used for 
particle transport calculations in MCNPX. Absorbed energy was calculated in the dose 
scoring regions within the cavity filled with radioactivity and the cross dose to the other 5 
well cavities. Absorbed dose rates per unit activity (or S-values) for each radionuclide and 
dose scoring region were calculated following the MIRD schema [26].
The cells in the clonogenic assay were assumed to lie on the bottom surface of the 6-well 
plate cavities and therefore the macroscopic mean absorbed dose 
 
 
 
Figure 1, Illustration of layers (25 m) divided over a total volume of 2 mL for the calculation of the 
absorbed dose in a 6-well plate. The lowest layer of 25 µm was used for the calculation of absorbed dose 
at the bottom of the well containing 500 cells. 
Radiation energy spectra for 177Lu, 213Bi and its daughters were derived from the MIRD radionuclide data 
handbook [25]. For each emission (-, - particles, low energy Auger- and internal conversion electrons 
and -rays) 10 million particle histories were used for particle transport calculations in MCNPX. Absorbed 
energy was calculated in the dose scoring regions within the cavity filled with radioactivity and the cross 
dose to the other 5 well cavities. Absorbed dose rates per unit activity (or S-values) for each radionuclide 
and dose scoring region were calculated following the MIRD schema [26]. 
The cell  in the clonogenic assay were assumed to lie on the bottom surface of the 6-well plate cavities 
and ther fore the macroscopic me n absorbed dose ?̅?𝐷 to the cells during the 1 h incubation was calculated 
from the S-value in the bottom 25 m layer and the time-integrated activity Ã by: 
D̅(25μm←fluid)= Ãfluid(1)×S(25μm←fluid)=∫ Afluide-λtdt ×S(25μm←fluid)T
T0
 
The integration was performed for the activity in the fluid from T0 = 0 to T = 1 h, also taking into account 
the progeny activity from 213Bi together with their specific S-values. The contributions to the absorbed 
dose by -particles were considered separately from the dose by -particles, low energy electrons and -
rays. 
to the cells during t e 
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1 h incubation was calculated from the S-value in the bottom 25 μm layer and the time-
integrated activity Ã by:
 
 
 
Figure 1, Illustration of layers (25 m) divided over a total volume of 2 mL for the calculation of the 
absorbed dose in a 6-well plate. The lowest layer of 25 µm was used for the calculation of absorbed dose 
at the bottom of the well containing 500 cells. 
Radiation energy spectra for 177Lu, 213Bi and its daughters were derived from the MIRD radionuclide data 
handbook [25]. For each emission (-, - particles, low energy Auger- and internal conversion electrons 
and -rays) 10 million particle histories were used for particle transport calculations in MCNPX. Absorbed 
energy was calculated in the dose scoring regions within the cavity filled with radioactivity and the cross 
dose to the other 5 well cavities. Absorbed dose rates per unit activity (or S-values) for each radionuclide 
and dose scoring region were calculated following the MIRD schema [26]. 
The cells in the clonogenic assay were assumed to lie on the bottom surface of the 6-well plate cavities 
and therefore the macroscopic mean absorbed dose ?̅?𝐷 to the cells during the 1 h incubation was calculated 
from the S-value in the bottom 25 m layer and the time-integrated activity Ã by: 
D̅(25μm←fluid)= Ãfluid(1)×S(25μm←fluid)=∫ Afluide-λtdt ×S(25μm←fluid)T
T0
 
The integration was performed for the activity in the fluid from T0 = 0 to T = 1 h, also taking into account 
the progeny activity from 213Bi together with their specific S-values. The contributions to the absorbed 
dose by -particles were considered separately from the dose by -particles, low energy electrons and -
rays. 
The integration was performed for the activity in the fluid from T0 = 0 to T = 1 h, also 
taking into account the progeny activity from 213Bi together with their specific S-values. 
The contributions to the absorbed dose by α-particles were considered separately from the 
dose by β-particles, low energy electrons and γ-rays.
Specific binding absorbed dose
For cell dosimetry calculation, the total uptake (ƒmem and ƒint) of 0.5x106 cells (CA20948) 
was extrapolated to the uptake of 500 cells. The percentage of uptake was then used for 
cell dosimetry with the assumption that the radioactivity was bound to the cell membrane 
(fint = 0 and fmem = 1) over a period of 12 d without dissociation of the radioactivity.
The dosimetry for the specific uptake of radioactivity in the cells was calculated with the 
multicellular dosimetry code MIRD cell [27]. For the calculation of dosimetry in CA20948, 
a cell radius of 6 μm was taken, as the uptake in the cells was not further differentiated, 
only uptake on the cell surface and homogeneous cell uptake were considered. Initially 500 
cells were plated over the 9.62 cm2 surface of the well. For evenly distributed cells over 
the surface the mean inter-cell distance would be 770 μm. In reality the cells were more 
clustered to the center of the well. Furthermore, the inter-cell distance was larger than the 
range of the α-particles and hence the cross-dose contribution from radioactivity taken up 
in neighboring cells was assumed to be minimal.
figure 1, Illustration of layer  (25 μm) divided over a total volume of 2 mL for th  alculation of the 
absorbed dose in a 6-well plate. The lowest layer of 25 µm was used for the calculation of absorbed dose 
at the bottom of the well containing 500 cells.
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The number of disintegrations within each cell (or Time-Integrated Activity per cell ã) was 
calculated by integration of the decay function of 177Lu and 213Bi and its progeny over the 12 
d irradiation time multiplied by the ƒint and ƒmem per cell. This assumes that ƒmem will remain 
bound to the cells and ƒint remains trapped in the cell over a period of 12 d. The cellular S 
values were obtained from the MIRD cell code for a cell with a radius of 6 μm and indicated 
in Table 1. The absorbed doses to the cell are indicated per decay of 213Bi and its daughters 
213Po, 209Tl, 209Pb and for 177Lu in the cell or on the surface of a spherical cell with a radius 
of 6 μm. Also the cross-dose S-values for cells with radioactivity at 50 μm and at 100 μm 
are indicated.
The mean self-absorbed dose to the cells was calculated by the product of Ãcell the mean 
cumulated activity per cell with the cellular S-values specific for the binding site:
 
 
209Tl 0.73 0.44 1.31-3 3.15-4 
209Pb 0.34 0.22 1.61-3 3.46-4 
213Bi + progeny 50.2 33.6 0.52 3.48-2 
177Lu 0.67 0.42 2.00-3 4.18-4 
OOR= out of range C = cell, C’= other cell, CS = cell surface  
The mean self-absorbed dose to the cells was calculated by the product of Ãcell the mean cumulated 
activity per cell with the cellular S-values specific for the binding site: 
Dcell̅̅ ̅̅ ̅̅ =Ãcell[fintS(C←C)+fmem(C←CS)], with  
Ãcell(Bi-213)=∫ AcellBi̅̅ ̅̅ ̅̅T
T0
 e-λBitdt 
Ãcel(Po-213)=∫AcelBi̅̅ ̅̅T̅T0 BRPoλPoλBi-λPo(e-λPot-e-λBit)dt 
Ãcel(Tl-209)=∫AcelBi̅̅ ̅̅T̅T0 BRTlλTlλBi-λTl(e-λTlt-e-λBit)dt 
Ãcel(Pb-209)=∫AcelBi̅̅ ̅̅T̅T0 {BRPoλPoλPbλBi-λPb(e-λPbt-e-λBitλBi-λPb+e-λPot-e-λPbtλPo-λPb)-BRTlλTlλPbλBi-λTl(e-λPbt-e-λTltλTl-λPb+e-λPbt-e-λBitλBi-λPb)}dt 
The integration over time was performed between T0 = 1 h and T = 12 d. It was assumed that no 
radioligand cleared from the cells once it was bound. The absorbed dose originating from the cellular 
uptake during the 1 h incubation period was neglected. 
Results 
Labelling 
The incorporation for all used radiolabelled peptide was > 99% and the RCP of 111In-DOTATATE, 177Lu-
DOTATATE and 213Bi-DOTATATE were > 95%, > 95%, and > 85%, respectively. The RCP of 125I-Tyr3-
octreotide was > 99%. The chemical yield of 115In-DOTATATE, 175Lu-DOTATATE and 209Bi-
DOTATATE were > 99%. 
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The integration over time was performed between T0 = 1 h and T = 12 d. It was assumed that no 
radioligand cleared from the cells once it was bound. The absorbed dose originating from the cellular 
uptake during the 1 h incubation period was neglected. 
Results 
Labelling 
The incorporation for all used radiolabelled peptide was > 99% and the RCP of 111In-DOTATATE, 177Lu-
DOTATATE and 213Bi-DOTATATE were > 95%, > 95%, and > 85%, respectively. The RCP of 125I-Tyr3-
octreotide was > 99%. The chemical yield of 115In-DOTATATE, 175Lu-DOTATATE and 209Bi-
DOTATATE were > 99%. 
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Results 
Labelling 
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The integration over time was performed between T0 = 1 h and T = 12 d. It was ssumed 
th t no adioligand le red from the c lls once it was bound. The absorbed dose originating 
from the cellular uptake during the 1 h incubation period was neglected.
Table 1, S-values (mGy/MBq.s) of 213Bi, 213Po, 209Tl, 209Pb and 177Lu for a cell with a radius of 6 μm ac-
cording to MIRDcell code
self-dose cross-dose s(c←c’)
s(c ← c) s (c ← cs) cell distance 
50 µm
cell distance  
100 µm
213Bi 1.71 1.14 7.02–3 3.03–4
213po 49.2 33.0 0.40 OOR
209Tl 0.73 0.44 1.31–3 3.15–4
209pb 0.34 0.22 1.61–3 3.46–4
213Bi + progeny 50.2 33.6 0.52 3.48–2
177lu 0.67 0.42 2.00–3 4.18–4
OOR= out of range C = cell, C’= other cell, CS = cell surface
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labelling
The incorporation for all used radiolabelled peptide was > 99 % and the RCP of 111In-
DOTATATE, 177Lu-DOTATATE and 213Bi-DOTATATE were > 95 %, > 95 %, and > 85 %, 
respectively. The RCP of 125I-Tyr3-octreotide was > 99 %. The chemical yield of 115In-
DOTATATE, 175Lu-DOTATATE and 209Bi-DOTATATE were > 99 %.
Affinity study and internalization
Under the conditions applied, DOTATATE, 115In-DOTATATE, 175Lu-DOTATATE and 209Bi-
DOTATATE showed similar affinities to SSTR2 on the membranes of K562-SST2 cells. 
IC50 values of 3.0 ± 0.9 nM, 2.5 ± 0.4 nM, 2.7 ± 0.4 nM and 5.2 ± 1.0 nM were found, 
respectively. No significant differences were found between the IC50 values.
internalization in ssTr2 positive cA20948 cell line
Internalization was performed to determine the amount of radioligand bound to the re-
ceptors, at the cell membrane and internalized into the cell. Optimized concentration of 
111In-DOTATATE for internalization on CA20948 was 1 nM. At this concentration, the fint 
increased linearly as a function of incubation time. However, the fmem remained constant at 
a level of 0.008 %A as a function of incubation time, see Fig. 2.
Binding assays with 213Bi-DOTATATE involved high concentrations of unlabelled pep-
tide due to the low molar activity of labelled peptide. At the highest peptide amount used 
for the experiment (390 nM), an equilibrium of association and dissociation was found 
within 30 min for ƒmem and 10 min for fint. Here we mimicked the internalization of 213Bi-
DOTATATE and 177Lu-DOTATATE by using 111In-DOTATATE as a surrogate to study the 
uptake kinetics with the concentration used in the clonogenic assay. Cells were incubated 
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figure 2, Specific membrane binding and specific internalization of 1 nM 111In-DOTATATE on 0.5x106 
cells of CA20948 as function of incubation time, n = 3. The lines indicate the fitted curves with the 95 % 
confidence intervals, internalization data linear curve (R2 = 0.97) with slope: 0.096 ± 0.003 %IA/min and 
for the fmem the mean value of 0.56 ± 0.06 %IA.
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with decreasing concentrations of peptide (ranging 390 to 15 nM) for 1 h. The uptake was 
found to be relatively low, the ƒmem and ƒint were difficult to distinguish from each other, 
and therefore the sum of ƒmem and ƒint was used for further cell dosimetry calculations, see 
Fig. 3A. The uptake was used to calculate the number labelled peptide, 213Bi-DOTATATE 
or 177Lu-DOTATATE, bound per cells during clonogenic assay with 213Bi-DOTATATE and 
177Lu-DOTATATE in CA20948, see Fig. 3B.
clonogenic assay of BOn and cA20948 cells using external irradiation
The survival of BON and CA20948 cells after exposure to escalating absorbed doses with 
a 137Cs source is showed in Fig. 4. Up to absorbed doses of 4 Gy similar survival curves 
were found for both cell lines. At absorbed doses above 4 Gy, CA20948 showed to be more 
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figure 3A-3B, A) Total binding of 1.5x10–8 to 3.9x10–7 M 111In-DOTATATE with 0.5 million CA20948 
cells after 60 min incubation (n = 3) and B) the number of labelled 213Bi-DOTATATE or 177Lu-DOTA-
TATE molecules bound per cell (y-axis) versus the total number of peptide present per cell (x-axis) 
during clonogenic assay. The line and shaded area in Fig. 3A indicate the fit (R2 = 0.4) and its 95 % 
confidence interval of a single exponential curve Ae-k[M] + B with A = 1.0 ± 0.5 %A, k = 39 ± 24 μmol-1 
and B = 0.38 ± 0.07 %A.
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figure 4, Survival curves of BON and CA20948 cells obtained after exposure at different doses of 137Cs 
γ-radiation, n = 3.
The x-axis is expressed in dose (Gy) and the y-axis in survival fraction. Each data point is plotted as the 
mean survival ± SD. The curves through the data lead to the following LQ model parameters; BON: α 
< 0.11 Gy-1, β = 0.12 ± 0.02 Gy-2 and CA20948: α = 0.21 ± 0.07 Gy-1, β = 0.05 ± 0.02 Gy-2.
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radio-resistant than BON, see Table 2. Curves according to the LQ model were fitted with 
high correlation coefficients (R2 = 0.98 and 0.93, respectively), indicating that the curvature 
of the BON cells was more profound than for CA20948.
DOsimETry
The time-integrated activity coefficient in the well cavity during the 1 h incubation period 
was 2361 MBq.s per MBq 213Bi, leading to an absorbed dose of 1.60 Gy/MBq in the 2 mL 
fluid and 1.12 Gy/MBq in the bottom 25 μm layer. The absorbed dose was delivered 96.2 % 
by the α-particles, see Table 3.
clonogenic assay of BOn and cA20948 cells using radiolabelled ligand
BON and CA20948 cells were treated with increasing amounts of radioactivity coupled to the 
radioligand; 213Bi-DTPA, 213Bi-DOTATATE, 177Lu-DTPA and 177Lu-DOTATATE. The BON cells 
showed increased cytotoxic effect at increasing radioactivity of 213Bi-DTPA and 213Bi-DOTATATE.
In BON cells, similar survival curves were found after irradiation with 213Bi-DOTATATE or 
213Bi-DTPA. No significant differences were observed in the slopes of the survival curves 
(Fig. 5A). The α/β ratio obtained from the linear-quadratic model describing irradiation 
by 137Cs was found to be < 0.01 Gy for BON and 4.5 ± 3.6 Gy for CA20948. The survival 
curves of BON and CA20948 treated with non-specific binding of 213Bi-ligand fitted with a 
one-phase decay model. In CA20948 cells, a decreased survival at increased radioactivity 
of 213Bi-radioligand was observed. No significant differences in survival were observed 
between 213Bi-DOTATATE and 213Bi-DTPA, see Fig. 5B.
Table 3, Absorbed fraction of energy f and absorbed dose rate per MBq radioactivity 213Bi and its daugh-
ters calculated in the bottom 25 μm of the 2 mL fluid, which contributed to the calculated absorbed dose
213Bi f 
(%)
S (25µm←well) 
(mgy/mBq.s)
213po f 
(%)
S (25µm←well) 
(mgy/mBq.s)
209Tl f 
(%)
S (25µm←well) 
(mgy/mBq.s)
209pb f 
(%)
S (25µm←well) 
(mgy/mBq.s)
α 1.00 0.0082 0.82 0.4570
β 0.56 0.0159 0.50 0.0218 0.64 0.0084
Auger/ic 0.61 0.0008 0.72 0.0015
γ 0.03 0.0001 0.01 0.0010
Total 0.0249 0.4570 0.0243 0.0084
Table 2, Survival fraction of BON and CA20948 cells after exposure of 137Cs at 2, 4, 6 and 8 Gy
cell line sf2 sf4 sf6 sf8
BOn 0.65 ± 0.10 0.14 ± 0.016 0.031 ± 0.010 0.07 ± 0.002
cA20948 0.60 ± 0.09 0.15 ± 0.013 0.043 ± 0.014 0.036 ± 0.014
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No reduction of BON cell survival was found after treatment with 177Lu-DOTATATE for 1 h. 
A very low binding was present, resulting in low calculated dose, < 1Gy (Fig. 5C). As for irra-
diation of CA20948 cells with 177Lu-DTPA, cell survival was found to be around 100 % after 
irradiation with > 6 MBq 177Lu-DTPA for 1 h (data not plotted). In case of 177Lu-DOTATATE, 
a reduction of cell survival was found with increased radioactivity, see Fig. 5D.
The LQ model parameters α, β and α/β calculated after 137Cs, 213Bi-DTPA, 213Bi-DOTATATE, 
177Lu-DOTATATE irradiation for BON and CA20948 are shown in Table 4.
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figure 5A-5D, Survival curves of BON and CA20948 after exposure of 137Cs γ-radiation, 177Lu-DOT-
ATATE, 213Bi-DTPA, and 213Bi-DOTATATE, n = 3. The x-axis is expressed in absorbed dose to the cells 
(Gy) and the y-axis in percentage survival. Each data point is plotted as the mean survival ± SEM. Cells 
were incubated with 177Lu-DOTATATE, 213Bi-DOTATATE and 213Bi-DTPA for 1h. Cells were fixed and 
colonies were measured 12 d after treatment.
Table 4, The LQ model parameters α, β and α/β calculated for BON and CA20948
BOn cA20948
α(/Gy) β(/Gy2) α/β(Gy) α(/Gy) β(/Gy2) α/β(Gy)
137cs < 0.11 0.12 ± 0.02 0 0.21 ± 0.07 0.05 ± 0.02 4.5 ± 3.6
213Bi-DTpA 0.87 ± 0.1 - - 0.74 ± 0.08 - -
213Bi-DOTATATE 0.91 ± 0.05 - - 0.56 ± 0.03 - -
177lu-DOTATATE - - - 0.08 ± 0.03 0.003 ± 0.004 25.2 ± 37.8
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DiscussiOn
In this study we selected DOTATATE as a targeting ligand. To investigate the distribution, 
time-dependent and peptide amount-dependent uptake, DOTATATE was labelled with 
the γ-emitting radionuclide 111In. The results obtained were used for further cell averaged 
dosimetry. The effect on cell survival caused by radiation was compared using β-emitting 
177Lu-DOTATATE and α-emitting 213Bi-DOTATATE. Cellular uptake is an important and 
critical parameter for the success of peptide receptor radionuclide therapy due to receptor-
mediated process, therefore a high and a low SSTR2 expression cell line were chosen here, 
to compare the receptor-dependent-survival. Cell averaged dosimetry was performed. The 
activity uptake in the cells was analyzed for 500 cells and the high LET character of the 
individual α-particle tracks were averaged out for dosimetry calculation.
111In-DOTATATE, 177Lu-DOTATATE, 213Bi-DOTATATE and DOTATATE were shown to 
have similar affinity for SSTR2. IC50 values were similar of labelled peptides i.e. in the 
nM range. Cellular uptake of 1nM 111In-DOTATATE demonstrated an increase of inter-
nalization in cells with increase of incubation time, compared to the time-independent 
specific membrane bound fraction fmem in CA20948. In this study the specific binding and 
internalization of 390 nM peptide as function of incubation time was also investigated. 
Since the MA of 213Bi-DOTATATE obtained after labelling with a 213Bi/225Ac generator of 
222 MBq was low [18], a concentration of 390 nM labelled peptide was required for the 
sufficiently high radioactivities (approximately 4 MBq) in the clonogenic assays. To mimic 
the peptide concentrations used for further clonogenic assays, peptide-amount dependent 
uptakes resulting from incubation with 15 to 390 nM 111In-DOTATATE were investigated. 
Very low ƒmem and ƒint were found in this range of concentrations, see Fig. 3A. Based on 
the activity measured of 177Lu-DOTATATE or 213Bi-DOTATATE, the data obtained from 
peptide-amount dependent uptake with 111In-DOTATATE, extrapolated to 500 cells and 
taking the radionuclides’ MA into account, about 150 ± 30 213Bi-DOTATATE molecules 
were bound per cell with the highest radioactivity amount used for clonogenic assay. This 
is low in comparison to the 44000 ± 8000 177Lu-DOTATATE molecules at the same peptide 
amount, but still high enough to warrant average cellular dosimetry.
In this study we found that the highest cytotoxic effect was caused by 213Bi-ligands. The 
theoretical advantage of using α-emitters as therapeutic agents is the independence of dose 
rate, oxygenation and cell proliferation [28, 29]. Cytotoxic effects caused by 213Bi-DOTA-
TATE demonstrated no discrimination between cell types and level of SSTR2 expression. 
We observed a similar cytotoxic effect with 213Bi-DTPA and 213Bi-DOTATATE in CA20948, 
indicating a cytotoxic dose can be delivered to the cells in vitro without specific binding 
and peptide receptor-mediated endocytosis. The low MA of the labelled peptide led to rapid 
saturation of the receptors by unlabelled peptides thereby causing a higher concentration 
of labelled peptide in the incubation medium. The effect and absorbed dose by the specific 
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binding was therefore reduced in comparison to the contribution by the medium. The 
absorbed dose during incubation of the cells, which is independent of specific uptake, 
forms the main contribution to the total dose, 53–76 % depending on the amount of activity. 
The absorbed dose by the specific binding fraction can be increased to levels similar to the 
dose contribution from the medium exposure by using activities > 10 MBq. This would 
correspond to a minimal requirement of a 225Ac generator twice the activity used in the 
current experiments (222 MBq). Furthermore, the irradiation time can then be reduced to 
30 min.
In our study the D10 in BON was 4.5 Gy for 137Cs, 2.5 Gy with 213Bi-DTPA and 2.6 Gy 
with 213Bi-DOTATATE. In CA20948, D10 values observed with 137Cs, 213Bi-DOTATATE and 
213Bi-DTPA in CA20948 were 5.1, 3.3 and 2.6 Gy, respectively. Due to the low uptake at 
low dose of 213Bi-DOTATATE, heterogeneous distribution of 213Bi-DOTATATE, MA (Bq/
nmol) on the cell played a significant role here, the number of DNA hits appeared to be 
insufficient to influence cell survival. Heterogeneous distribution can influence the amount 
of ionizations traversing to the DNA of the cell causing irreparable DBS, as described 
by Pasternak et al [9]. The advantage of increasing the MA of labelled antibodies by an 
antibody cocktail caused a more homogenous binding to the cells and increased the cell-
killing ability of α-emitters [9].
In the case of 177Lu-ligand, peptide receptor-mediated endocytosis is essential to cause cy-
totoxic effect in the cells. Due to the low LET of β-emitters, at least 1000–4000 β-particles 
are required to lead to non-dividing cells and cell death. BON cells, with low SSTR2 ex-
pression, showed no reduction in cell survival after irradiation with 177Lu-DOTATATE. In 
CA20948 cells survival showed a correlation with absorbed dose using 177Lu-DOTATATE, 
a D10 of 17.8 Gy was found after extrapolation of the LQ model fit to D10. For both cell 
lines, 177Lu-DTPA showed no effect on cell survival. We found that the absorbed dose was 
low for 177Lu-DTPA in both cell lines and for 177Lu-DOTATATE in BON, < 0.2 Gy. There-
fore, D10 cannot be determined. Specific binding of 177Lu-DOTATATE (0.33 MBq, lowest 
radioactivity used to treat cells) to CA20948 resulted in an absorbed dose at least 7 times 
higher than without specific binding (177Lu-DTPA).
In our study, only 500 cells were plated in the well for the clonogenic assay and were as-
sumed to be spherical in shape with a diameter of 12 µm and homogenously distributed on 
the bottom of the well. The average distance between homogeneously distributed cells was 
approximately 1500 μm. The maximum path length in tissue for α-particle is 50–100 μm 
and for β-particle is 1–10 mm. Absorbed dose by cross-fire contributed from 177Lu after in-
cubation with 177Lu-DOTATATE can be neglected, since the maximum path length of 177Lu 
in tissue is approximately 2000 µm [30], the dose caused from cross-fire effect of 177Lu 
was less than 1x10–12 Gy with a distance of the 1500 µm [31]. As for 213Bi-DOTATATE, 
the maximum path length of 213Bi is 80 µm and the distance between the cells was > 1500 
μm, an additional dose to the calculated absorbed dose caused by cross-fire effect was not 
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taken into account. Despite this we assumed that the cells were homogeneous distributed, 
as clustering of cells can still occur, leading to an increase of the absorbed dose caused by 
cross-fire effect of neighboring cells. This was often observed in studies using low energy 
β-particles such as 177Lu [31]. Therefore, this might have resulted in an underestimation 
of the absorbed dose caused by 177Lu in our calculations. The bound activity was assumed 
to remain on the cells during the 12 d irradiation, as externalization was excluded. This 
assumption will have no effect on the absorbed dose by 213Bi-DOTATATE, since the 
half-life of 213Bi is short, 90 % of the dose was delivered to the cells within 3.5 h. For 
177Lu-DOTATATE, the calculated absorbed dose will consequently be an overestimation 
the actual absorbed dose.
The calculated RBE at D10 with 213Bi-DTPA compared to 137Cs irradiation was 2.0 in 
CA20948 and 1.8 in BON. As for 213Bi-DOTATATE compared to 137Cs in CA20948 and 
BON, the RBE was found to be 1.5 and 1.7, respectively. At D20, Nayak and co-workers 
found 213Bi-DOTATOC to be 3.4 times more cytotoxic than 177Lu-DOTATOC in terms of 
RBE in CAPAN-2 cell line (human pancreatic adenocarcinoma) [7]. In our study we also 
found that 213Bi-DOTATATE was more potent for cell killing than 177Lu-DOTATATE. The 
amount of 213Bi-DOTATATE molecules bound per cell was a factor of approximately 300 
less than 177Lu-DOTATATE molecules bound per cell. RBE’s of 5.4 at D10 and 5.7 at D20 
were found for 213Bi-DOTATATE in comparison to 177Lu-DOTATATE. The RBE was higher 
compared to that found in the study of Nayak et al., this was probably caused by the high 
dose contributed from the internalization medium in our study. Graf et al. demonstrated 
the high cytotoxic effect caused by α-emitters using 225Ac-DOTATOC in rat pancreatic 
carcinoma cell line, AR42J [6]. An ED50 of 14 kBq/mL was found for 225Ac-DOTATOC 
and 10 MBq/mL for 177Lu-DOTATOC. Higher amounts of γH2AX (biomarker of DSB) 
were observed in cells treated with 225Ac-DOTATOC. They found a comparative cytotoxic-
ity assessment by a factor approximately of 700 between 177Lu and 225Ac at ED50. In our 
study, we found a factor of approximately 5.7 between 213Bi-DOTATATE (0.33 MBq/mL) 
and 177Lu-DOTATATE at ED50 (1.88 MBq/mL). The large difference was caused by the 4 
α-particles release of 225Ac compared to one α-particles release of 213Bi and the exposure 
time; 48 h versus 1 h.
Radionuclide therapy with 213Bi-DOTATATE showed to be capable of treating both small 
metastasis and observable large tumours [5]. Cell uptake for targeted radionuclide therapy is 
an essential factor for the calculation of absorbed dose in TAT, as well as selected endpoints 
and experimental design. Absorbed dose calculation methods used in this study described 
the average absorbed dose caused by TAT with 213Bi, enabling comparisons between differ-
ent cell irradiation experiments on basis of average absorbed doses at D10.
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cOnclusiOn
213Bi-DTPA and 213Bi-DOTATATE showed higher cytotoxic effects than 177Lu-DTPA and 
177Lu-DOTATATE in highly SSTR2 expressing cells. RBE’s at 10 % cell survival ranging 
from 1.5–2.0 were found for 213Bi-DTPA and 213Bi-DOTATATE in both low and high SSTR2 
expressing cell lines under the conditions applied. Cellular dosimetry calculations allow 
comparisons to be made between α-, β-emitters and external γ-radiation sources. Per Gy 
delivered 213Bi-DOTATATE was at least 5 times more effective in cell killing in comparison 
to 177Lu-DOTATATE.
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ABsTrAcT
The combined alpha, gamma, and X-ray emitter 213Bi (half-life 46 min) is very promising 
for radionuclide therapy. SPECT imaging of 213Bi is challenging, since the majority of emit-
ted photons has a much higher energy (440 keV) than common in SPECT. We assessed 213Bi 
imaging capabilities of the Versatile Emission Computed Tomograph (VECTor) dedicated 
to (simultaneous) preclinical imaging of both SPECT and PET isotopes over a wide photon 
energy range of 25–600 keV.
methods
VECTor was equipped with a dedicated clustered pinhole collimator. Both the 79 keV 
X-rays and 440 keV gamma-rays emitted by 213Bi could be imaged. Phantom experiments 
were performed to determine the maximum resolution, contrast-to-noise ratio and activity 
recovery coefficient for different energy window settings. Additionally, imaging of [213Bi-
DOTA,Tyr3]-octreotate and 213Bi-DTPA in mouse models was performed.
results
Using 440 keV gamma-rays instead of 79 keV X-rays in image reconstruction strongly 
improved the resolution (0.75 mm) and contrast-to-noise characteristics. Results obtained 
with a single 440 keV energy window setting were close to those with a combined 79 
keV/440 keV window. We found a reliable activity recovery coefficient down to 0.240 
MBq/mL with 30 minutes imaging time. In a tumor-bearing mouse injected with 3 MBq 
[213Bi-DOTA,Tyr3]octreotate, tumor uptake could be visualized with a one hour post-mortem 
scan. Imaging a non-tumor mouse at 5 minute frames after injecting 7.4 MBq 213Bi-DTPA 
showed renal uptake and urinary clearance, visualizing the renal excretion pathway from 
cortex to ureter. Quantification of the uptake data allowed kinetic modeling and estimation 
of the absorbed dose to the kidneys.
conclusion
It is feasible to image 213Bi down to 0.75 mm resolution by using a SPECT system equipped 
with a dedicated collimator.
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inTrODucTiOn
New opportunities for high linear energy transfer (LET) radionuclide therapy with the alpha 
particle emitters 225Actinium and 213Bismuth are increasingly being investigated [1–3]. The 
research for peptide receptor radionuclide therapy with alpha particles is mostly focused on 
labeling peptides with 213Bi. Not only is its short half-life of 46 minutes in good accordance 
with the rapid targeting to receptor-positive tumors as well as the rapid clearance of peptides, 
it also raises less concern for detrimental effects because of the absence of non-specific uptake 
by daughters detached from its peptide or linker due to alpha decay recoil [4].
213Bi offers the best imaging opportunities through its 440 keV gamma-ray and is therefore 
important for biodistribution and dosimetry studies [5]. All other gamma-rays and X-rays 
emitted by 213Bi and its daughters are either too low in abundance or in energy to be suitable 
for imaging, possibly with the exception of the X-rays from 213Bi at 77 and 79 keV if ap-
propriate correction methods for down-scatter of the 440 keV gamma-rays are applied (see 
table 1 supplemental data [6]). Patient imaging of the uptake pattern of 213Bi labeled antibody 
HuM195, targeted to CD33 leukemia, and 213Bi-DOTATOC targeting neuroendocrine tumors 
has been performed by imaging the 440 keV gamma-ray with high-energy collimators [7–9].
Pre-clinical biodistribution studies with 213Bi are challenging due to its short half-life. 
Typically 213Bi labeled peptide biodistributions have been determined at 1h and 3h in rats 
and mice, thereby missing essential information on the kinetics in the uptake phase [2]. 
Dynamic imaging of this uptake phase will show the kinetic pattern, but usually lacks good 
quantification. Imaging of the high-energy (440 keV) photons is severely compromised for 
most small animal SPECT systems, due to penetration of pinhole edges and the collimator 
wall. Recently, however, a new dedicated small animal SPECT system based on use of 
many clustered pinholes has been developed that enables imaging over an energy range 
from 25 to 600 keV [10]. This system has shown to be able to e.g. image SPECT and PET 
tracers simultaneously at 0.5 mm and 0.75 mm resolution, respectively [10, 11].
The aim of the study was to investigate the capability to (dynamically) image 213Bi in 
small animals, e.g. using 213Bi labeled peptides. Resolution, contrast-to-noise ratio and 
activity recovery coefficient for different energy window settings and combinations thereof 
were optimized in phantom studies. Subsequently imaging of 213Bi-DTPA and [213Bi-
DOTA,Tyr3]-octreotate in mice was performed.
mATEriAls AnD mEThODs
radiochemistry
213Bi was eluted from a standard 225Ac/213Bi generator (European Commission, Institute 
for Transuranium Elements (ITU). For phantom experiments the elution was not chemi-
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cally altered. 213Bi was labeled with diethylene triamine pentaacetic acid (DTPA) for renal 
function imaging. 213Bi eluate was added directly into a ready-for-use solution containing, 
0.15M TRIS and 64μM DTPA, at total volume 800 µL and pH 8.5.
For tumor imaging, 213Bi was labeled to [DOTA,Tyr3]octreotate according to the label-
ing procedure described earlier [12], the incorporation of the radioactivity was > 99 %, 
radiochemical purity was > 85 %. Specific activity was 14.8 MBq/nmol.
small Animal imaging system
The VECTor (MILabs B.V.) uses three gamma cameras in a triangular set up. It enables 
high-energy gamma photon imaging including single 511 keV photons by using a tungsten 
collimator with clustered pinholes with relatively small opening angles. This reduces the 
image-degrading effects of pinhole edge penetration by these high-energy photons. The 
collimator contains 162 pinholes with a diameter of 0.7 mm grouped in clusters of 4. All 
clustered pinholes together observe a field-of-view which has the shape of an hourglass 
with a diameter of 44 mm and an average longitudinal length of 33 mm [10]. Total body 
images are obtained by moving the animal through the scanner along a spiral trajectory 
[13]. Data is collected in list mode.
image reconstruction
SPECT images were reconstructed by using projections from all bed positions simulta-
neously [14] using Pixel-based OSEM [15]. Three photo peak energy window settings 
were tested: a window set at the 440 keV photo peak, a window set at 79 keV, or both 
energy windows simultaneously. Scatter and background were corrected for with the triple-
energy window method [16]. The 440 and 79 keV photo peak windows had two adjacent 
background windows each (Fig. S1 in supplemental data). For reconstruction the standard 
SPECT system matrix was used [17] for the 79 keV energy window, and a 511 keV system 
matrix for reconstructions using the 440 keV or the combined energy windows.
phantom Experiments
A 5 mL syringe (internal diameter: 12.06 mm) was filled with 86.2 MBq 213Bi in a volume 
of 2.0 mL (fill height: 17.7 mm) for determining the ability to recover different amounts 
of activity. A volume of interest (VOI) was drawn around the activity in the reconstructed 
image. On a dynamic scan (20 frames of 30 minutes) the activity concentration at the start 
of the acquisition was 36.2 MBq/mL 213Bi, at the start of the last frame 0.0062 MBq/mL.
A second dynamic scan (90 frames of 5 minutes) of a 213Bi filled syringe was performed. 
The initial activity concentration in 2.0 mL within the 5 mL syringe was 25.1 MBq/mL 213Bi 
and 0.0352 MBq/mL at the start of the last frame.
Reconstructions of both experiments were done with 4 subsets and 30 iterations, voxel size 
was 0.8 mm. A post-reconstruction filter (3D Gaussian) with 0.4 mm Full Width at Half 
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Maximum (FWHM) was applied. All data were corrected for decay. System performance 
was characterized with the recovery coefficient (RC), defined as the measured apparent ra-
dioactivity concentration divided by the true radioactivity concentration. For large objects 
and sufficient imaging times RC should equal 1.
Spatial resolution was determined by using a Jaszczak resolution phantom (HR-micro 
phantom, Vanderwilt Techniques) with hollow channels of 0.7, 0.8, 0.9, 1.0, 1.2 and 1.5 mm 
diameter. It was filled with 119 MBq 213Bi (activity concentration 198 MBq/mL) and scanned 
for 45 minutes. Images were reconstructed using 32 subsets, 60 iterations and a voxel size of 
0.4 mm. No post-reconstruction filters were used. Profiles were determined from five single 
slices through the measured signal over a 0.4 mm cross-hair line drawn over the rods. Gaus-
sian curves were fitted to these profiles and averaged, and their FWHM values were reported.
To assess the impact of lower numbers of counts on resolution, we also reconstructed this 
dataset using only 20 %, 5 % and 1 % of the counts from the list-mode data. This emulates 
scans with shorter scan times or lower activities. We reconstructed the lowest activity scan 
with 4 subsets and 30 iterations on 0.4 mm voxels which are the same reconstruction set-
tings as used for the mouse scans. For the higher activities more iterations were needed to 
recover finer details and thus we chose the same reconstruction settings as for the high-
count reconstructions. Images were post-filtered with a 3D Gaussian with a 0.6, 0.9 and 1.0 
mm FWHM for scans with 20 %, 5 % and 1 % of the counts respectively.
An analysis of contrast-noise characteristics was performed similar to [18]. Resolution phan-
tom images were resampled to a fine 0.05 mm grid, and ROIs with a diameter 90 % of the rod 
diameter were placed on top and in between the rods (Fig. S2c in supplemental data). This 
was repeated over 20 slices. The mean activity inside the ROIs placed over the rods (hd) and 
in between the rods (bd) was determined. The contrast Cd for rod size d is then defined to be
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The standard deviation  of hd and bd were calculated over all ROIs in 1/3 of the 20 slices to reduce inter-
ROI covariance. The denominator 𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑑𝑑̅̅ ̅̅ ̅̅ ̅ indicates the mean value taken over all ROIs. The contrast-to-
noise ratio was defined as Cd/Nd. 
Quantification calibration procedure and determination of the calibration factors are described in the 
supplemental data and based on the method in [19]. 
Ex-vivo Experiment 
A nu/nu mouse bearing a CA20948 tumor xenograft was injected intravenously (iv) in a tail vein with 3.0 
MBq [213Bi-DOTA,Tyr3]-octreotate. The mouse was euthanized 38 minutes after injection and 
immediately imaged for 1 hour. A CT scan was made following SPECT with the integrated CT scanner 
(acquisition parameters 55 kV and 615 µA and reconstructed with filtered Back Projection), which was 
used only as an anatomical reference. SPECT reconstruction parameters comprised 4 subsets, 30 iterations 
and a voxel size of 0.4 mm. A post-reconstruction filter (3D Gaussian) of 1.5 mm FWHM was applied. 
Tumor volume was determined by drawing VOIs in the CT-images. The radioactivity uptake was based 
on the VOIs drawn in the SPECT images. Organs and tumor tissue were counted for 60 s in a Wallac 
Wizard gamma counter (PerkinElmer). Counting started 2.3 hours after injection. 
In vivo experiment 
In an in vivo experiment, a balb/c mouse was injected iv in a tail vein with 7.4 MBq 213Bi-DTPA under 
isoflurane anaesthesia. Dynamic acquisition of the abdominal region was started 3 minutes after injection 
over a total of nine 5-minute frames. Equal reconstruction parameters were used as for the ex-vivo 
experiment. SPECT-based VOIs were drawn over the urinary bladder and over both kidneys to determine 
their kinetics. The absorbed dose to the kidneys was determined by using the sphere model within the 
Olinda/EXM code [19] and calculated for an average single kidney mass of 0.286 mg, determined from 
the mouse of the ex-vivo experiment. 
All animal studies were conducted in accordance with the guidelines and after approval of the Animal 
Welfare Committee of the Erasmus MC.  
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Ex-vivo Experiment
A nu/nu mouse bearing a CA20948 tumor xenograft was injected intravenously (iv) in a tail 
vein with 3.0 MBq [213Bi-DOTA,Tyr3]-octreotate. The mouse was euthanized 38 minutes 
after injection and immediately imaged for 1 hour. A CT scan was made following SPECT 
with the integrated CT scanner (acquisition parameters 55 kV and 615 µA and reconstructed 
with filtered Back Projection), which was used only as an anatomical reference. SPECT 
reconstruction parameters comprised 4 subsets, 30 iterations and a voxel size of 0.4 mm. 
A post-reconstruction filter (3D Gaussian) of 1.5 mm FWHM was applied. Tumor volume 
was determined by drawing VOIs in the CT-images. The radioactivity uptake was based on 
the VOIs drawn in the SPECT images. Organs and tumor tissue were counted for 60 s in a 
Wallac Wizard gamma counter (PerkinElmer). Counting started 2.3 hours after injection.
In vivo experiment
In an in vivo experiment, a balb/c mouse was injected iv in a tail vein with 7.4 MBq 213Bi-
DTPA under isoflurane anaesthesia. Dynamic acquisition of the abdominal region was started 
3 minutes after injection over a total of nine 5-minute frames. Equal reconstruction parameters 
were used as for the ex-vivo experiment. SPECT-based VOIs were drawn over the urinary blad-
der and over both kidneys to determine their kinetics. The absorbed dose to the kidneys was 
determined by using the sphere model within the Olinda/EXM code [19] and calculated for an 
average single kidney mass of 0.286 mg, determined from the mouse of the ex-vivo experiment.
All animal studies were conducted in accordance with the guidelines and after approval of 
the Animal Welfare Committee of the Erasmus MC.
statistics
Statistical analysis of the syringe experiments was performed with the Graphpad Prism software 
(GraphPad Software, Inc.). Average values of the RC from 213Bi –filled syringes, normalized 
to the initial value, were determined for each frame. Deviations from the horizontal line were 
analyzed according to the D’Agostini & Pearson normality test. Additionally the Runs test was 
performed to decide whether the residuals followed a random pattern. The cut-off value for the 
linearity of RC was determined by the 3 σ outlier criterion on the moving average.
rEsulTs
Quantitative properties
On the 30-minute dynamic series, the RC was averaged over the linear range (Fig. 1). 
Cut-off values or lower limits for linearity found are indicated in Table 1. The RC was 
comparable for all energy window settings. The single 440 keV window setting showed the 
largest linearity range (lower limit: 0.24 MBq/mL).
6213Bi SPECT in mice | 121
     



 

   




 





 

     



 

   




 





 

     



 

   




 





 

     



 

   




 





 

     



 

   




 





 

     



 

   




 





 

     



 

   




 





 

     



 

   




 





 

     



 

   




 





 

figure 1, Recovery coefficients for a syringe initially filled with 86.2 MBq 213Bi (in 2.0 mL) scanned in 
15 frames of 30 minutes. Results were fitted with a horizontal line when both residuals were normally 
distributed (D’Agostini-Pearson test) and showed no significant systematic deviation (Runs test). The 
open markers indicate the excluded RC values. Some data points at low activity concentrations did not 
fall within the Y-axis boundaries.
Table 1. Results from the measurements of the 213Bi filled phantoms
Energy window 79 keV 440 keV 79 + 440 keV
rc 30 min frames (mean±sE) 1.03 ± 0.007 1.04 ± 0.007 1.04 ± 0.009
lower limit linearity 30 min (mBq/ml) 0.94 0.24 0.94
rc 5 min frames (mean±sE) 0.93 ± 0.007 1.00 ± 0.003 1.01 ± 0.003
lower limit linearity 5 min (mBq/ml) 2.33 0.90 0.32
fwhm 0.7 mm rods (mm) 1.1 ± 0.3 1.4 ± 0.3 1.4 ± 0.3
fwhm 0.8 mm rods (mm) 1.6 ± 0.5 1.4 ± 0.2 1.4 ± 0.2
fwhm 0.9 mm rods (mm) 1.4 ± 0.6 1.33 ± 0.14 1.29 ± 0.09
fwhm 1.0 mm rods (mm) 1.4 ± 0.5 1.34 ± 0.29 1.29 ± 0.12
fwhm 1.2 mm rods (mm) 1.6 ± 0.6 1.30 ± 0.14 1.25 ± 0.08
fwhm 1.5 mm rods (mm) 2.0 ± 0.4 1.58 ± 0.14 1.61 ± 0.12
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figure 2, Recovery coefficient for a syringe initially filled with 67.69 MBq 213Bi (in 2.0 mL) scanned in 
45 frames of 5 minutes. Fitting was performed with the same statistical rules as in figure 2. Data for the 
first 13 frames were omitted from the graph, but were included in the averaging.
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For the 5-minute dynamic scans, the RC for the 79 keV/440 keV combined energy peaks 
showed the best results as it remained constant down to 0.32 MBq/mL (Fig. 2). Below 2 
MBq/mL a more scattered pattern of the data points was visible, but this was not a statistical 
deviation due to the equal variations in the signal above and under the average RC line. The 
RC for the 79 keV photo peak on the 5-minute dynamic scans did not meet all statistical 
tests. Therefore the RC line in this graph can only serve as an indication.
In general the quantitative properties for activity recovery for images using the 440 keV 
peak and the combined peaks are comparable. Especially in the 5-minute scans these two 
settings have better quantitative properties than the single 79 keV peak setting. There was 
no difference in results when a 0.4 mm or a 0.8 mm voxel size was applied in the recon-
struction settings (data not shown).
spatial resolution
Resolution phantom images are shown in Fig. 3. Visually, images using the single 440 
keV or the combined 79 keV/440 keV energy window setting appear to be much less noisy 
and have better resolution than the images using the single 79 keV energy window; on the 
reconstructions 0.7 mm rods could be distinguished for the combined 79 keV/440 keV set-
ting and for the single 440 keV window. Profiles are shown in Fig. 4 and the mean FWHMs 
for the three energy windows are indicated in Table 1. These values showed a significant 
difference for the combined 79 keV/440 keV setting compared to the single 79 keV setting. 
Differences between the 440 keV and the combined 79 keV/440 keV setting were small, 
but the combined setting resulted in a slightly lower variation, indicating the most stable 
settings. Contrast and contrast-to-noise curves for all 3 energy window settings are shown 
in Fig. 5 and are in agreement with the visual assessment; both contrast and contrast-to-
noise are much better for the 440 keV or the 79 keV/ 440 keV window settings compared 
to the single 79 keV energy window. All though 0.7 mm rods could be distinguished in 
reconstructions, profiles reveal that these are really at the resolution limit. The contrast for 
figure 3, Resolution phantom images of 213Bi SPECT. The phantom has 6 segments containing capillary 
diameters of 1.5, 1.2, 1.0, 0.9, 0.8 and 0.7 mm. The images show reconstructions for different energy 
window settings summed over 5 slices (2 mm in total).
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these rods was found to be C0.7 = 0.34 for the 79 keV/440 keV combined window setting. 
To emulate lower activities, we also reconstructed resolution phantom images with only 
part of the listmode data used (Fig. S3, supplemental data). When only 20 %, 5 % or 1 % of 
the counts were used respectively, rods that could still be distinguished were 0.8 mm, 0.9 
mm and 1.2 mm.
Ex-vivo Experiment
Tumor uptake by [213Bi-DOTA,Tyr3]-octreotate in the euthanized mouse was clearly visual-
ized with the 440 keV and the combined 79 keV/440 keV energy window setting, but not 
with the 79 keV setting (Fig. 5), 213Bi uptake in the kidneys was not visible though. The 
uptake in the xenograft amounted to 38 kBq, corresponding to a concentration of 0.42 
MBq/mL for the 90 mm3 volume tumor. The activity in the abdomen below the tumor 
figure 4, Profiles through 0.7, 0.8, 0.9 and 1.2 mm rods for the single 79 and 440 keV and the combined 
79 keV/440 keV energy windows (graphs A, B, C and D). Contrast and contrast-to-noise curves for the 
different rod sizes are shown in graphs E and F.
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corresponded to 0.16 MBq/mL. A region within the mouse on the contralateral side of the 
tumor, not clearly linked to physiological uptake, showed an uptake of 0.12 MBq/mL. The 
biodistribution assay of this mouse showed a tumor uptake of 5.3 % of the injected activity 
(%IA) and with activity concentration of 0.36 MBq/g. The uptake in the left kidney was 
1.9 %IA (0.48 MBq/g).
figure 5, Ex-vivo image of 3.0 MBq [213Bi-DOTA,Tyr3]-octreotate injected in a nude mouse. From top 
to bottom: mip images reconstructed at 79 keV, 440 keV and at both energy windows. The numbers in 
the color table indicate the radioactivity concentration in MBq/mL.
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In vivo Experiment
In vivo mouse maximum intensity projection (mip) images are shown in Fig. 6 for the com-
bined energy window as this setting was generally found to be optimal. The first frame in 
Fig. 6 shows activity in both kidneys and bladder after injection with 7.4 MBq 213Bi-DTPA. 
figure 6, In vivo mouse mip images with 7.4 MBq 213Bi-DTPA. Images were reconstructed using the 
combined 79 keV/440 keV photo peak setting. In the 9 consecutive 5-minute frames kidneys show up in 
each frame, initially showing the ureters at the top of the image with gradually a distribution to the renal 
cortices and filling of the bladder. The numbers in the color table indicate the radioactivity concentration 
in MBq/mL.
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The filling of the urinary bladder was also visible by its enlargement over time and in the 
first frame already exceeded the maximum displayed intensity. The activity in the kidneys 
gradually accumulated in the renal medulla as visualized in the mip image of Fig. 6 and the 
quantitative VOI-based results in Fig. 7.
The peak uptake of in the kidneys was 18 %IA. The kidney radioactivity uptake ranged 
between 0.34 and 0.66 MBq (1.2 and 2.3 MBq/mL). These SPECT-based activity concen-
trations in the kidneys were found to be well above the 0.32 MBq/mL threshold for linear 
response.
The decay-corrected radioactivity accumulation in the urinary bladder followed a single-
exponential build-up pattern with an 11 ± 2 min half-life. The non-decay corrected uptake 
data of the kidneys could be fitted with a single exponential curve with an effective clear-
ance half-life of 52 min (95 % confidence interval: 36–96 min). A horizontal line was the 
preferred fit through the decay corrected kidney data. The residence time for the 213Bi-DTPA 
uptake in the kidneys was 11.7 ± 0.4 min, leading to an absorbed dose of 26 ± 2 Gy by 7.4 
MBq. The largest part (94 %) of this dose was delivered by the 213Po α-particles.
DiscussiOn
Direct imaging of the 440 keV gamma-rays from 213Bi is possible with dedicated high-
energy SPECT, despite the low activity injected to avoid an undesirably high dose to the 
animal. We found that including the 440 keV setting in image reconstruction is essential; 
only using 79 keV X-rays has a strong negative effect on image quality. Generally, the 
results for the 440 keV and the combined 440 keV/79keV setting are close. Resolution and 
contrast-noise properties were slightly better for the combined setting which also showed 
better quantification properties for short time frames. However, on longer time frames 440 
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figure 7, Kinetic modeling of 213Bi-DTPA in the urinary bladder and the kidneys. In the decay-corrected 
data (A) the bladder activity is fit by a single exponential with a T1/2 = 11 ± 2 min (Teff = 15 min). The 
kidneys did not show clearance, whereas in the uncorrected data (B) the renal clearance proceeded with 
Teff = 52 ± 10 min half-life. Images were reconstructed from combined 79 keV/440 keV photo peaks.
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keV alone performed slightly better. We believe that for low-count studies the combined 
window performs better as it contains more counts, while for higher count levels the down-
scatter of 440 keV gammas in the 79 keV photo peak adversely affects quantification.
Quantification sensitivity of the camera in the 5-minute frame setting was high enough 
to allow kinetic modeling of the kidney uptake and bladder filling, which is apparent 
when comparing the results from the 5-minute phantom scan and the results of the in vivo 
213Bi-DTPA scan. Tumor and pancreas modeling should also be possible for most DOTA-
conjugated somatostatin analogues as their uptake in mice is in the order of approximately 
10 %IA/mL [5] to even 225 %IA/g for Exendin [21]. With an injected activity of 5–10 MBq 
this will lead to activities in these organs that enable 5-minute frame scanning, but results 
will become uncertain when the activity concentration will drop below 0.32 MBq/mL. In 
those cases, longer time frames should be used with the risk of missing essential fast kinetic 
effects.
The maximum resolution reported here was achieved with a static scan and relatively 
high activity compared to that injected in mice. This was done to test (maximum) system 
performance for 213Bi imaging and to investigate optimal energy window settings which 
is easiest on almost noiseless data. As common in SPECT and shown in the supplemental 
data, the resolution that can be obtained depends on the number of detected counts and 
thus increasing system sensitivity may be very beneficial for 213Bi imaging in mice. Such 
sensitivity improvements have already been realized in practice through increasing crystal 
thickness which makes the system 2.5 times more efficient. Furthermore, new high-energy 
collimators with larger sensitivity have been developed. The choice of collimator depends 
on the imaging task and these higher sensitivity collimators may be very suitable for 213Bi 
imaging. The VECTor system used in this paper is a first-generation scanner and could not 
benefit yet from these improvements.
Ex-vivo and in vivo mouse experiments were performed as proof of principle, to investigate 
the feasibility to image the tumor and physiological uptake using 213Bi. The reported kidney 
dose of 26 Gy by 213Bi-DTPA is however high and most probably would lead to renal toxic-
ity at a later stage. Renal toxicity has been observed after scanning 111In labeled peptides 
with cumulative kidney doses of 20–40 Gy [20]. Considering the high LET nature of its 
radiation 26 Gy by 213Bi will be at least as equitoxic as 20–40 Gy by 111In.
In the biodistribution assay for [213Bi-DOTA,Tyr3]-octreotate showed an absolute tumor 
uptake of 5.3 %IA and in the kidney of 1.9 %IA. The renal uptake was therefore too low to 
be detectable on SPECT. These uptake values are higher than found from the SPECT data. 
It is not clear what caused this discrepancy.
The uptake of 111In-DTPA in rat kidneys has been reported to be 0.9 ± 0.2 %/mL at 38 
minutes after injection [21]. Initially (at 2–4 min) the peak activity in the renal cortex is 5–7 
times higher by perfusion with radioactive blood. The uptake of 213Bi-DTPA in the kidneys 
seems to be much higher than that observed with 111In-DTPA. This may be the result of 
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the persistent uptake of 213Bi in the kidneys, independent of the compound administered 
[22]. Species-specific differences in DTPA uptake by mice and rats could also cause this 
difference, but the reported renal uptake of 111In-DTPA in dogs was found to be comparable 
to the rat values [23].
Using significantly higher injected activities of 213Bi labeled peptides for better quantifica-
tion is not ideal both for the consequentially higher amount of peptide needed, which might 
partially block receptor-mediated targeting, as well as for increased probability of radiation 
toxicity.
cOnclusiOn
We have shown that it is possible to image 213Bi at sub-mm resolution level with a SPECT 
system equipped with a dedicated high-energy collimator. We found that the use of the 
440 keV gamma-ray peak is essential and produced significantly better images than the 
79 keV X-ray peak. Quantification of the 213Bi activity concentration was reliable above 
0.240 MBq/mL with 30-minutes image time using the 440 keV energy window setting and 
above 0.320 MBq/mL with 5-minutes frames using the combined energy window setting. 
Uptake of [213Bi-DOTA,Tyr3]-octreotate in a CA20948 tumor xenograft was well visual-
ized. Dynamic in vivo imaging of the 213Bi-DTPA distribution in a mouse showed distinct 
renal uptake patterns, enabling identification of sub-organ distributions (renal cortex). 
Quantification of the uptake data allowed kinetic modeling and estimation of the absorbed 
dose to the kidneys, albeit with uncertainties of around 20 %.
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supplEmEnTAl DATA
Quantification Calibration
For quantification calibration, radioactivity of 213Bi was determined on the gamma-spectrum 
count rate measured with a high‐purity germanium detector (Canberra Industries Inc.). 
The counting efficiency of the HPGe detector at 440 keV was determined using a known 
amount of 225Ac activity provided and calibrated at the ITU with a high‐resolution gamma 
spectrometer [1,2]. The measurements showed an accuracy of 10 %.
For converting reconstructed images in Nifti index (Nii) values to MBq, a calibration factor 
(in MBq/nii) was determined [3]. To this end, a point source of 70 MBq 213Bi (volume 
0.6 mL) in an Eppendorf tube was placed in the center of VECTor and scanned in 30 
minutes net measuring time. Calibration factors to convert the image NII values into MBq 
are indicated in Table 2.
Table 1, Radiation characteristics of 213Bi and its decay-chain daughters. In this table the half-lives of the 
listed isotopes are shown, as well as the transition energy E for the emission of the listed particles, and 
the emission yield per transition Yi. [4, 13, 14].
yield Decay α particles β particles γ-rays X-rays
ratio T1/2 E (meV) yi (/nt) E (keV) yi (/nt) E (keV) yi (/nt) E (keV) yi (/nt)
213Bi 45.62 
min
5.878 0.0214 435 0.9786 440.5 0.261 77.1
79.6 
0.0121
0.0202
213po 0.9786 3.708 μs 8.375 1.0
209Tl 0.0214 2.16 min 656 1.0 117.2
465.1
1567
0.843
0.969
0.998
73.0
75.3
85 
0.0635
0.107
0.035
209pb 3.232 h 198 1.0
Table 2, Calibration Factors (CF) using energy windows around the 79 keV X-ray peak, the 440 keV 
gamma ray peak, or the 79 keV and 440 keV peaks combined.
Energy window 79 keV 440 keV 79 keV + 440 keV
Voxel size 0.8 mm 0.4 mm 0.8 mm 0.4 mm 0.8 mm 0.4 mm
cf (mBq/nii) 16560 16440 2260 2220 1850 1820
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figure s2, Resolution phantom images of 213Bi SPECT. A) Phantom has 6 segments containing capillary 
diameters of 1.5, 1.2, 1.0, 0.9, 0.8 and 0.7 mm. B) Across 0.9 and 1.2 mm diameter rods profiles were 
drawn. C) Position of the ROI’s to obtain contrast and contrast-to-noise ratios.
figure s3, Resolution phantom images for the same phantom as shown in figure 3 for various count 
levels. Recontructions were based on (A) all listmode data or (B) 20 %, (C) 5 %, (D) 1 % of all detected 
counts. The combined 79 keV/440 keV photo peak window setting was used. Post-reconstruction 3D 
Gaussian filters with 0.4, 0.6, 0.9 and 1.0 mm FWHM were applied to (A-D).
figure s1, Measured pulse height distribution of 213Bi. The 440 keV photo peak window setting (width 
16 %: 405–475 keV) is represented by the green dotted area. The adjacent green striped areas represent 
the background windows (width 35 keV: 307–405 and 475–510 keV) used for scatter correction. The 
dotted blue areas represent the 79 keV window (witdh: 20 %: 71–87 keV) and the striped blue areas are 
the background windows (width 8 keV: 63–71 and 87–95 keV).
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summAry
Over the past decades 177Lu- DOTA-Tyr3-octreotate (177Lu-DOTATATE) has been applied 
to treat patients with metastatic neuroendocrine tumours (NETs) in our institute. Most 
favorable results have been obtained regarding anti-tumour responses and improved quality 
of life, complete cure in these patients is rarely reached however. Therefore, the search 
for better treatment for patients with metastasized NETs continues. The use of α-emitting 
radionuclides in targeted alpha therapy (TAT) has become very attractive, since α-emitting 
particles such as 213Bi shows greater cytotoxic effects than β-emitting radionuclides. In this 
thesis we investigated 213Bi-DOTATATE for applications in preclinical models, with the 
ultimate aim to improve TAT for patients suffering from metastatic NETs.
In chapter 1 of this thesis, a general introduction on NETs, the concept of targeted radio-
nuclide imaging and radionuclide therapy, and TAT is given. Furthermore, in this chapter 
we have introduced the use of the α-emitter 213Bi as a potential radionuclide for labelling 
of DOTATATE and application in TAT. General requirements and limitations of targeted 
radionuclide therapy for (pre)clinical applications are given in this chapter as well.
Due to the low radioactivity 225Ac/ 213Bi generator (< 222 MBq) available and used in 
our preclinical studies, adjustments of the labelling procedure were required to meet the 
criteria for preclinical studies, e.g. highly stable labelled peptide with high molar activity 
(MA). Furthermore, a small injection volume at physiological conditions is required in 
mice to maintain the homeostasis of the animal. Therefore, the labelling conditions of 213Bi-
DOTATATE were optimized in stepwise fashion as described in chapter 2 for preclinical 
applications. The optimized labelling procedure resulted in high incorporation yield, high 
radiochemical purity and high stability up to 2 hours after labelling. The addition of quench-
ers such as ascorbic acid during radiolabelling appeared to be essential for the protection of 
the peptide from radiolysis, since the absorbed dose rate within the reaction vial was high, 
> 165 mGy.s-1 with 100 MBq of 213Bi. However, at high concentrations ascorbic acid also 
appeared to be cytotoxic to the CA20948 cells, pancreatic rat carcinoma cells with high 
expression of somatostatin receptor subtype 2 (SSTR2). The ascorbic acid concentration 
used for labelling was therefore optimized as well. An 225Ac/ 213Bi generator containing 
higher radioactivity is recommended to fully overcome the limitations encountered.
Investigations on pharmacokinetics and pharmacodynamics of 213Bi-DOTATATE in vivo in 
mice were described in chapter 3. The tumour model used was the rat pancreatic tumour 
cell line AR42J with well-characterized overexpression of SSTR2. The optimal amount of 
peptide was determined in mice using 111In-DOTATATE as a model radiopeptide to obtain 
biodistribution data and estimates of the radiation absorbed dose to the tumour and other 
organs. Tumour uptake appeared similar for 111In-DOTATATE and 213Bi-DOTATATE, but 
renal activity of 213Bi-DOTATATE was significantly higher than that of 111In-DOTATATE. 
The optimal amount of peptide injected was 0.3 nmol; this amount was therefore used for all 
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following in vivo studies. The calculated mean radiation absorbed dose was approximately 
0.5 Gy/MBq for tumour. Next, the maximum tolerated dose (MTD) of 213Bi-DOTATATE 
was determined. 213Bi-labelled compounds tend to accumulate in the kidneys, resulting in 
a high radiation absorbed dose to the kidney and potential nephrotoxicity. In this study, 
the high renal uptake could be reduced with 50 % by pretreatment with L-lysine, a renal 
protectant applied for peptide receptor radionuclide therapy. Acute radiation nephrotoxic-
ity occurred at a mean renal radiation absorbed dose > 20 Gy (LD50). A correlation was 
found between the amount of injected radioactivity and Neutrophil Gelatinase-Associated 
Lipocalin (NGAL) levels. The therapeutic potential of 213Bi-DOTATATE was illustrated by 
significantly improved overall survival. Renal protection with L-lysine immediately prior 
to TAT with 213Bi-DOTATATE prolonged survival. The MTD was found to be 22 MBq with 
L-lysine for renal protection and without L-lysine this was < 13 MBq.
As described elsewhere, α-emitters are thought to be mainly suitable for treatment of small 
tumour clusters and metastases. Reduction of larger tumour volumes was however also 
observed in patients after TAT with 213Bi- DOTA-Tyr3-octreotide. In chapter 4 we com-
pared the efficacy of 213Bi-DOTATATE between large and small tumour volumes (50 and 
200 mm3), for two different tumour models showing low and high SSTR2 expression levels 
in mice; a rat pancreatic tumour (CA20948) and human small cell lung carcinoma (H69). 
The amount of radioactivity injected was below the MTD without L-lysine. Anti-tumour 
effects following TAT with 213Bi-DOTATATE were observed in all tumour-bearing animals. 
The effects were more pronounced in H69 tumour-bearing animals; their survival rate was 
higher. The response to the therapy was similar for both tumour sizes with no significant 
differences observed, indicating that 213Bi-DOTATATE was suitable for TAT in small and 
in larger tumours. Renal function was evaluated using in vivo SPECT imaging with 99mTc-
DMSA; no renal dysfunction was observed after TAT in 213Bi-DOTATATE-treated mice 
using the doses applied in this study.
In chapter 5, cell survival assays were performed to compare the relative biological effect 
(RBE) in vitro of 213Bi-ligand with that of the gold standard 137Cs (external radiation) and 
177Lu-ligand. Two cell lines (CA20948, a rat pancreatic tumour and BON, a human carci-
noid) with different radio-sensitivity and different expression levels of SSTR2 were used. 
The radiation absorbed doses were calculated using a small-scale dosimetry model, this 
enabled comparison of different radiation types to determine the RBE. 111In-DOTATATE 
was used to mimic the cellular uptake of 213Bi-DOTATATE and 177Lu-DOTATATE, since 
111In-DOTATATE, 213Bi-DOTATATE and 177Lu-DOTATATE have similar receptor affinities 
(in the low nM range) for SSTR2. Survival curves of both cell lines after exposure to 137Cs 
as function of dose fitted the linear quadratic model, showing the typical curvature for 
low LET irradiation. BON cells have very low expression of SSTR2 and cellular uptake 
could therefore be neglected. 177Lu-DTPA (177Lu-diethylenetriaminepentaacetic acid) and 
177Lu-DOTATATE showed no effect on cellular survival with increased radioactivity in 
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these cells. In CA20948 cells on the other hand, with high expression of SSTR2, no ef-
fect on survival was observed with increased amounts of 177Lu-DTPA. However, survival 
decreased with increasing amounts of 177Lu-DOTATATE. Linear exponential decline in cell 
survival was observed in both BON and CA20948 cells after exposure to increased activi-
ties of both 213Bi-DTPA and 213Bi-DOTATATE, indicating both the high LET nature of this 
exposure and the radiation absorbed dose from the incubation medium to be higher than 
the radiation absorbed dose from cellular uptake. Both 213Bi-DTPA and 213Bi-DOTATATE 
showed a 6-fold advantage in cell killing compared to 177Lu-DOTATATE in CA20948 cells. 
The RBE of 213Bi-ligand ranged from 1.5–2.0 compared to 137Cs in both cell models.
In chapter 6, the feasibility of 213Bi imaging by Single Photon Emission Computed To-
mography (SPECT) was investigated. 213Bi emits γ-radiation of 440 keV that could be 
used to follow the pharmacokinetics of 213Bi-DOTATATE in vivo. A phantom study was 
performed to determine the lowest detectable radioactivity concentration using a multiple 
pinhole small-animal SPECT camera, followed by imaging in vivo in mice as well as 
ex-vivo. A spatial resolution of 0.75 mm was obtained. In non tumour-bearing mice, 213Bi-
DTPA showed renal uptake and urinary clearance in vivo, allowing visualization of the 
renal excretion pathway from cortex to ureter to be visualized. In ex-vivo studies, tumour 
uptake of 213Bi-DOTATATE could still be visualized at one hour post-mortem.
cOncluDing rEmArks
α-Emitters offer enhanced possibilities to treat tumours, due to their high ionization en-
ergy deposition, resulting in high cell-killing abilities [1–4]. Therefore, the interest to use 
α-emitters for TAT is continuously growing. As discussed in this thesis and elsewhere, 213Bi 
is a widely used α-emitter for preclinical research, due to the availability of an 225Ac/213Bi 
generator. Confounding issues regarding 213Bi include its short half-life of 45.9 min and 
the limited availability of the mother radionuclide 225Ac. Despite this relatively short half-
life of 213Bi, a reliable labelling protocol with DOTA-biomolecules could be successfully 
achieved, which can be easily transferred to clinical targeted therapy [5]. Furthermore, the 
limited availability of 225Ac may be overcome by the development of accelerator-driven 
production processes of 225Ac, this would enable unrestricted production of high activity 
225Ac/ 213Bi generators for preclinical (> 370 MBq) and clinical applications (> 2 GBq) 
[5–7]. The use of receptor antagonistic peptides could be another approach to obtain higher 
radioactivity delivered at the target, as several studies demonstrated higher tumour uptake 
could be achieved with antagonists compared to that obtained with a receptor agonistic 
peptide with similar receptor affinity [8–10].
Actinium-225 (225Ac) is a very attractive radionuclide for TAT because of its longer half-life 
and the emission of four α-particles in its decay and that of its four α-emitting daughters. 
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The challenge of working with 225Ac is the recoil effect of the four daughters, which might 
lead to off-targeting when released from the chelator. Kratochwil et al. demonstrated that 
225Ac-PSMA-617 can be applied as salvage therapy for end-stage mCRPC patients. The 
tolerated dose was 100 kBq/kg and the treatment was safe and could be repeated with 
8 weeks interval [11]. Concerns for late toxicity by 225Ac-PSMA-617 prevent currently 
its use in an earlier phase of the disease. Besides 213Bi and 225Ac, Astatine-211 ( 211At) is 
also considered to be an attractive radionuclide for TAT because of its 7.2 h half-life and 
the possibility to produce 211At by a particle accelerator [12]. These radionuclides emit 
γ-rays with low abundance, like 213Bi. Terbium-149 (149Tb) is also highly appealing for 
radiotheranostic applications in future clinical applications, since 149Tb is an α-emitter as 
well as a β+-emitter [3, 13].
Caution must be made for dosimetry calculation for α-emitters, since it is different from that 
for β or γ-radiation. Inhomogeneous activity distribution is often seen in targeted radionu-
clide therapy as not all tumour cells show equal receptor-density. Inhomogeneous activity 
distribution over the tumour cells in combination with the short path length of α-emitters 
leads to a wrong estimation of overall effects when using the macrodosimetric approach 
for TAT. Macrodosimetry assumes that all cells receive the same absorbed dose with the 
assumption of a uniform energy distribution over the target mass. Microdosimetry can also 
be used to determine the probability for radiation damage. Microdosimetry includes the 
absorbed specific energy deposited to the target mass and the stochastic effect at cellular 
level. It is, however, not possible to perform a full microdosimetry model for complete 
tumours and whole organs at risk. Small-scale dosimetry for representative geometries 
at the cellular level makes use of the same macrodosimetry concept and could serve as a 
bridge between macrodosimetry and microdosimetry [14]. Information from small-scale 
dosimetry might be used to correct the mean absorbed dose for α-emitters [14]. In general 
small-scale dosimetry models like MIRDcell can be used to estimate the cellular absorbed 
dose, which will resemble the total macroscopic dose in most therapeutic settings with high 
amounts of activity which is homogeneously distributed [15].
To summarize, in this thesis 213Bi-DOTATATE showed therapeutic efficacy in vitro as well 
in vivo in mice with different tumour models as well as in tumours of different size, even 
in tumours with low SSTR2 expression. An MTD of 22 MBq was found in mice corre-
sponding to a renal LD50 of 20 Gy. High renal uptake and α-particle induced toxicity could 
be managed by renal protectants [16], such as L-lysine. The relative biological effect of 
213Bi-DOTATATE was 6 times higher with than that of 177Lu-DOTATATE in vitro, making 
213Bi-DOTATATE a suitable candidate radionuclide for treatment of patients with meta-
static NETs in larger patient studies. However, the short half-life of 213Bi makes the therapy 
logistically too demanding for routine clinical use; α-emitters with a longer half-life (like 
225Ac) are therefore considered to be more suitable for clinical applications.
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sAmEnVATTing
Sinds jaren wordt 177Lu-DOTA-Tyr3-octreotate (177Lu-DOTATATE) in ons ziekenhuis 
toegepast voor behandeling van patiënten met gemetastaseerde neuroendocriene tumoren 
(NET). Indrukwekkende anti-tumor resultaten zijn geboekt en de kwaliteit van leven wordt 
verbeterd in deze patiënten, maar totale genezing wordt helaas niet vaak bereikt. De zoek-
tocht naar betere behandeling voor deze patiënten is daarom volop gaande. Het gebruik van 
α-emitters voor doelgerichte alfa-therapie (TAT) is zeer aantrekkelijk, omdat α-emitters, 
zoals bijvoorbeeld 213Bi, meer cytotoxisch zijn dan β-emitters. In dit proefschrift beschrij-
ven we de applicatie van 213Bi-DOTATATE in preklinische modellen, dit onderzoek had 
als uiteindelijk doel om TAT veilig en effectief te kunnen toepassen voor behandeling van 
patiënten met gemetastaseerde NET.
In hoofdstuk 1 van dit proefschrift wordt een algemene introductie gegeven over NET en 
het concept van doelgerichte beeldvorming en therapie met behulp van radioactief gelabelde 
peptiden. Verder worden in dit hoofdstuk het gebruik van 213Bi als potentieel radionuclide 
voor het labelen van DOTATATE en de toepassing van TAT geïntroduceerd. De algemene 
voorwaarden en beperkingen van doelgerichte alfa-radionuclidentherapie voor klinische en 
preklinische applicaties worden hierin ook behandeld.
Doordat er in ons onderzoek gebruikt is gemaakt van een laag actieve 225Ac /213Bi generator 
(< 222 MBq) voor preklinische doeleinden was het noodzakelijk om de labelingsprocedure 
van 213Bi-DOTATATE aan te passen om onder andere een stabiel en met hoge specifieke 
activiteit gelabeld peptide te verkrijgen. Dit was nodig, omdat er met een klein injectievo-
lume gewerkt moet worden in de kleine proefdieren. In hoofdstuk 2 wordt de optimalisatie 
van de labelingsprocedure van 213Bi-DOTATATE voor preklinische doeleinden beschreven, 
hierdoor was het mogelijk om 213Bi-DOTATATE te labelen met een hoge incorporatie en 
een hoge radiochemische zuiverheid. Het product bleef stabiel gedurende meer dan 2 uur 
na labeling. Toevoeging van ascorbinezuur gedurende labeling bleek zeer essentieel te zijn 
om radiolyse te voorkomen, het absorbeerde dosistempo in de labeling was namelijk hoog: 
> 165 mGy.s-1 bij 100 MBq 213Bi. Een te hoge concentratie van ascorbinezuur bleek echter 
cytotoxisch voor CA20948 tumorcellen, een pancreas rat carcinoom met hoge expressie 
van de somatostatine receptor subtype 2 (SSTR2). De toegevoegde hoeveelheid ascorbi-
nezuur gedurende de labeling is daarop aangepast. Een 225Ac /213Bi generator met hogere 
radioactiviteit is echter sterk aan te raden om deze beperkingen te voorkomen.
Onderzoek betreffende de farmacokinetiek en farmacodynamiek van 213Bi-DOTATATE in 
vivo is uiteengezet in hoofdstuk 3. Als tumormodel werd gebruik gemaakt van AR42J 
tumorcellen, pancreas tumorcellen met een hoge SSTR2 expressie. De peptidemassa-afhan-
kelijke tumoropname in muizen werd bepaald met behulp van verschillende hoeveelheden 
111In-DOTATATE. Ook de biodistributie en de optimale geabsorbeerde dosis in tumoren 
en verschillende organen werd bestudeerd. De tumoropnames van 111In-DOTATATE en 
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213Bi-DOTATATE bleken goed vergelijkbaar, maar de nieropnames verschilden significant. 
De optimale hoeveelheid geïnjecteerd peptide bleek 0.3 nmol, deze hoeveelheid is daarom 
in alle verdere in vivo studies gebruikt. De berekende geabsorbeerde dosis in de tumor 
was circa 0.5 Gy/MBq. Daarnaast is de maximaal toelaatbare dosis (MTD) van 213Bi-
DOTATATE in de muizen bepaald. Het is bekend dat 213Bi-complexen zich ophopen in 
de nieren, dit heeft een hoge nieropname met mogelijk ook nierschade tot gevolg. Uit 
deze studie bleek dat de nieropname kon worden verminderd tot 50 % door pre-injectie 
van L-lysine, een nierbeschermer die meer wordt toegepast in klinische peptide- receptor-
radionuclidentherapie. Acute nierschade trad op bij een gemiddelde nierdosis > 20 Gy. 
Een correlatie tussen de hoeveelheid geïnjecteerde radioactiviteit en de marker Neutrophil 
Gelatinase-Associated Lipocalin (NGAL) werd ook gevonden. 213Bi-DOTATATE zorgde 
voor een betere overleving, het overlevingspercentage was nog hoger bij toediening van 
L-lysine voor aanvang van de therapie; een MTD van 22 MBq met L-lysine en < 13 MBq 
zonder L-lysine werd gevonden.
Zoals eerder beschreven, wordt algemeen verondersteld dat α-emitters voornamelijk 
geschikt zijn voor de behandeling van kleine tumorclusters en metastasen. In bepaalde 
klinische onderzoeken werd echter ook een afname van tumorgrootte waargenomen in pa-
tiënten met grote tumoren na 213Bi-DOTA-Tyr3-octreotide therapie. hoofdstuk 4 beschrijft 
de effectiviteit van 213Bi-DOTATATE in muizen met tumoren van verschillende grootte, 
namelijk 50 en 200 mm3, we maakten gebruik van twee verschillende tumormodellen 
met verschillende expressie van SSTR2 (CA20948 en H69 cellen, de laatste zijn humane 
kleincellige longkankercellen). De geïnjecteerde activiteit van 213Bi-DOTATATE was onder 
de MTD zonder L-lysine. In alle behandelde muizen werd een afname van tumorgrootte 
waargenomen. Sterkere anti-tumoreffecten werden waargenomen in H69-tumordragende 
muizen; de overlevingskans was ook hoger in deze dieren. Wat betreft de behandeling 
van dieren met verschillende tumorgrootte werden geen significante verschillen gevonden, 
213Bi-DOTATATE bleek dus geschikt voor behandeling van zowel grotere als kleine tumo-
ren. De nierfunctie is onderzocht door middel van een 99mTc-DMSA-scan; geen nierafwij-
kingen werden waargenomen na therapie met de toegepaste hoeveelheid 213Bi-DOTATATE.
In hoofdstuk 5 is de bepaling van het relatieve biologische effect (RBE) van 213Bi-ligand 
beschreven. Dit onderzoek is gedaan met behulp van kolonievormingsexperimenten met 
tumorcellen. De vorming van kolonies na externe bestraling van 137Cs en na bestralen met 
177Lu-liganden of 213Bi-liganden is met elkaar vergeleken. Twee cellijnen werden in dit expe-
riment gebruikt; CA20948 cellen en BON cellen, deze laatste zijn humane carcinoidcellen. 
Deze cellijnen verschillen met betrekking tot SSTR2 expressie en stralingsgevoeligheid. 
De geabsorbeerde dosis in de cellen werd berekend met een microdosimetrisch model, 
hierdoor was het mogelijk om de RBE-waarden te bepalen na bestraling met verschillende 
bronnen en konden ze onderling vergeleken worden. 111In-DOTATATE is gebruikt om de 
celopname van 177Lu-DOTATATE en 213Bi-DOTATATE te simuleren. Dit was mogelijk, 
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omdat 111In-DOTATATE dezelfde affiniteit voor SSTR2 heeft als 177Lu-DOTATATE en 
213Bi-DOTATATE. De overlevingscurves na bestraling met 137Cs verliepen volgens het 
lineair kwadratisch model bij toenemende bestralingsdosis, dit gold voor beide cellijnen. 
Het lineair kwadratisch model is typerend voor β- en γ-bestraling. Een lineaire afname 
van celoverleving werd waargenomen in beide cellijnen na het bestralen met toenemende 
hoeveelheden 213Bi-DTPA of 213Bi-DOTATATE. 213Bi-DTPA en 213Bi-DOTATATE waren 6x 
meer toxisch dan 177Lu-DOTATATE in CA20948 cellen. De RBE verkregen na bestraling 
van 213Bi-liganden varieerde van 1.5–2 in vergelijking met externe bestraling met 137Cs in 
beide cellijnen.
In hoofdstuk 6 is het onderzoek naar 213Bi beeldvorming door middel van Single Photon 
Emission Computed Tomography (SPECT) beschreven. 213Bi zendt 440 keV γ-straling 
uit waarmee het mogelijk zou kunnen zijn de farmacokinetiek van 213Bi-DOTATATE te 
volgen in vivo met behulp van SPECT. Klassieke fantoomstudies werden uitgevoerd om de 
laagst detecteerbare hoeveelheid radioactiviteit te bepalen met een pinhole SPECT camera 
geschikt voor kleine dieren, gevolgd door in vivo en ex-vivo beeldopnames in muizen. Een 
resolutie van 0.75 mm werd gevonden in de fantoomstudie; in muizen kon de nieropname 
en klaring van 213Bi-DTPA goed waargenomen worden. In ex-vivo studies in dieren met 
een CA20948 tumor was de tumoropname van 213Bi-DOTATATE een uur na euthanasie nog 
steeds waar te nemen.
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